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Abstract  
Abdulaziz Saad Abdulaziz Bin SAEEDAN 
 
The role of MMP10 in non-small cell Lung cancer, and 
pharmacological evaluation of its potential as a target for 
therapeutic intervention 
Keywords: NSCLC, Matrix metalloproteinase-10 (MMP10), MMP3, histone 
deacetylase-7, Metabolism, siRNA, Angiogenesis, LC-MS/MS, pharmacology 
 
Non-Small Cell Lung Cancer (NSCLC), which accounts for 80% of all lung 
cancer cases, is associated with resistance to chemotherapy and poor 
prognosis. Exploitation of NSCLC-upregulated pathways that can either be 
targeted by novel therapeutics or used to improve the tumour-delivery of current 
chemotherapeutics are required. Among the matrix metalloproteinases (MMPs) 
that are essential for tumour development, MMP10 is a potential candidate as a 
therapeutic target based on its expression and contribution to NSCLC 
development. This research aims to explore the expression and functions of 
MMP10 in the tumour microenvironment of NSCLC and evaluate the potential of 
MMP10 as a target for therapeutic intervention. Herein, MMP10 expression at 
gene and protein levels were analysed in a panel of NSCLC cell lines using RT-
PCR and Western blotting analysis. To determine MMP10 functional relevance, 
an in vitro angiogenesis assay using cell conditioned media was carried out. To 
identify specific peptide sequences for the design of prodrugs rationalised to be 
MMP10 activated, in vitro substrate cleavage studies were performed using a 
mass spectrometry approach to differentiate between MMP10 and the 
structurally similar MMP3. This study demonstrates that MMP10 is highly 
expressed in NSCLC and that high levels of MMP10 are associated with 
induction of angiogenesis, a crucial process supporting tumour growth. In 
addition to the achievement of having been able to differentiate between closely 
similar MMP3 and MMP10 through carefully monitoring the hydrolysis rate of 
compound 444259 (a known MMP substrate), data generated herein provides 
the basis for further studies to exploit MMP10 as a prodrug-activator. 
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Chapter 1: Introduction 
1.1 Cancer  
Cancer is a major public health issue with approximately 8.2 million deaths 
globally in 2012 (CRUK, 2014b). In the UK, a new patient is diagnosed with 
cancer every two minutes (CRUK, 2014a). Development of cancer begins 
with the accumulation of genetic and epigenetic alterations in cells, such as 
reduced expression of tumour suppressor genes and enhanced expression 
of oncogenes (Podlaha et al., 2012). At the cellular and molecular levels, ten 
hallmarks have been identified as being essential for cancer growth 
(Hanahan and Weinberg, 2011). These include self-sufficiency in growth 
signals, insensitivity to antigrowth signals, enabling of replicative immortality, 
presence of genome instability and mutation, tissue invasion and metastasis, 
deregulation of cellular energetics, sustained angiogenesis, inflammation 
promotion, avoidance of immune destruction and evasion of apoptosis 
(Hanahan and Weinberg, 2011). Many drugs show limited success for a 
range of different tumours (with a response rate of almost 100% for testicular 
cancer to less than 20-35% for NSCLC (Schiller et al., 2002; Verweij and de 
Jonge), but issues with off-target toxicity and drug resistance limit the overall 
effectiveness. Therefore, the need arises to acquire better understanding of 
cancer biology to search for new therapeutic targets that would offer the 
chance to develop improved cancer therapy. 
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1.1.1 Overview of Lung Cancer 
As the name implies, lung cancer involves the abnormal, uncontrolled 
proliferation of epithelial cells in the tissue of the lungs. It arises due to 
serious morphological changes in the normal epithelium as shown in Figure 
1.1. Histologically, lung cancer is generally classified according to the size 
and appearance of malignant cells under the microscope into two major 
types: small cell lung cancer (SCLC) and NSCLC. Non-small cell lung 
carcinoma is further classified into three histological subtypes: 
adenocarcinoma, squamous cell and large cell anaplastic carcinomas. This 
classification has important implications for the treatment and diagnosis of 
the disease. 
The main cause of NSCLC is cigarette smoking, which is responsible for 
nearly 85% of all new cases of lung cancer (Mao et al., 1997; Spira et al., 
2004). The remaining lung cancer cases are due to other non-smoking 
related factors (Thun et al., 2008), such as exposure to radon gas (Catelinois 
et al., 2006), asbestos (O'Reilly et al., 2007) and air pollution (Kabir et al., 
2007). These contributing factors interact with the host genetic susceptibility 
leading to altered protein expression involving genetic and epigenetic 
changes (Wistuba et al., 2000), consequently resulting in lung cancer 
development. 
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Figure 1.1. The morphological multistage development of squamous cell 
lung carcinoma. Pathogenesis of the disease involves progressive 
morphological events occurring in the normal lung epithelium, resulting in 
abnormal and irregular tissues. Adapted from (Minna et al., 2002). 
 
1.1.2 Lung Cancer Clinical Incidence and Mortality 
There are 1.35 million new cases of lung cancer annually, comprising over 
17% of the total new cancer cases worldwide (Jemal et al., 2011). Currently, 
lung cancer is the 2nd commonest (after breast cancer) in the UK, which 
accounts for 13% of the total cancer cases (331,487) diagnosed in 2011 
(CRUK, 2014a). 
Lung cancer is now the leading cause of cancer deaths worldwide (Jemal et 
al., 2011). The predominant form of lung cancer is NSCLC, which accounts 
for over 80% of the total lung cancer cases and shows a low survival rate for 
patients (Wood et al., 2014). Statistics has shown that 85% of patients with 
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NSCLC die within five years of first diagnosis. This period of time decreases 
to 18 months for those who were diagnosed at the advanced stages of 
NSCLC as they suffered from metastatic complications (Langer et al., 2010). 
Therefore, NSCLC is a serious life threatening disease, and better 
understanding of the mechanistic basis of its development is essential for 
improving patients' quality of life and survival. 
1.1.3 Current Treatment for Lung Cancer 
Currently, there are four approaches available to treat NSCLC. These include 
surgery, radiation therapy, classical chemotherapy and targeted therapy. 
Treatment choices depend on the nature and stage of the disease. For 
NSCLC, surgery is the primary treatment approach; however, only 30% of 
patients are appropriate for resection (Group, 2010). The majority must 
receive chemotherapy as part of their curative or palliative treatment. As a 
consequence, tremendous efforts have been concerned with improving 
chemotherapy for NSCLC. A major step forward in the treatment of lung 
cancer is the introduction of platinum-based chemotherapeutics, especially 
cisplatin and carboplatin. The combination of platinum derivatives with other 
agents, including gemcitabine, vinorelbine, docetaxel and pemetrexed 
improved the   five-year survival rate from 5% to 14% (Khuri et al., 2001), 
thereby this approach is commonly used for the first-line treatment of 
advanced NSCLC (Peters et al., 2012). In the last decade, personalised 
medicine, which is based on the identification of specific and druggable 
genetic alterations in the tumour tissue of an individual patient, has been 
introduced (Crinò and Metro, 2014; Sechler et al., 2013). This means that 
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patients with NSCLC that have activating mutations in relevant genes should 
receive a drug that specifically targets the oncoprotein associated with the 
mutated gene, as exemplified with use of erlotinib against the gain-of-function 
mutations of the epidermal growth factor receptor (EGFR). Despite the 
robustness of this strategy, only a minority of patients with the requisite gene 
mutations can benefit (Crinò and Metro, 2014). However, even with a drug 
combination strategy being used for a more effective treatment of NSCLC, it 
soon became obvious that the use of chemotherapy or molecular targeted 
therapy has reached a limit, in part due to the occurrence of drug resistance 
(Sechler et al., 2013).  
A major issue in the treatment of NSCLC is that most of the patients have 
reached an advanced stage at the time of diagnosis due to the initial 
asymptomatic course; hence, poor prognosis is often associated with 
NSCLC. Patients with an advanced stage of NSCLC are most likely to have 
metastatic disease, making the treatment options limited to chemotherapy 
rather than surgery or radiation therapies (Nishio et al., 1999). In addition, 
NSCLC is well known to be associated with acquired resistance to 
chemotherapy (Nishio et al., 1999). Several cellular mechanisms have been 
identified to contribute to the resistance of NSCLC cells to chemotherapy. 
These include increased efflux of chemotherapeutic drugs, involvement of 
several alternative DNA-repair pathways, mutations or functional 
modifications of the drug target and loss of apoptotic functionality (Ambudkar 
et al., 1999; Eastman and Schulte, 1988; Kavallaris et al., 1997; Sethi et al., 
1999; Townsend and Tew, 2003). Thus, there is still an urgent need for 
research to develop awareness on the emergence and development of 
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NSCLC, which hopefully will lead to the discovery of new tumour markers 
and potential targets for therapeutics that can be utilised to improve the 
diagnosis and management of the disease (Atkinson et al., 2007). 
1.1.4. Molecular Signature of NSCLC and Targeted Therapy 
Recent advances in our knowledge on the mechanisms of tumourigenesis 
and on the molecular biology of cancer have recognised key molecular 
targets involved in several oncogenic pathways that have been proven 
essential for NSCLC progression. Interfering with these targets can be useful 
for NSCLC therapy (Reungwetwattana and Dy, 2013). Such important targets 
include EGFR, vascular endothelial growth factor receptors (VEGFR), 
hepatocyte growth factor receptor (MET) and insulin-like growth-factor 
receptors (IGFRs) (Reungwetwattana and Dy, 2013). The majority of the 
molecular targets with their signalling pathways identified in the context of 
NSCLC are listed in Figure 1.2. Due to their role in NSCLC progression, 
extensive work to develop inhibitors for several molecular targets has been 
made. Several promising molecular-targeted drugs have been tested 
clinically for NSCLC and their outcome or current status is shown in Table 
1.1. 
Epidermal growth factor receptor and VEGF were most extensively 
implicated in NSCLC. This will be explained in more detail. It was reported 
that 60% of NSCLC cases showed EGFR overexpression and that its 
presence was associated with poor prognosis (Brabender et al., 2001; 
Sechler et al., 2013). This tyrosine kinase protein receptor is vital for tumour 
cell proliferation, angiogenesis migration and survival (Wells, 1999). In 
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addition, VEGF, a key player in angiogenesis, is revealed in the majority of 
NSCLCs and its overexpression is linked to poor prognosis (Han et al., 
2001). Based on their expression and role in tumour development, EGFR 
and VEGFR represent attractive therapeutic targets for NSCLC. Despite the 
development of several inhibitors for EGFR and VEGFR, clinical results with 
molecularly targeted agents remain modest. This highlights the need to 
continue screening for other molecular targets for novel therapeutic options. 
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Table 1.1. Molecular-Targeted Drugs Evaluated in NSCLC. Abbreviations, 
EGFR: epidermal growth factor receptor; FGFR: fibroblast growth factor 
receptors, EML4-ALK: echinoderm microtubule-associated protein-like 4 
(EML4) fused to the anaplastic lymphoma kinase (ALK), VEGF: vascular 
endothelial growth factor, IGF: insulin-like growth factor, FLT4: Fms-related 
tyrosine kinase 4, C-kit: tyrosine-protein kinase Kit. 
Drug Target Current  status in the development as a 
drug for NSCLC  
Gefitinib, 
Erlotinib 
EGFR 
 
Approved for first, second and third line 
treatment of advanced stage NSCLC (Fukuoka 
et al., 2011). 
Afatinib Approved for first line treatment of advanced 
stage NSCLC and still under evaluation  
(Sequist et al., 2013) 
Cetuximab 
(mAb) 
Reported in clinical phase III trial as useful only 
in combination with chemotherapy (Pirker et 
al., 2009). 
AZD4547 FGFR Under evaluation in clinical phase II trial for 
advanced NSCLC (Reungwetwattana and Dy, 
2013). 
Crizotinib EML4-ALK Approved for advanced ALK-positive NSCLC 
patients (Camidge et al., 2012). 
XL647 EGFR, 
VEGFR, 
FLT4, C-kit 
Under evaluation in clinical phase III trial 
compared to erlotinib (Reungwetwattana and 
Dy, 2013). 
Bevacizumab 
mAb 
VEGF 
 
Approved in first line metastatic non-squamous 
NSCLC (Sandler et al., 2006). 
Sorafenib Failed to improve overall survival in NSCLC 
patients at advanced stage (Paz-Ares et al., 
2012; Scagliotti et al., 2010). 
Cixutumumab IGF-IR 
 
Under evaluation in clinical phase II for 
advanced NSCLC (Reungwetwattana and Dy, 
2013). 
Figitumumab 
(mAb) 
No further use in NSCLC based on clinical 
phase III trial (Jassem et al., 2010). 
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1.2 Tumour Microenvironment 
The solid tumour microenvironment encompasses a mixture of tumour cells 
together with extracellular matrix (ECM), tumour vasculature and immune 
and stromal cells (Joyce and Pollard, 2008; Junttila and de Sauvage, 2013) 
(Figure 1.3). This heterogeneous environment has similar characteristics to 
the initiation of an inflammatory response in a healing wound. In the case of 
tissue damage, an initiation of several chemokines helps in the healing of the 
injured tissue and maintains a suitable host response. Immune cells 
(monocytes and neutrophils) are controlled and recruited by the released 
chemokines. These cells participate in the repair process (Epstein and 
Luster, 1998). This inflammatory environment causes the activation of local 
fibroblasts, leading to the activation and induction of numerous proteolytic 
enzymes, particularly the matrix metalloproteinases (MMPs), which are 
involved in angiogenesis and in the remodelling of the extracellular matrix. 
When there is complete healing of the wound, the inflammatory response, in 
general, subsides and tissue function returns to normal (Eming et al., 2007; 
Kalluri and Zeisberg, 2006; Liddiard et al., 2011). 
It is known that tumour cells can synthesise and secrete chemokines and 
cytokines, which help in recruiting endothelial cells, fibroblasts, monocytes, 
and neutrophils, along with VEGF. Moreover, as evident in healing wounds, 
the secretion of proteolytic enzymes and cytokines is carried out by the 
infiltrating inflammatory cells and fibroblasts that are activated at the site of 
the cancerous tissue. The secretion of cytokines and MMP in the cancer 
tissue seems dedicated to support cancer progression by recruiting MMPs to 
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create extracellular space for the further proliferation and metastasis of 
cancer cells, rather than taking part in the reconstitution of tissues (Coussens 
et al., 2002; Eming et al., 2007). 
Additionally, the low level of oxygen and nutrients in the tumour tissue 
permits the formation of an aggressive metabolic microenvironment. It was 
reported that the tumour’s metabolic microenvironment might encompass 
acidosis, high levels of lactate, bicarbonate depletion, high CO2 levels, low 
oxygen levels (Vaupel et al., 1989) and low blood sugar, thereby aiding 
cancer progression and supporting resistance to drugs (Hanahan and 
Folkman, 1996b; Trédan et al., 2007; Vaupel et al., 1989). Overall, this 
aggressive inflamed microenvironment represents unique differences 
between normal and tumour tissue, which can be exploited for novel 
targeted-tumour therapies. 
12 
 
Figure 1.3. The heterogeneous tumour microenvironment. Solid 
tumours comprise of tumour cells, along with various immune and 
stromal cells that are embedded in an ECM and nourished by blood 
and lymph vessels. This complex microenvironment supports the 
progression of cancer and resistance to chemotherapeutics; therefore, 
a better understanding of its influence is essential for a more effective 
cancer therapy. EC: endothelial cell, BMDCs: bone marrow-derived 
cells, TEMs: TIE2-expressing monocytes, MDSCs: myeloid-derived 
suppressor cells and MSCs: mesenchymal stem cells. Adapted from 
(Joyce and Pollard, 2008). 
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1.2.1 Tumour Vasculature and Angiogenesis 
Angiogenesis is the development of new blood vessels from pre-existing 
vessels. This dynamic process results from the interaction between 
endothelial cells, surrounding pericytes, extracellular matrix, angiogenic 
cytokines/growth factors and smooth muscle cells (Rundhaug, 2003). The 
molecular mechanism of angiogenesis involves the degradation of the 
basement membrane surrounding an existing vessel, migration and creation 
of endothelial cells towards the holes in the basement membrane, forming 
angiogenic endothelial vessel sprouts. The endothelial cells eventually 
undergo maturation, differentiation, and adherence to each other, creating a 
lumen that runs through the capillary sprouts (Lockhart et al., 2003).  
Angiogenesis has important functions in several normal physiological 
processes, such as foetal growth and wound healing (Folkman, 1990). It also 
has key roles during some pathological conditions, such as tumour growth 
and atherosclerosis (Carmeliet, 2003; Ferrara et al., 2003; Ha et al., 2008). 
Under normal circumstances, angiogenesis is highly controlled by the 
balance between proangiogenic factors and endogenous angiogenesis 
inhibitors (Harris, 2003). Proangiogenic factors, such as VEGF and platelet-
derived growth factor (PDGF), act on endothelial cells by directly stimulating 
the growth and migration of endothelial cells, or indirectly by influencing other 
cells involved in angiogenesis (Ferrara, 2000). A series of endogenous 
antiangiogenic factors, such as arrestin, endorepellin, endostatin, fibulins and 
thrombospondins, have been reported (Nyberg et al., 2005). These inhibitors 
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and proangiogenic factors work in concert to generate and sustain the 
functional vasculature in the body as required.   
However, tumours have lost the equilibrium between anti and proangiogenic 
signals due partially to the influence of the tumour microenvironment (Crinò 
and Metro, 2014). For example, proangiogenic factors in the tumour tissue 
were confirmed to be highly expressed as a consequence of hypoxia, 
especially in NSCLC (De Bock et al., 2011; Ferrara and Kerbel, 2005). The 
overproduction of proangiogenic factors makes the tumour vasculature 
vulnerable to various disorders, including high vessel permeability; 
exceedingly irregular, elevated inconsistency in vascular density; severe 
tortuous; arterio-venous shunts and deprived or no lymphatic drainage 
system (Figure 1.4). In addition, the internal structure of the tumour 
vasculature is weak due to the lack of supporting pericyte cells, perivascular 
smooth muscle and basement membrane (Benjamin et al., 1999; Grunt et al., 
1985). Elevated vascular permeability in tumours allows plasma leakage into 
the extravascular compartment, adding to the chaotic and inconsistent blood 
flow (Benjamin et al., 1999; Grunt et al., 1985). 
Angiogenesis is essential for tumour growth and metastasis. It constitutes a 
significant point in the control of cancer development. The suggestion that 
tumour growth requires the development of the vascular network was first 
reported by Algir and Chalkley (Algire et al., 1945). In the 1970s, Folkman 
claimed that the growth of tumours beyond 1-2mm3 depends on their ability 
to initiate angiogenesis (Sherwood et al., 1971). Tumours can develop to 
about 1 mm without angiogenesis by obtaining oxygen and nutrients through 
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diffusion from adjacent tissues; however, for further growth, they must 
develop an angiogenic phenotype, which leads to the formation of a 
functioning blood vessel (Sherwood et al., 1971). Several preclinical models 
demonstrate that angiogenesis is important for tumour progression and 
survival and metastasis dissemination (Algire et al., 1945; Folkman, 1990; 
Nishida et al., 2006). In NSCLC, richly vascularised tumours coupled with 
high VEGF levels support the angiogenesis process (Crinò and Metro, 2014; 
Stefanou et al., 2004). Targeting angiogenesis, therefore, would provide a 
good therapeutic strategy for malignant solid tumours in NSCLC. For 
example, the inhibition of VEGF in tumours using the anti-VEGF monoclonal 
antibody bevacizumab results in a significant prolongation of both overall 
survival and progression-free survival in patients with NSCLC (Sandler et al., 
2006). 
While the tumour microenvironment has always been associated with the 
growth and progression of cancer, it is also the basis of the phenotypic 
difference with normal tissue, a difference that can be exploited for novel 
therapeutic targeting approaches. For example, banoxantrone (AQ4N) and 
TH-302 are both hypoxia-activated prodrugs that have a remarkable capacity 
to specifically target the tumour hypoxic cells, thereby facilitating the 
sensitivity of solid tumours to therapy (Duan et al., 2008; Meng et al., 2012; 
Patterson and McKeown, 2000). 
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Figure 1.4. Diagram showing several abnormalities in tumour vasculature 
compared to normal tissue. These abnormalities include severely twisted, 
high variability in vascular density; extremely irregular, several blind ends; 
arterio-venous shunts; high permeability and temporary occlusion. Areas in 
blue are hypoxic regions that resulted from these abnormalities in tumour 
vasculature (Brown and Giaccia, 1998). 
 
1.3 Matrix Metalloproteinases (MMPs) 
Matrix metalloproteinases are key players in the tumour microenvironment 
that have been implicated in the tumour progression in part due to the 
remodelling of the ECM, thereby promoting angiogenesis and enhancing 
tumour cell migration (Coussens et al., 2002; Kessenbrock et al., 2010). 
There are 24 human MMP members of the MMP family that have been 
described (Puente et al., 2003) and they have been initially classified into two 
groups based on their cellular localisation (secreted versus membrane 
bound). Another alternative classification of the MMPs was reported later, 
Normal Blind Ends 
Break in 
vessel wall 
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dividing them according to their structure and substrate specificity into 
collagenases, gelatinases, membrane type, stromelysins and matrilysins 
(Bourboulia and Stetler-Stevenson, 2010). Table 1.2 illustrates most of these 
MMPs with their common name and localisation.  
 
Table 1.2 Human MMPs 
MMP Member Common Name Localisation 
MMP1 Colagenase-1 
Secreted (zymogen) 
MMP8 Colagenase-2 
MMP13 Colagenase-3 
MMP3 Stromelysin-1 
MMP10 Stromelysin-2 
MMP12 Metalloelastase 
MMP18 Colagenase-4 
Secreted 
MMP19 RASI-1 
MMP20 Enamelysin 
Secreted (zymogen) 
MMP27 N/A 
MMP2 Gelatinase A 
MMP9 Gelatinase B 
MMP7 Matrilysin/ Uterine 
MMP26 Matrilysin-2/ Endometase 
MMP11 Stromelysin-3 
Secreted (active) 
MMP28 Epilysin 
MMP21 MMP-23A Secreted 
MMP14 MT1-MMP 
Trans-membrane  
MMP15 MT2-MMP 
MMP16 MT3-MMP 
MMP24 MT5-MMP 
MMP17 MT4-MMP 
Membrane bound GPI-linked 
MMP25 MT6-MMP 
MMP22 NA membrane-associated 
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In addition to the MMP, there is a close protease subfamily called a 
disintegrin and metalloproteinases (ADAMs), has proven to be equally 
important. This family contains 23 members in human and all are membrane-
anchored glycoproteins that involves in a wide variety of biological process 
including  proteolysis, cell adhesion, cell fusion, and intracellular signalling 
(Blobel, 2005; Schlondorff and Blobel, 1999; Zhong et al., 2008). In cancer 
pathophysiology, preclinical studies have shown that several ADAM family 
members (ADAM9, ADAM10, ADAM12, ADAM15 and ADAM17) can play 
roles in cancer formation and progression (Duffy et al., 2009a; Duffy et al., 
2009b; Duffy et al., 2011). This is through an activation of positively-
stimulating pathways (e.g. EGFR-PI3K-AKT), inactivation of growth-inhibitory 
pathways (e.g. mediate shedding of the type 1 TGF-β receptor), shedding of 
adhesion proteins (e.g. cadherin E), or mediating angiogenesis (Duffy et al., 
2011). based on these functions, ADAMS could be one of key players in 
tumours microenvironment, However, due to the nature of this research, the 
main focus  will be on MMP. 
1.3.1 Structure of MMPs 
The structure of MMPs consists of the following homologous domains: 1) 
signal domain essential for directing MMPs to the endoplasmic reticulum 
prior to secretion; 2) hydrophobic pro-peptide region that protects enzymatic 
activity by occupying the active site, making the catalytic enzyme 
inaccessible to substrates or inhibitors until activated; 3) zinc containing 
catalytic domain responsible for enzymatic activity after pro-peptide removal; 
4) hemopexin-like domain at the C-terminus, which is found in all MMPs 
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except for MMP-7, MMP22 and MMP-26 (Table 1.3) (Bourboulia and Stetler-
Stevenson, 2010; Foda and Zucker, 2001; John and Tuszynski, 2001). This 
domain is linked to the catalytic domain by a flexible hinge region, conferring 
the specificity of the enzyme and the mediation of the substrate or MMP 
inhibitors (Bourboulia and Stetler-Stevenson, 2010). In the transmembrane 
MMP subclass, there is an additional hydrophobic transmembrane binding 
domain at the C-terminal end of the protein. In type II MT-MMPs (MMP17 
and 25), this is a glycosyl-phosphatidyl inositol (GPI) anchor domain. In type I 
MT-MMPs, this is a transmembrane domain linked to the cytoplasmic tail in 
MMP14, 15, 16 and 24. The major role of these domains is to allow the MMP 
to anchor to the cell surface (Table 1.3). 
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Table 1.3. Structural Classes of Human MMPs. signal peptide (SP); pro-peptide 
(Pro); catalytic domain (CAT); fibronectin repeats (F); hemopexin-like domain; 
(PEX); transmembrane domain (TM); glycosyl-phosphatidyl inositol anchor 
domain (GPI); cytoplasmic domain (C); cysteine array (CA); immunoglobulin-like 
domain (Ig). The flexible, variable length linker or hinge region is depicted as a 
wavy black ribbon (Radisky and Radisky, 2010). 
Structural Class Domain Structure 
Simple Hemopexin Domain 
 
(MMP1, 3, 8, 10, 11, 12, 13, 19, 20, 21, 27, 28) 
Gelatin-Binding 
 (MMP2, 9) 
Minimal Domain 
   
(MMP7, 22, 26) 
 
 
Type-I Transmembrane 
 
     
(MMP14, 15, 16, 24,) 
        
(MMP17, 25) 
Type-II Transmembrane 
cysteine array   
(MMP23) 
 
1.3.2 Regulation of MMP Expression and Activity 
Matrix metalloproteinases are tightly regulated at three levels— 
transcriptional level, post transcriptional level, and the proteolytic level—via 
activators, inhibitors and cell surface localisation (Sounni et al., 2003). 
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1.3.2.1 Transcriptional and post- transcriptional regulation 
Matrix metalloproteinases  are generally are not synthesised until required, 
supporting the theory that the synthesis of MMPs is highly governed and 
depends on specific stimuli at the transcriptional level (Löffek et al., 2011; 
Rundhaug, 2003). It is well known that the regulation of gene expression is 
mediated by transcription factors that bind to specific sites in the gene 
promoter region (Latchman, 1997; Yan and Boyd, 2007). In terms of MMPs, 
the most crucial transcription factors involved in the regulation belong to the 
NFκB, AP-1, PEA3, and to the signal transducer and activator of transcription 
(STAT) families (Fanjul-Fernández et al., 2010; Yan and Boyd, 2007), which, 
in turn, are increased in response to several stimuli, such as cytokines 
(interleukin [IL]-1, IL-6 and tumour necrosis factor [TNF]), growth factors 
(epidermal growth factor [EGF] and transforming growth factor β [TGF-β]) 
and mechanical stress (Fanjul-Fernández et al., 2010; Sorsa et al., 2004; 
Yan and Boyd, 2007). These extracellular signals mediate the induction of 
MMP expression in mammals through several mitogen-activated protein 
kinase (MAPK) signalling pathways, including extracellular signal-regulated 
kinase (ERK1- 2), stress-activated protein kinase/Jun N-terminal kinases 
(SAPK/JNK) and p38-MAPK (Kerkelä and Saarialho‐Kere, 2003). The basal 
outcome of activating these pathways might be amplified due to the 
contribution of other transcriptional pathways in several cancers (Kerkelä and 
Saarialho‐Kere, 2003). In NSCLC, emerging evidence supports the 
retinoblastoma (Rb)–E2F transcriptional pathway in regulating some MMPs 
(MMP9, 14, and 15) (Johnson et al., 2012). In contrast to stimulation 
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pathways, MMP transcription is suppressed when the SMAD family of the 
transcriptional factors binds to TGF inhibitory elements (TIEs) in the gene 
promoter regions of several MMPs (MMP-1, MMP-7, MMP-13, and MT1-
MMP) (Gorman et al., 2011; Spinale, 2007). Furthermore, epigenetic 
mechanisms, including histone acetylation and DNA methylation, are also 
involved in MMP regulation (Fanjul-Fernández et al., 2010). As post-
transcriptional modulators of MMP gene expression, mRNA stability, protein 
translational efficiency and microRNA-based mechanisms have been shown 
to have been implicated (Fanjul-Fernández et al., 2010). 
1.3.2.2 Post-translational activation of MMPs 
Matrix metalloproteinases share several common properties, one of which is 
the requirement of zinc in their catalytic site for activity. It is well known that 
most MMPs, with the exception of MT-MMPs, are secreted by the cell in a 
latent form as inactive pro-enzymes owing to the presence of a pro-domain 
(John and Tuszynski, 2001; Rundhaug, 2003). This domain interacts with the 
zinc atom at the catalytic site, leading to the inhibition of the enzymatic 
activity (Rundhaug, 2003). Therefore, MMPs require first to be activated 
extracellularly to exert their activity. The removal of the pro-domain is usually 
enough to activate the zymogens (Rundhaug, 2003). This is usually a two-
step process, which includes the destabilisation of the protein by an activator 
protease followed by a final cleavage that is usually catalysed by another 
MMP; for example, the activation of pro-MMP2 by MT1-MMP/MMP14 or 
serine proteases, such as plasmin or furin (Rundhaug, 2003). Once the N-
terminal pro-domain of the zymogens is cleaved, the enzyme becomes fully 
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functional. In terms of MT-MMPs, they are activated intracellularly before 
translocation to the membrane (Overall and López-Otín, 2002). 
1.3.2.3 MMP regulation by endogenous MMP inhibitors 
A more important regulatory mechanism of the MMP activity is shown 
through their specific endogenous inhibitors, the Tissue Inhibitors of 
MetalloProteinases (TIMPs). These low-molecular weight (21-30kDa) 
secreted proteins form non-covalent complexes with active MMPs through 
the binding of the N-terminal domain of the TIMP molecule with the active 
site of the MMP in a stoichometric ratio of 1:1, inhibiting MMP activity (Brew 
et al., 2000). At present, homologous mammalian TIMP family members, 
including TIMP-1, -2, -3 and -4, have been identified (Brew et al., 2000; 
Curran et al., 2001; Gomez et al., 1997). Other endogenous MMP inhibitors 
have also been reported, such as the membrane-anchored glycoprotein 
(RECK) and the plasma protein alpha-2-Macroglobulin (Oh et al., 2001; 
Sottrup-Jensen, 1989). Under normal conditions, the levels of protease and 
inhibitor are firmly balanced for controlling net proteolytic activity (John and 
Tuszynski, 2001). However, this balance between protease and inhibitor is 
lost in some pathological conditions, such as cancer, wherein MMPs are 
mainly overexpressed in tissue while TIMPs do not show such a consistent 
expression pattern (John and Tuszynski, 2001). However, high mRNA 
expression of TIMP1 and several MMP in NSCLC clinical tissues compared 
to normal tissue have been reported in several studies (Jumper et al., 2004; 
Pesta et al., 2011; Safranek et al., 2009), highlighting that TIMP1 was unable 
to inhibit all MMPs associated with tumourigenesis. 
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1.3.3 MMPs and Pathophysiology 
As has been mentioned, controlling MMP expression and activation is critical 
for their proteolytic activity (Rundhaug, 2003). Once they become 
deregulated, serious diseases, such as cardiovascular diseases 
(atherosclerosis and heart failure), tissue ulceration, rheumatoid arthritis and 
cancer, may emerge (Rundhaug, 2003; Woessner, 1991).  
1.3.3.1 Roles of MMPs in cancer 
Despite the role of MMPs in several physiological processes, most attention 
is placed on their functions during the pathological states where the 
degradation of the ECM is the main feature. In terms of cancer, MMP 
proteolytic activity is essential for most cancers, including NSCLC, as it is 
implicated in various stages of disease development, such as migration, 
invasion, angiogenesis and metastasis (Rundhaug, 2003). Figure 1.5 
summarises the contribution of MMP to the numerous stages of cancer 
development. Due to the involvement of the MMPs in these functions, they 
are often highly expressed in the tumour microenvironment of several 
cancers, especially NSCLC (Atkinson et al., 2010). In addition to the 
synthesis of MMPs by tumour cells,  host cells (e.g. fibroblasts) in the tumour 
microenvironment are proven to be another source of MMPs in response to a 
stimulation by several ligands (interleukins and growth factors) that are 
released by tumour cells (Gialeli et al., 2011; Noël et al., 2008). 
This activity of the MMP is not purely due to ECM cleavage (Folgueras et al., 
2004), but also to the release of several growth factors that adhered on the 
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ECM or cell surface. Matrix metalloproteinases make these growth factors 
more accessible to the cancer cells and the tumour microenvironment, 
thereby promoting tumour development (Folgueras et al., 2004). For 
instance, MMPs regulate proliferation through the cleavage of insulin-growth-
factor-binding protein (IGF-BP) and release IGF. They also shed growth 
factors, such as TGF-α and HB-EGF from the cell surface, thereby modifying 
the ECM, which supports growth indirectly via the interactions between the 
integrins and the ECM molecules (Egeblad and Werb, 2002).  
One major mechanism that shows how MMPs support further tumour growth 
is the adverse influence on cell apoptosis. Matrix metalloproteinases are 
reported to cleave the FAS ligand (FASL), a key apoptotic factor, leading to 
the inhibition of apoptosis (Folgueras et al., 2004). In addition, MMP has 
been seen to  activate the serine ⁄ threonine kinase Akt ⁄ protein kinase B by 
indirect activation of EGFR and IGFR (Folgueras et al., 2004), which are both 
frequently up-regulated in NSCLC (Ludovini et al., 2009), resulting in an anti-
apoptotic effect. 
Another contribution of MMPs to cancer progression is through the 
stimulation of cell migration. While the proteolytic activity of the MMPs to 
degrade physical barriers of ECM is needed during cell migration, the 
production of ECM-protein fragments also has further extracellular roles, 
such as cryptic sites from laminin and collagen, which can improve the 
migration of different cell types (Curran and Murray, 2000; Nagase et al., 
2006). Furthermore, MMPs can influence the cell phenotype (epithelial to 
mesenchymal transition (EMT)) and enhance migration through a role in the 
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cell-cell and cell-ECM adhesion by processing E-cadherin and integrins, 
respectively (Gialeli et al., 2011). 
 
 
 
 
27 
 
Figure 1.5. Schematic demonstration of the involvement of MMP in cancer 
progression. MMP modulates four hallmarks of cancer, including tumour growth, 
invasion, metastasis and angiogenesis. MMP in tumour microenvironment is 
synthesised and secreted by both tumour and stromal cells. The degradation of 
ECM by MMP is essential for angiogenesis, tumour cells invasion and 
metastasis. Improving the availability of several signalling molecules, such as 
IGF, bFGF and VEGF EGF, TGF-α and the heparin-binding EGF (HB-EGF)  due 
to MMP-ECM degradation is also critical for tumour growth and angiogenesis. 
The negative regulators of angiogenesis, including angiostatin, tumstatin, 
endostatin and endorepellin, are also released. MMP can influence the cell 
phenotype (epithelial to EMT) and enhance migration through a role in the cell-
cell and cell-ECM adhesion by processing E-cadherin and integrins, respectively. 
Adapted from (Gialeli et al., 2011). 
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1.3.3.1.1 MMPs and tumour angiogenesis 
Matrix metalloproteinases play a dual role in tumour vasculature regulation. 
They can function both as inducers and inhibitors of angiogenesis 
(Rundhaug, 2005). This is dependent on the time point of their expression 
during tumour angiogenesis, as well as on the availability of their substrates 
(Rundhaug, 2003; Rundhaug, 2005). 
Proangiogenic factors, MMPs, such as MMP2, MMP3 and MMP9, are heavily 
implicated in the angiogenesis process, in which they degrade the basement 
membrane. This allows the detachment of the endothelial cells and the 
migration of these cells into the surrounding tissues (Bergers et al., 2000; 
Rundhaug, 2003). Matrix metalloproteinase activity results in a shift in the 
physiological equilibrium between the pro-angiogenic factors and the 
angiogenic inhibitor as a consequence of the MMP proteolytic activity 
(Rundhaug, 2005). Numerous studies have shown that the expression of 
angiogenic inducers, such as bFGF and VEGF, involve MMP activity in 
tumour tissue (Hanahan and Folkman, 1996a; Kerbel and Folkman, 2002). 
Under hypoxic conditions, endothelial progenitor cells secrete MMP9, which 
also induce angiogenesis by releasing VEGF from the ECM (Du et al., 2008). 
In contrast, MMP-mediated degradation of the ECM can also release several 
factors that have an antiangiogenic activity, such as angiostatin, endostatin, 
neostatin, tumstatin and endorepellin (Chang et al., 2005; Heljasvaara et al., 
2005). These small endogenous angiogenesis inhibitors are generated 
through the cleavage of type IV, XVII collagen, plasminogen and the inactive 
precursor of serine proteinase plasmin and perlecan (Iozzo et al., 2009; 
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O'Reilly et al., 1999; Theocharis et al., 2010). Overall, this suggests the 
opposing effects of MMPs as both positive and negative regulators of 
angiogenesis as shown in Figure 1.5. 
1.4 MMP Inhibition as a Therapeutic Strategy for Cancer 
The understanding that MMP expression is enhanced in many cancer types 
supports the rationale for targeting MMPs in cancer therapy (Egeblad and 
Werb, 2002). This strategy is strongly supported by in vitro and animal model 
studies that show MMP inhibition as beneficial (Folgueras et al., 2004). More 
than 50 matrix metalloproteinase inhibitors (MMPIs) have been tested as 
clinical candidates over the last decade (Zucker and Cao, 2009). 
Hydroxamates, such as Batimastate and Marimastat, were first generation 
MMPIs that showed a good potential in preclinical studies. They were, 
however, broad spectrum inhibitors and not available orally. To overcome the 
latter issue, second generation MMPIs were introduced. They entered phase 
III clinical trials for the treatment of diverse types of advanced cancers 
(Fingleton, 2003; Overall and Kleifeld, 2006; Zucker et al., 2000). 
Unfortunately, broad spectrum MMP inhibitors failed to provide significant 
anti-tumour effects in the clinic. Instead, they were found to be associated 
with adverse patient outcomes and a number of serious side effects, such as 
tendonitis and myalgia (Bissett et al., 2005; Coussens et al., 2002; 
Nemunaitis et al., 1998; Pavlaki and Zucker, 2003). Many patients who were 
enrolled into the clinical trial of MMPI declined to participate further because 
of the decrease in their quality of life (Pavlaki and Zucker, 2003).  
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The lack of success of the MMP inhibitors in clinical trials was attributed to 
several reasons, which include the following: Only patients with advanced 
cancer stage were included in the trial despite some inhibitors demonstrating 
potential activity at the early stage in animal models. An unrealistic endpoint 
(reduction in tumour size) was used while time to tumour progression or 
patient survival benefit was more appropriate. Treatment response could not 
be monitored as no prognostic marker was available. Toxicity resulted from 
the poor selectivity of these inhibitors due to the close homology of the 
catalytic domains of different MMPs, with many MMPs now known to 
contribute to tumour-inhibition (Sparano et al., 2004). 
In summary, the previous trials of MMPI’s showed that a general systemic 
inhibition of a broad spectrum of MMPs as a therapeutic strategy was too 
simplistic. Such an approach did not consider the physiological and non-
ECM-degrading properties affected by the broad spectrum inhibition of MMPs 
(Szarvas et al., 2011). Fortunately, this time elucidation of the specific roles 
of MMPs and their complex mechanisms are more complete. It’s worth 
noticing that the discovery of other metalloenzymes such as ADAMS, which 
were demonstrated to be involved in tumour growth and progression (Duffy et 
al., 2009a), further supports the inhibition of MMP-associated enzymes as  
an attractive target for cancer therapy. In this regards, there are other 
protease families (e.g. cysteine and aspartic) which also provide good targets 
for therapeutic intervention given their expression and activity in cancer 
development (Palermo and Joyce, 2008; Ullmann et al., 2004), however the 
main focus of this research will be restricted to MMPs. 
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Overall, it is now clear that different MMPs can play opposing roles in cancer.  
Some MMPs may be beneficial for inhibiting the cancer process, indicating 
that they should not be targets for inhibition themselves (Rundhaug, 2003). 
For instance, MMP3-deficient mice demonstrate an increase in pulmonary 
metastasis compared to wild-type (McCawley et al., 2004). Furthermore, 
tumours in MMP12-deficient animals demonstrate greater angiogenesis as a 
result of the reduction of angiostatin synthesis (Acuff et al., 2006). 
Interestingly, studies have shown that specific MMPs can demonstrate 
contradictory negative and positive roles during the development of the 
disease (Rio, 2005). For example, stromelysin-3 (MMP11), demonstrating a 
collagenolytic activity specifically against collagen VI at normal and tumour 
tissue (Motrescu et al., 2008), is a stimulator for primary tumour progression, 
but is also an inhibitor for metastasis (Rio, 2005). Therefore, the complexity 
of the MMP functions has a serious impact on the possibility of using MMPs 
as a target for therapy. 
With respect to tumour angiogenesis, although MMPs in general have 
opposing effects as both positive and negative regulators of angiogenesis, 
controlling angiogenesis through targeting selected MMPs remains a 
potential therapeutic approach for cancer (Rundhaug, 2003). It is, therefore, 
crucial to elucidate the specific role of individual MMPs in tumour evolution 
and progression with respect to their validity as target or anti-targets for 
therapeutic exploitation. 
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1.5 MMP10 in NSCLC 
In comparison to other MMPs, little is known about the involvement of 
MMP10 (stromelysin-2), a secreted endoproteinase, in NSCLC tumour 
development, although its expression is associated with poor clinical 
outcomes in NSCLC patients (Frederick et al., 2008). Unlike several other 
MMPs that are localised predominantly in tumours surrounding the stroma, 
MMP10 is found to be localised predominantly in tumour cells (Gill et al., 
2004; Kerkela et al., 2001). Several studies have shown that MMP10 is 
extensively expressed by tumour cells (Gill et al., 2004; Impola et al., 2004; 
Kerkela et al., 2001; Muller et al., 1991; Nakamura et al., 1998). One main 
feature of MMP10 is the broad substrate specificity. In vitro, it can degrade 
elastin, nonfibrillar collagens, proteoglycans, gelatin, and casein (Duffy et al., 
2000; Egeblad and Werb, 2002; Murphy et al., 1991; Nicholson et al., 1989; 
Vihinen and Kähäri, 2002). In vivo, it degrades numerous ECM proteins such 
as collagen type IV, laminin, proteoglycans and fibronectin (Baricos et al., 
1988; Bejarano et al., 1988; Nicholson et al., 1989; Saunders et al., 2005). 
MMP10 participates also to activate several proMMPs, including proMMP 1, 
7, 8, 9 and 13 (Nakamura et al., 1998; Ramos-DeSimone et al., 1999). In 
general, degradation of specific substrates by MMP10 as well as other MMPs 
might be through  an interaction between conserved glutamic acid, zinc ion 
and water molecule at the cleavage site during the acid-base catalysis 
reaction. A full description of the mechanism is shown in figure 1.6. High 
expression levels of MMP10 have been reported in many different tumour 
types, such as carcinoma of the head and neck, NSCLC, oesophageal and 
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oral squamous cell carcinoma (SCC) and squamous and basal cell 
carcinomas of the skin (Gill et al., 2004; Impola et al., 2004; Kerkela et al., 
2001; Mathew et al., 2002; Rhys-Evans and Eccles, 2001). In particular, 
significantly higher levels of proteolytically active MMP10 are detected in 
NSCLC as compared to corresponding normal lung tissue (Gill et al., 2004). 
The elevation of MMP10 expression in NSCLC is independent of tumour 
grade, stage, histological type or lymph node status (Gill et al., 2004).  
Interestingly, high levels of MMP10 mRNA are observed in tumour tissues 
from recurrent human NSCLC patients following surgical resection, 
supporting MMP10 as a prognostic marker for patients with high risk of 
recurrence (Cho et al., 2003). In an animal study, a complete knockout of 
MMP10 results in the development of fewer tumours, indicating the role of 
MMP10 in tumour initiation (Frederick et al., 2008). In the same study, an 
overexpression of MMP10 in primary NSCLC tumours was observed and the 
high MMP10 expression was correlated to poor survival. MMP10 has been 
also reported to support the autonomous growth of cancer stem cells in lung 
tumours, resulting in an improvement in tumour-initiating activity, tumour 
maintenance and metastasis, thereby promoting lung cancer formation 
(Frederick et al., 2008; Justilien et al., 2012). Together, these findings 
suggest that MMP10 can also be expressed in the early stages of tumour 
and that they play a role in the development of human NSCLC rather than 
just tumour invasion and metastasis (Gill et al., 2004; Kerkela et al., 2001; 
Seargent et al., 2005). Further investigation of the nature of the role of 
MMP10 in NSCLC is required. 
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Figure 1.6. Schematic description of proteolysis mechanism by MMP. 
Zn:zinc; Glu: glutamic acid; Ala: alanine Adapted from (Verma and Hansch, 
2007) 
 
1.6 Regulation of MMP10 Gene Expression 
Like other MMPs, MMP10 gene expression is tightly regulated at the 
transcriptional level. Its gene is only expressed when transcriptional factors 
are activated in response to several stimuli, such as cytokines, chemokines, 
growth factors, matrix protein, adhesion molecules, matrix protein fragments 
and hormones (Nagase and Woessner, 1999; Sternlicht and Werb, 2001). In 
addition to the universal transcriptional factors involved in the regulation of 
MMP gene expression (previously described in section 1.3.2.1), CHF1/Hey2, 
MEF-2 and STAT3 transcription proteins are reported to have been 
implicated, specifically in controlling the MMP10 gene expression (Ishikawa 
et al., 2009; Wu et al., 2011; Zhang et al., 2009). Additionally, the 
transcriptional regulation of MMP10 is believed to be influenced by epigenetic 
mechanisms, such as histone acetylation (Chang et al., 2006; Ha et al., 
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2008; Ishikawa et al., 2009), as evidenced by histone deacetylase 7 down-
regulation in two cellular pathway studies (Chang et al., 2006; Ha et al., 
2008). These studies did not address the regulation of the MMP10 gene 
expression by histone deacetylases (HDACs) in the context of cancer; 
therefore, this relationship received more focus in the study reported here. 
1.6.1 Histone Deacetylases 
Histone deacetylases are a class of enzymes that remove acetyl groups from 
ε-N-acetyl lysine amino acid on histones (Sengupta and Seto, 2004). They 
are generally grouped into two major classes: class I (HDAC1, 2, 3 and 8) 
and Class II (HDAC4, 5, 6, 7, 9 and 10) (Sengupta and Seto, 2004). In 
contrast to class I HDACs, which are located predominantly in the nucleus, 
Class II HDACs, including HDAC7, constantly shuttle between the nucleus 
and cytoplasm (Harms and Chen, 2007; Kim et al., 2007; Lagger et al., 
2002). The deacetylation of histone proteins is the initially discovered and 
best understood enzymatic activity of HDACs. During this process, HDACs 
can regulate the interaction of positively charged histones with the negatively 
charged DNA and, as a consequence, control chromatin conformation and 
transcriptional activity. High levels of histone acetylation (hyperacetylation) 
are associated with improved transcriptional activity while low levels of 
acetylation (hypoacetylation) are linked with the suppression of gene 
expression (Forsberg and Bresnick, 2001; Ito et al., 2000; Wade, 2001). 
Among other HDACs, HDAC7 is of particular interest to this research as it 
was reported to specifically regulate MMP10 gene expression (Chang et al., 
2006). 
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1.6.2. Regulation of MMP10 by HDAC7 
It has been reported that HDAC7 regulates MMP10 gene expression through 
the transcriptional factor (myocyte enhance factor 2 [MEF2]) in endothelial 
cells (Chang et al., 2006). In vivo silencing of HDAC7 in the vascular 
endothelium during early embryogenesis causes a failure in endothelial cell-
cell adhesion, dilatation and collapse of blood vessels, leading consequently 
to embryonic lethality (Chang et al., 2006). Histone deacetylases-7 contains 
a small N-terminal peptide sequence that linked them to MEF2, resulting in 
the repression of MEF2 target genes (Verdin et al., 2003). Following the 
exposure of endothelial cells to VEGF, the phosphorylated protein kinase D 
(PKD) is translocated from the cytoplasm to the nucleus, leading to HDAC7 
phosphorylation at ser178, ser344 and ser479 residues in the N-terminal. 
This creates docking sites on the HDAC7 for the 14-3-3 chaperone proteins 
to bind on (Kao et al., 2001), thereby stimulating the shuttling of the HDAC7 
from the nucleus to the cytoplasm and resulting in HDAC7 cytoplasmic 
accumulation. It is well known that HDAC7 suppresses the promoter of the 
MMP10 gene through interaction with the MEF2, a direct activator of MMP10 
transcription and a key regulator of blood vessel development. The low level 
of HDAC7 in the nucleus leads to free MEF2 and allow p300 to bind with 
MEF2. This results in the induction of MEF2-dependent transcription of the 
target gene for MMP10 (Ha et al., 2008) (figure 1.7). 
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Figure 1.7. PKD1-dependent phosphorylation of HDAC7 upon VEGF. 
signalling. In response to VEGF ligand on the cell membrane, a downstream 
signalling cascade involving PKD1 is activated, leading to HDAC7 
phosphorylation. This allows 14-3-3 chaperon protein to catalyse the shuttling 
of HDAC7 from the nucleolus to the cytoplasm, resulting in a free MEF2. At 
this stage, the free MEF2 binds to P300, allowing the stimulation of the 
MEF2-dependent transcription of the MMP10 gene. Adapted from (Ha et al., 
2008) with a slight modification. 
 
1.7 Limitations of Classical Chemotherapeutics 
Currently, the efficacy of chemotherapeutics is unquestionable and cancer 
treatment still highly depends on these cytotoxins. However, there are key 
disadvantages to the use of conventional chemotherapy, notably narrow 
therapeutic index and drug resistance. In an attempt to overcome these 
issues, a molecular targeted approach on the inhibition of pathways that drive 
the cancer process has been focused on in the last 15 years. This was 
intended to reduce systemic toxicity associated with cytotoxic drugs, adopting 
P300 
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a more conventional pharmacological approach to cancer treatment. 
However, this therapeutic approach against malignancies has not been as 
successful as was predicted. The molecular targeted drugs are not good at 
debulking tumours and they possess significant normal tissue toxicity on their 
own (Huang and Oliff, 2001). Subsequently, majority of molecular targeted 
therapies are frequently used in combination with classical 
chemotherapeutics. This has led to a resurgence in the interest on 
developing chemotherapeutics using approaches that address their negative 
effect on normal tissue. One such approach is the re-emergence of the 
development of prodrugs. 
1.8 The Prodrug Concept 
The most significant goals of current cancer drug discovery are to delineate 
between toxicity to healthy tissue and the tumour. This requires the 
development of new therapeutics with increased tumour discrimination, lower 
systemic toxicity and, consequently, a wider therapeutic margin. A possible 
approach has emerged that meets all these requirements is the use of 
cancer chemotherapeutic prodrugs. The term prodrug was first described by 
Adrien Albert in the 1950’s (Albert, 1958) as an inactive compound that 
needs to be enzymatically or chemically converted to the active drug in vivo 
to exhibit a pharmacological effect. The prodrug approach is currently used to 
improve the biopharmaceutical, physicochemical or pharmacokinetic 
properties of pharmacological agents. These parameters include chemical 
instability, poor aqueous solubility, rapid pre-systemic metabolism, deficient 
oral absorption and local irritation. In terms of drug targeting improvement, 
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when existing drugs are re-developed as a prodrug, this can prolong the life-
cycle of patented drugs (Rautio et al., 2008). Designing new agents as 
prodrugs is a growing trend worldwide, with up to seven percent of approved 
drugs categorized as prodrugs (Rautio et al., 2008).  
The deep understanding of pharmaceutical concepts alongside tumour 
biology has enabled the design of pharmaceutically more complex prodrugs 
with improved targeting (Huttunen et al., 2011). This thesis focuses on 
exploiting MMP10 expression to improve tumour-targeting for a prodrug 
development strategy. A prodrug not only improves the pharmacokinetic 
properties of a compound; it also restricts the pharmacological effect of a 
drug to its intended tissue. Thus, there is a strong rationale to use this 
approach to develop smart anticancer drugs. 
1.8.1 Tumour-Activated Prodrugs (TAPs) 
A number of methods have been employed to develop prodrugs that rely on 
tumour biology. These include antibody- or gene-directed enzyme prodrug 
therapy, antigen targeting, and tumour enzyme-activated chemotherapy. The 
latter approach, in particular, takes advantage of the elevated enzymes that 
are selectively present in the tumour microenvironment to activate a prodrug. 
This has demonstrated great promise with the development of bioreductive 
drug AQ4N, polymer-paclitaxel conjugate (Ct-2103), polymer-doxorubicin 
conjugates (PK1, FCE28068) and the approved brentuximab vedotin (an 
antibody- auristatin E conjugate) (Albertella et al., 2008; Atkinson et al., 2010; 
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Choi et al., 2012; Patterson, 2002; Paz-Ares et al., 2008; Senter, 2009; 
Seymour et al., 2009). 
In the development of tumour-activated prodrugs (TAPs), the effective 
therapeutic entity is required to be masked until only being activated in the 
malignant tissue by tumour enzymes, such as endoproteases (Atkinson et 
al., 2008; Denny, 2001). The structure of a TAP must contain three domains: 
the trigger, linker and effector. The trigger is linked to the effector. The 
function of the trigger is to control selectivity and the effector is responsible 
for the therapeutic effect. The cytotoxic effect of a prodrug is ideally released 
only when the trigger is activated in the tumour and not in any other tissue 
(Atkinson et al., 2008; Denny, 2001) (see Figure 1.8).  
The selection of enzymes to activate TAPs is the most critical step in the 
development of these agents. The main features of the tumour enzyme 
appropriate for targeting TAPs are as follows: 
 1. Enzyme has relatively high affinity to the prodrug. 
 2. Overexpression and high activity in the tumour environment. 
 3. Low or no expression of enzyme in normal tissues. 
 4. Enzyme can rapidly activate the prodrug (Atkinson et al., 2008). 
 Proteolytic endoproteases, especially metalloproteases, are now considered 
to satisfy these criteria for TAP development. Consequently, they have 
received much attention. 
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Figure 1.8. Schematic description of TAPs therapeutic strategy. This 
concept is not exclusive for proteolytic endoproteases, but they were used 
above to exemplified enzymes that meet the requirement for TAP 
development. The primary structure of TAPs involves trigger, linker and 
effector. No cytotoxicity is exhibited until the prodrug is activated by tumour 
enzymes, such as endoproteases. Adapted from (Atkinson et al., 2008). 
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1.8.2 MMPs as Target for Tumour Selective Anticancer Drug 
Delivery 
The focus on proteases provides a wide range of opportunities in the process 
of prodrug development. Proteases account for about 2% of mammalian 
genes and 5% of all drug targets (Atkinson et al., 2008; Lee et al., 2004; 
Overall and Blobel, 2007; Overall and Dean, 2006). Several classes of 
proteases (Cysteine, metalloproteases and serine) have been investigated as 
prodrug activators (Atkinson et al., 2008; Lee et al., 2004; Lim and Craik, 
2009). Given their high and often selective activity in tumours and ability to 
cleave short peptides, the MMPs are an attractive class of prodrug activating 
enzymes. 
The overexpression of numerous MMPs is linked to poor clinical outcome in 
several cancers, including gastric (MMP 2 and 9), breast (MMP 11), NSCLC 
(MMP 3, 10, 11 and 13) (Atkinson et al., 2008; Atkinson et al., 2007; Bodey 
et al., 2000; Brinckerhoff et al., 2000; Hoekstra et al., 2001; Kamat et al., 
2006; Vizoso et al., 2007), oesophageal (MMP-7), SCLC  (MMP-3, MMP-11 
and MMP-14) (Hoekstra et al., 2001; Vizoso et al., 2007). 
The difference in MMP expression and the activity between malignant and 
normal tissue can be exploited to activate TAPs, in principle leading to a high 
concentration of active anticancer drug only in the tumour tissue. This was 
confirmed experimentally when MMPs were shown to activate cytotoxic 
anthracycline prodrugs into active cytotoxins. In vivo, various peptide 
derivatives of doxorubicin were enzymatically converted into active agents by 
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MMPs. These peptide derivatives demonstrated a lower systemic toxicity with 
higher anti-tumour efficacy in comparison to doxorubicin itself (Albright et al., 
2005; Lee et al., 2006). Although these results were promising, it has been 
reported that successful releasing of potent chemotherapeutic in the intended 
site is highly dependent on the catalytic efficiency of MMPs and their 
expression (Atkinson et al., 2008). Therefore, the enzymatic competence and 
appropriateness of individual MMPs must be taken into consideration when 
designing TAPs. 
1.8.2.1 Tumour-activated prodrugs directed to the matrix 
metalloproteinases 
Several structure-activity relationship studies that evaluate the specificity of 
many MMPs against synthetic peptide substrates have been described. 
These include MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP13 and 
MMP14 (Deng et al., 2000; Netzel-Arnett et al., 1991; Turk et al., 2001). This 
has led to the identification of a structure-activity relationship that can be 
used to distinguish between the peptide substrate selectivity of different 
MMPs, a feature useful in designing TAPs selective to specific MMPs. As 
there is, in particular, a lack of data about the cleavage site specificity of 
MMP10, further structure-activity relationship studies in this regard are 
required. 
The choice of cytotoxin to be developed as a prodrug is equally important. 
Colchicine is a plant alkaloid extract that is classified as a mitotic spindle 
poison or tubulin inhibitor. Colchicine and its derivatives are shown to inhibit 
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microtubule polymerisation by binding to tubulin, leading to the blocking of 
the mitosis of cells (Stanton et al., 2011). Due to the potent antimitotic 
capability of colchicine, it can be rationalised as an effective anticancer 
therapy. It has also been shown that when colchicine enters the blood supply 
of solid tumours, it destroys the endothelial cells that constitute the blood 
vessels, disrupting the tumour blood supply. This results in a reduction of 
tumour mass due to a starvation of oxygen and nutrients supply (Gaya and 
Rustin, 2005). Targeting the tumour vasculature by systemically activating 
tubulin binding inhibitors based on colchicine has been used as a strategy for 
the development of vascular disrupting agents (VDAs). One problem with this 
approach is their narrow therapeutic index and recognised cardiac toxicity 
(Chaplin et al., 1996). On this basis, a TAP approach to improving the 
therapeutic index of colchicine utilising MMPs is most attractive. 
1.9 Aims and Objectives 
Despite the development of a number of molecular targeted therapeutics to 
treat NSCLC, their efficacy is modest, such that the mean five-year survival 
rate of NSCLC has not greatly improved in the last decade. The use of 
chemotherapeutics has reached the limit, in part due to toxicity and drug 
resistance. This highlights the need for the identification of new molecular 
targets that can be either targeted for novel therapeutics or exploited to 
improve the tumour delivery of current chemotherapeutics, thereby 
minimising systemic toxicity. Matrix metallopeptidase 10 is a candidate for 
TAP developed for NSCLC based on its expression and contribution to 
NSCLC development. Specifically, the high expression and associated 
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catalytic activity of MMP10, which is observed in NSCLC compared to normal 
tissue, indicates its use in the design of NSCLC TAPs.  
The overall aim of this project is to further explore the expression profile of 
MMP10 in the tumour microenvironment of NSCLC and evaluate it as a 
target for therapeutic intervention. 
The specific objectives include: 
 Characterisation of preclinical models for the evaluation of MMP10 
functionality in NSCLC by screening the MMP10 mRNA and protein 
levels in a panel of NSCLC cell lines. In addition, mass spectrometric-
based proteomics techniques for the detection of secreted MMP10 will 
be evaluated.  
 Development of functionally active high MMP10 expressing in vitro 
models for the evaluation of the role of MMP10 in NSCLC. 
Overexpression models will be developed either by direct transfection 
with MMP10 or by the functional alteration of MMP10 levels due to the 
knockdown of HDAC7. The functionality of MMP10 will be evaluated 
using an assay to assess effects on vascularity, the tube formation 
assay.  
 Identification of MMP10-specific cleavable sequences to incorporate 
into MMP10 targeted TAP. To achieve this, several known 
commercially available MMP substrates and MMP-targeted 
compounds developed in-house will be assessed for cleavability by 
MMP10 using LC-MS techniques. 
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Chapter 2: General Materials and Methods 
2.1 Materials 
All chemicals, solutions and media were stored at 4°C unless otherwise 
specified. 
2.1.1 Cell culture 
All plasticware were bought from Corning (Amsterdam, The Netherlands). 
Cell culture medium, supplements and chemicals, including Roswell Park 
Memorial Institute (RPMI) 1640 culture medium, Hanks’ Balanced Salt 
Solution (HBSS) (stored at room temperature (RT)), Foetal Calf Serum 
(FCS), L-glutamine, Sodium pyruvate, trypsin/ethylenediaminetetraacetic 
acid (EDTA) (stored at -20°C) and dimethyl sulfoxide (DMSO) (stored at RT), 
were all obtained from Sigma-Aldrich (Poole, Dorset, UK). For in vivo work, 
female BALB/c immunodeficient nude mice were purchased from Harlan 
Laboratories, Inc. (Blackthorne, UK). 
2.1.1.1 Cell lines 
The human NSCLC cell lines (A549, H460, and H661), human colorectal 
adenocarcinoma cell line Colo205 and fibrosarcoma cell line HT-1080 were 
all obtained from the American Type Culture Collection (ATCC) (Middlesex, 
UK). The three lung cancer cell lines were chosen as they represent two of 
the most common subtypes of NSCLC, the main focus of this research. The 
HT-1080 cell line was used because of its known high expression of multiple 
MMPs, while the Colo205 was due to its overall weak expression of MMPs as 
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previously reported (Atkinson et al., 2010). Table 2.1 outlines the origin of the 
human cell lines used in this project. 
 
Table 2.1. Cell Line General Information 
Cell Line Origin/Source Reference 
A549 Lung carcinomatous tissue from a 58-
year-old Caucasian male 
(Giard et al., 1973) 
H460 Pleural fluid from a male patient with 
large cell cancer of the lung 
(Banks-Schlegel et al., 
1985) 
H661 Lymph node metastasis from large cell 
cancer of the lung in a 43-year-old 
Caucasian male 
(Banks-Schlegel et al., 
1985) 
Colo205 Ascitic fluid from a 70-year-old 
Caucasian male with carcinoma of the 
colon 
(Semple et al., 1978) 
HT-1080 Fibrosarcoma arising adjacent to the 
acetabulum of a 35 year old Caucasian 
male 
(Rasheed et al., 1974) 
 
2.1.2 Gene Expression Analysis 
Chemicals for mRNA analysis, including β-mercaptoethanol (β-ME), 
phosphate buffered saline (PBS), ethanol, tris base, glacial acetic acid, 
EDTA, gel loading buffer, agarose and ethidium bromide, were obtained from 
Sigma-Aldrich and stored at RT. 3-(4,5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) was also purchased from Sigma-Aldrich. 
RNeasy Mini Kit, RNase-Free DNase Set and Taq DNA Polymerase PCR Kit 
were purchased from Qiagen (Crawley, UK) and stored at -20°C. The 
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RevertAid First Strand cDNA Synthesis Kit was purchased from Thermo 
(Loughborough, UK) and stored at -20°C. PCR primers and 1KB Plus DNA 
ladder were obtained from Life Technologies Ltd (Paisley, UK) and stored at -
20°C. 
2.1.3 Protein Expression Analysis 
Tris-HCl (BioRad Laboratories), Sodium Chloride (NaCl), ethylene glycol 
tetraacetic acid (EGTA), dithiothreitol (DTT), Triton-X-100, protease inhibitor 
solution, Sodium Dodecyl Sulfate (SDS), Bovine serum albumin (BSA), 
plastibrand disposable cuvettes, tetramethylethylenediamine (TEMED), 
Glycine, Ponceau S solution, sodium deoxycholate, urea, thiourea, 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 4-
aminophenylmercuric acetate (APMA) and phosphatase inhibitor cocktail 2 
and 3 were purchased from Sigma-Aldrich. Complete Mini EDTA-free 
protease inhibitor cocktail (PIC) tablets were bought from Roche Diagnostics 
Limited (Sussex, UK). Bradford dye reagent and acrylamide/bisacrylamide 
mix were purchased from BioRad Laboratories (Hertfordshire, UK). 
Ammonium persulfate (AP), full range rainbow marker 10-250kDa, Hybond 
nitrocellulose membranes (stored at -20°C), blotting papers and hyper X-ray 
film (both stored at RT) were bought from Amersham Biosciences 
(Buckinghamshire, UK). High purity methanol was obtained from Fisher 
Scientific (Loughborough, UK) and stored at RT. Full length recombinant 
human MMP3 and MMP10 proteins were purchased from R and D system 
(Abingdon, UK). B-actin primary antibody A1978 was purchased from Sigma-
Aldrich and the HDAC7 antibody C-18 was from Santa Cruz Biotechnology 
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(Heidelberg, Germany). In addition, MMP10 antibody Ab49473 and MMP3 
antibody ab38907 were bought from Abcam (Cambridge, UK). All 
recombinant proteins and primary antibodies were aliquoted upon receipt and 
stored at -20°C until required. All secondary antibodies, including Polyclonal 
Goat anti-rabbit and Polyclonal rabbit anti-mouse, were purchased from Dako 
Cytomation (Cambridgeshire, UK). Western Lightning™ plus-ECL Enhanced 
Chemiluminescence substrate (ECL) was obtained from PerkinElmer 
(Cambridge, UK). 
2.2 Methods 
2.2.1 Cell Lines Maintenance 
All epithelial cell lines were routinely maintained as monolayer cultures in 
RPMI-1640 medium supplemented with 1mM Sodium Pyruvate, 10% FCS 
and 2mM L-Glutamine. All cells were incubated at 37°C in a humidified 
atmosphere of 5% CO2 and 95% air. 
Cells were passaged when a confluency of no more than 80% was reached. 
Cells were washed with HBSS and detached using 0.25% Trypsin-EDTA 
solution at 37°C. Cells were collected through the addition of complete 
medium, with the resulting cell suspension centrifuged at 1500g for five 
minutes and the cell pellet resuspended in fresh complete medium. For 
studies requiring the calculation of the cell number, 10μl of cell suspension 
was added to each chamber of the haemocytometer. Under a microscope, 
cell numbers were counted in five 1mm x 1mm squares of each chamber of 
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the haemocytometer and the mean value calculated and expressed as 
number of cells/mL. 
2.2.2 Growth Curve Analysis 
Growth curve analysis was performed to determine the growth pattern of 
NSCLC and the endothelial cell lines used in this project. Cells at 
concentrations of 1x104 cells/cm2 were seeded in twelve 25cm2 flasks in 
10mL of complete RPMI medium. On days one, three, five, seven, nine and 
11, the number of cells grown in the two flasks was determined using the 
haemocytometer. The mean density was also calculated. For all the four cell 
lines, the data obtained was used to plot the growth curves of time versus 
cell number.   
2.2.3 Animals and Experimental Tumour System 
All the in vivo work in this research was carried out by experienced ICT staff 
holding the appropriate Home Office licences. Female Balb/c 
immunodeficient nude mice were housed according to the guidelines for the 
welfare of animals of the Institute of Cancer Therapeutics (ICT), which was 
approved by the Home Office and met all current regulations and standards 
of the United Kingdom. Mice were fed Teklad 2018 diet (Harlan) and water 
ad libitum and were accommodated in an air-conditioned room with regular 
alternating cycles of light and darkness. Mice with ages between six and 
eight weeks were used in this project. All animal procedures were carried  out 
under a project licence issued by the UK Home Office and following the UK 
National Cancer Institute guidelines (Workman et al., 2010).  
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Cultured cells in vitro were harvested by trypsinisation and one million cells 
were injected into each flank of nude mice. Tumours were allowed to grow 
until they reached ∼17 mm in size. When they were removed, they were 
snap-frozen in liquid nitrogen and stored at −70°C.  
2.2.4 Reverse Transcription-Polymerase Chain Reaction (RT-
PCR) 
Reverse transcription-polymerase chain reaction was used in this project as 
described below: 
2.2.4.1 RNA extraction 
Total RNA was extracted from each sample using the RNeasy Mini Kit 
according to the manufacturer’s protocol. All centrifugation steps were carried 
out at 8,000g at room temperature unless otherwise stated. Initially, cells 
were grown, harvested and counted as described in section 2.2.1. Cell 
pellets were directly lysed in 600µL lysis buffer RLT with 1% β-ME. The tube 
was vortexed and the lysates were transferred into a QIAshredder spin 
column for complete homogenisation. In the case of tissue samples, 30ug of 
frozen tissue was immediately ground to a fine powder in liquid nitrogen 
using a mortar and pestle prior to the addition of the lysis buffer. Following 
centrifugation of the QIAshredder spin column for two minutes at 10,000g, 
600µL of 70% ethanol was added to the homogenised lysate. This was then 
transferred to a RNeasy spin column. The tube was then centrifuged for 15 
seconds and the flow-through discarded. The RNA attached to the RNeasy 
spin column membrane was subsequently washed with 350µL of Buffer 
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RW1. The column was then centrifuged and the flow-through carefully 
discarded. To eliminate genomic DNA contamination, RNA was treated for 15 
minutes with DNase I enzyme mix diluted at 1:8 ratio in buffer RDD. RNeasy 
spin column was washed with 350µL of Buffer RW1 and then centrifuged. 
The flow-through was carefully discarded. This washing was repeated twice 
using 500µL buffer RPE. RNA was eluted by the addition of 30µL of RNase-
free water directly to the spin column membrane and centrifuged for one 
minute. The RNA samples were then either directly quantified and subjected 
to RT-PCR analysis or simply stored at -70°C until required for further use. 
2.2.4.2 RNA quantification analysis 
For the determination of the RNA concentration, 2uL of the RNA was 
analysed using a Thermo Scientific NanoDrop™ 1000 Spectrophotometer. 
Concentration was calculated based on one absorbance unit at 260nm, 
equivalent to 40μg of RNA per mL. The ratio between the absorbance at 
260nm and 280nm was used to evaluate RNA quality, such that RNA 
samples that have values located in the range of 1.9–2.1 were of high 
enough quality for complementary DNA (cDNA) synthesis. 
2.2.4.3 cDNA synthesis using reverse transcriptase enzyme 
Reverse transcription of mRNA to cDNA was carried out using the RevertAid 
First Strand cDNA Synthesis Kit according to manufacturer’s instructions. All 
reagents were thawed and kept on ice before and during the procedure. For 
each RNA sample to be reverse transcribed, a control reaction without 
reverse transcriptase was also performed to examine genomic DNA 
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contamination. A total of 1μg of RNA sample template was added to 1µL of 
oligo (dT)18 primer and then adjusted to a final volume of 12μL with 
nuclease-free water. Samples were denatured at 65°C for five minutes and 
then quenched promptly on ice to ensure primer annealing. Around 4µL of 5X 
Reaction Buffer, 1µL of RiboLock RNase Inhibitor (20u/µL) and 1µL of 10mM 
dNTP mix were then added to each sample. For positive samples only, 1µL 
of RevertAid M-MuLV Reverse Transcriptase enzyme (200u/µl) was then 
added to the reaction mixture. In parallel, 1uL of nuclease-free water was 
added to the negative controls. All samples had a final volume of 20µL. 
cDNA was synthesised via  the incubation of samples at 42°C for one hour to 
allow the RNA to be reverse transcribed, followed by the inactivation of the 
enzyme at 70°C for five minutes. cDNA was diluted at a 1:5 ratio with 
nuclease-free water before being subjected to PCR application or stored at -
70°C until required. 
2.2.4.4 PCR primers design and selection 
The PCR primers for HDAC7 and MMP10 genes were designed in-house 
according to the human sequence obtained from Genbank. Primer 
sequences for other MMPs, including MMP1, 2, 7, 8, 11, 12, 13, 14, 15, 16, 
17, 19, 20, 21, 23, 24, 25, 26 and 28, were chosen based on the findings of 
(Köhrmann et al., 2009). The primers used for MMP3 and MMP9 were based 
on those designed by Konttinen et al. (Konttinen et al., 1999; Yao et al., 
2001), respectively. One set of primers for Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), a house keeping gene, were also used based on 
those designed by Daja et al.(Daja et al., 2003). The primer Basic Local 
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Alignment Search Tool (primer -BLAST) was used to ensure that every 
primer's nucleotide sequence was specific and related to the human DNA 
sequence. All primers were custom-made. When received, they were 
reconstituted and adjusted with nuclease-free water to give a final 
concentration of 100μΜ prior to being aliquoted and stored at -20°C. Primer 
sequences are summarized in Table 2.2. 
2.2.4.5 PCR protocol 
PCR reactions were carried out using the Taq DNA Polymerase PCR Kit. All 
kit components were thawed and kept on ice during the procedure. 
Approximately 20uL of reaction mixture containing 5ng template DNA, 2.5 
units Taq polymerase, 10% standard reaction buffer, 20% of 5x Q-Solution, 
200μM dNTPs and 0.5μM of both forward and reverse primers was prepared. 
In the PCR tube, the reaction mixture was thoroughly mixed and centrifuged 
to ensure that all the liquid were collected at the bottom of the tube. PCR for 
the gene of interest was performed using an MJ PTC-200 thermal cycler and 
consisted of the optimal condition for each primer pair as described in Table 
2.2. For each cDNA sample, a negative control (sample produced in absence 
of reverse transcriptase) was used to detect any genomic DNA contamination 
or non-specific amplification in the reaction. In addition, cDNA samples 
amplified in the presence of GAPDH primers were used as positive controls 
to verify the success of cDNA synthesis and PCR functionality. 
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Table 2.2. Human Primers’ Sequence and Their Optimal Conditions Used for RT-
PCR Analysis. Length of PCR products are listed in base pairs (bp). F refers to 
forward while R is for reverse primer. 
Gene Primer Sequences PCR Conditions 
cDNA  
Size (bp) 
MMP1 
F: 5’-AAGGCCAGTATGCACAGCTT-3’ 
R:5’-TGCTTGACCCTCAGAGACCT-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 58°C, 60 sec at 72°C) 32 
cycles–10 min at 72°C 
480 
MMP2 
F: 5’-TTTCCATTCCGCTTCCAGGGCAC-3’ 
R:5’-TCGCACACCACATCTTTCCGTCACT-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 60°C, 40 sec at 72°C) 36 
cycles–10 min at 72°C 
253 
MMP3 
F: 5’-CTCACAGACCTGACTCGGTT -3’ 
R:5’-CACGCCTGAAGGAAGAGATG -3’ 
5 min at 95°C – (1 min at 94°C, 1 
min at 58°C, 1 min at 72°C) 40 
cycles–10 min at 72°C 
294 
MMP7 
F: 5’-TCCAACCTATGGAAATGGAGA-3’ 
R: 5’-GGAGTGGAGGAACAGTGCTT-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 58°C, 30 sec at 72°C) 34 
cycles–10 min at 72°C 
196 
MMP8 
F: 5’-TCTGCAAGGTTATCCCAAGG-3’ 
R:5’- ACCTGGCTCCATGAATTGTC-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 52°C, 30 sec at 72°C) 45 
cycles–10 min at 72°C 
154 
MMP9 
F: 5’-CTCCTCCCTTTCCTCCAGAACAGAA-3’ 
R:5’-GGAGCCGCTCTCCAAGAAGCTT-3’ 
4 min at 94°C – (1 min at 94°C, 30 
sec at 58°C, 45 sec at 72°C) 35 
cycles–10 min at 72°C 
522 
MMP10 
F: 5’-GTCCTTCGATGCCATCAGCA-3’ 
R:5’- CTTGCTCCATGGACTGGCTA-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 60°C, 40 sec at 72°C) 37 
cycles–10 min at 72°C 
380 
MMP11 
F: 5’-GGGGATGTCCACTTCGACTA-3’ 
R:5’-CAGTGGGTAGCGAAAGGTGT-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 56°C, 30 sec at 72°C) 32 
cycles–10 min at 72°C 
165 
MMP12 
F: 5’-ACAGATGATGGACCCTGGTT-3’ 
R:5’-AGAGTCAAGCAAGAATGGACAA-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 52°C, 30 sec at 72°C) 36 
cycles–10 min at 72°C 
392 
MMP13 
F: 5’-AACATCCAAAAACGCCAGAC-3’ 
R:5’-GGAAGTTCTGGCCAAAATGA-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 50°C, 30 sec at 72°C) 36 
cycles–10 min at 72°C 
166 
MMP14 
F: 5’-GAGCTCAGGGCAGTGGATAG-3’ 
R:5’-AGCAGATGACCCCATTTGAC-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 52°C, 1 min at 72°C) 33 
cycles–10 min at 72°C 
798 
MMP15 
F: 5’-AGGAGACACAGCGTGGAGAC-3’ 
R:5’-TTGCAGTAAAGCAGGACACG-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 56°C, 1 min at 72°C) 32 
cycles–10 min at 72°C 
514 
MMP16 
F: 5’-GACATGCTCTGGGATTGGAG -3’ 
R:5’-TCATTTTTCCTTGGGTCAGC -3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 54°C, 30 sec at 72°C) 32 
cycles–10 min at 72°C 
217 
MMP17 
F: 5’-GGAGCTGTCTAAGGCCATCA-3’ 
R:5’-CGACAGGTTCCTCTTGTTCC-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 58°C, 30 sec at 72°C) 28 
cycles–10 min at 72°C 
190 
MMP19 
F: 5’-CAGCCTCGTTGTGGCCTAGA-3’ 
R: 5’-ACCAGCCTGCACCTCTTGGA-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 60°C, 30 sec at 72°C) 32 
cycles–10 min at 72°C 
207 
MMP20 
F: 5’-CGACAATGCTGAGAAGTGGA-3’ 
R:5’-ATCTTTGGGGAGGTGGAATC-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 54°C, 30 sec at 72°C) 40 
cycles–10 min at 72°C 
169 
MMP21 
F: 5’-GACGACGACGAGCACTTCAC-3’ 
R:5’-TTTCCTGTCTGACCAGTCCA-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 52°C, 30 sec at 72°C) 36 
cycles–10 min at 72°C 
180 
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MMP23 
F: 5’-TGGGACCACTTCAACCTCAC-3’ 
R: 5’-CGTGTTGTGAGTGCATCAGG-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 58°C, 40 sec at 72°C) 32 
cycles–10 min at 72°C 
412 
MMP24 
F: 5’-GAACCTGTGGGCAAGACCTA-3’ 
R: 5’-TGACAACCAGAAACTGAGCG-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 51°C, 30 sec at 72°C) 45 
cycles–10 min at 72°C 
214 
MMP25 
F: 5’-CCATTATGAGGCCCTTCTACC-3’ 
R:5’-TAGGTCTTCCCGTTCTGTGG-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 60°C, 40 sec at 72°C) 38 
cycles–10 min at 72°C 
541 
MMP26 
F: 5’-GATATGAAGCCATCCGCAGT-3’ 
R:5’-GCTGGAAGGTTCTAGGGTCG-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 49°C, 30 sec at 72°C) 43 
cycles–10 min at 72°C 
378 
MMP28 
F: 5’-CACCTCCACTCGATTCAGCG-3’ 
R:5’-AAAGCGTTTCTTACGCCTCA-3’ 
5 min at 95°C – (30 sec at 94°C, 
30 sec at 55°C, 30 sec at 72°C) 32 
cycles–10 min at 72°C 
208 
HDAC7 
F: 5’- AGGCCAGCAAGATCCTCATTG -3’  
R: 5’-ACAGATGGCTGTGAGGTCATG -3’ 
5 min at 94°C – (30 sec at 94°C, 
30 sec at 58°C, 30 secat 72°C) 30 
cycles–10 min at 72°C 
458 
GAPDH 
F: 5’-CCACCCATGGCAAATTCCATGGCA-3’ 
R:5’-TCTAGACGGCAGGTCAGGTCCACC-3’ 
3 min at 95°C – (30 sec at 95°C, 
30 sec at 60°C, 90 sec at 72°C) 25 
cycles–10 min at 72°C 
561 
 
2.2.5.6 Agarose gel electrophoresis to analyse PCR products 
RT-PCR products were separated using 1% Agarose gel dissolved in Tris-
acetate buffer (TAE) (Appendix 1) and containing 0.01% Ethidium bromide. 
Gel loading solution was mixed with a sample at 1:4 ratio prior to loading. 1kb 
Plus DNA ladder was also loaded in parallel, allowing for the later verification 
of PCR product size. Electrophoresis was carried out at 100 volts for 90 
minutes. The amplified cDNA was visualised under UV light and scanned 
using the BioRad Molecular Imager FX®. Expression analysis was performed 
by densitometry using Quantity One software (Bio-Rad Laboratories Ltd, UK). 
All genes of interest were normalised to the corresponding GAPDH band 
density. Consequently, the relative expression of each target gene was 
determined. 
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2.2.5 PCR Optimisation 
To establish a suitable cDNA amount to use for PCR, a range of cDNA 
amounts (1ng, 5ng, 10ng and 20ng) from different samples were analysed for 
GAPDH amplification. In addition, since the concentration of primers 
influences the specificity and efficiency of the PCR, final concentration of the 
primer per 20µL PCR reactions were also optimised. A range of primer 
concentrations (0.5µM, 1µM, 2.5 µM and 5µM) were tested under the same 
PCR protocol as described above. 
2.2.6 Western Blotting 
2.2.6.1 Cell sample preparation 
Cells were grown, harvested and counted as described in section 2.2.1. The 
resulting cell pellet was washed twice with PBS then lysed or immediately 
stored at -20°C for further use. For cell lysis, cell pellets were resuspended in 
four volumes of lysate buffer containing 50mM Tris-HCl pH7.5, 165mM NaCl, 
2.5mM EDTA, 2.5mM EGTA, 1mM DTT, 1% Triton-X-100, 0.5% protease 
inhibitor solution and 0.5% phosphatase inhibitor cocktails 2 and 3. The 
mixture was incubated for 30 minutes on ice to ensure complete lysis. 
Samples were then sonicated three times for 10 seconds and centrifuged for 
10 minutes at 4°C and the supernatant was collected. Cell lysates were 
either immediately transferred to -70°C in small aliquots for storage or 
subjected to Bradford protein assay. 
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2.2.6.2 Collection of culture supernatant 
A549, H460, H661, HT-1080 and Colo205 cells were grown in T75 flasks to 
70-80% confluence before incubation overnight in serum-free RPMI media 
containing 2mM L-glutamine and 1mM sodium pyruvate. The next day cells 
culture medium was collected and centrifuged to remove dead cells and the 
supernatant was collected. If diluted sample was an issue, condition media 
were then concentrated at 4000g for 15minutes at 4°C using Amicon Ultra-15 
centrifuged filter device with nominal molecular weight limit (NMWL) of 
30,000. Samples that did not pass through the filter were collected, aliquoted 
and stored at -70 °C for later use. 
2.2.6.3 Tissue sample preparation 
Proteins were extracted from tissue xenograft samples using the binary lysis 
buffer approach according to Lambert et al. (Ngoka, 2008). This involves 
combining the solubilisation capability of Radio Immunoprecipitation Assay 
(RIPA) and urea lysis buffers, which was reported to improve protein yields. 
Tissue samples were incubated with RIPA buffer (containing 0.1% w/v SDS, 
and 0.25% w/v sodium deoxycholate in PBS, pH 7.4) for 30 minutes with 
constant vortexing. This was followed by sonication using a Status US70 
sonicating probe for 20 seconds on ice and centrifugation at 13400 rpm for 
20 minutes. Then, protein supernatants was collected. The remaining tissue 
pellets were subjected to further lysis using urea buffer (containing 7 M urea, 
2M thiourea, 4% w/v CHAPS, and 50mM DTT in PBS pH 7.4) under the 
same conditions described above. The resulting supernatant was combined 
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with the initial protein supernatant extracted by the RIPA buffer. Collected 
total protein was either transferred to -70°C in small aliquots for storage or 
subjected to the Bradford protein assay. 
2.2.6.4 Protein concentration assay (Bradford Assay) 
Total protein concentration was determined using the Bradford protein assay. 
Serial dilutions of BSA, including 1.0, 0.5, 0.25, 0.125 and 0.0625mg/ml, 
were prepared to generate a standard curve of absorbance. A blank control 
without BSA was also included for instrument calibration. The 100ul blank 
and standards were mixed with 3ml Bradford reagent then incubated for 15 
minutes at room temperature. The absorbance of BSA standards were read 
at a wavelength of 595nm using a Cary 50 Bio ultra-violet (UV)-visible 
spectrometer (Varian Inc.CA, USA). In parallel, samples of unknown 
concentration were treated in the same manner and results were collected. 
Total protein concentration of samples were determined using the BSA 
standard curve created. In case samples fall outside the linear regression, 
further appropriate sample dilution was carried out and the assay was 
repeated.  Microsoft Office Excel®2010 was used for data analysis. 
2.2.6.5 Protein gel electrophoresis 
Proteins were separated using 10% polyacrylamide SDS gels (appendix 2.). 
Freshly made gels were immersed in electrophoresis running buffer 
containing 25mM Tris Base, 192mM Glycine and 0.1% SDS. Samples 
equivalent to 50μg of protein were diluted in 2X Laemmli buffer before 
denaturing at 95°C for seven minutes. The denatured samples were then 
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loaded into wells at a volume of 20μl. One lane was also loaded with 
prestained full range Amersham rainbow markers (12 to 225 KDa) to allow 
for later mass identification. The electrophoresis was run at 50 volts all the 
way through the stacking gel, then at 125V for another hour to separate the 
proteins. 
2.2.6.6 Immunoblotting 
Protein was transferred from the acrylamide gel onto the Hybond-P 
nitrocellulose membrane using a BioRad transfer kit. The gel and membrane 
were immersed in a transfer buffer containing 0.25M Tris-Base, 1.92M 
Glycine and 20% methanol. Proteins were transferred on ice at 300mA for 60 
minutes. Once completed, membranes were stained with Ponceau S solution 
to confirm successful transfer.  
2.2.6.7 Blocking and antibody incubation 
Non-specific protein binding on the membrane was blocked through the 
incubation of the membrane for one hour at room temperature with 5% dried 
skimmed milk in Tris buffer solution (pH 7.4) containing 0.1% Tween20 
(TBST). 
Before use, all primary antibodies were initially tested and their optimal 
concentrations were determined (Table 2.3) using a human cell lysate 
prepared as described in section 2.2.6.1. To proceed with Western blotting, 
primary antibodies were made up to their relevant concentrations in 5% 
skimmed milk in TBST and incubated with membranes overnight at 4°C with 
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constant agitation. Following a brief wash with TBST to remove the excess 
primary antibody, the blot was incubated for 60 minutes with the appropriate 
horseradish peroxidase (HRP) conjugated in a secondary antibody at a 
1:2000 dilution in 5% skimmed milk in TBST. This was followed by further 
washes with TBST to ensure the removal of the residual secondary 
antibodies. 
2.2.6.8 Protein detection 
Probed proteins were revealed using Western Lightning™ plus-ECL 
according to manufacturer’s protocol. Western blots were exposed to ECL 
reagents for one minute at room temperature before being wrapped in 
Saran™ wrap. The blot was then exposed to the Amersham hyperfilm™ ECL 
in a dark room. Exposure times varied from 15 seconds to one hour, 
depending on the antibody. Films were developed in Multigrade Paper 
Developer Solution (Ilford) for up to two minutes, then rinsed in distilled water 
before being fixed in Rapid Film and Paper Fixer Solution (Ilford) for three 
minutes. The films were finally rinsed under running tap water then left to dry 
at RT. 
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Table 2.3. Primary and Associated Secondary Antibodies Used: Optimal 
Dilutions Used for Each Primary Antibody are Also Described. All antibodies 
used in this research have human cross-reactivity. 
Primary 
Antibody 
Type Protein 
Targeted 
Diluted 
as 
Secondary 
Antibody 
Bands’ 
Molecular 
Weight 
Predicted 
C-18    
(Santa Cruz )  
Goat 
polyclonal 
HDAC7 
isoform a 
1:500 Polyclonal 
rabbit anti- 
Goat (Dako 
Cytomation) 
105 KDa 
Ab49473 
(Abcam) 
Mouse 
monoclonal 
MMP10 1:1000 Polyclonal 
rabbit anti- 
mouse (Dako 
Cytomation) 
54 KDa 
A1978 
(Sigma) 
Mouse 
monoclonal 
Actin 
isoform B 
1:10000 Polyclonal 
rabbit anti- 
mouse (Dako 
Cytomation) 
42 KDa 
ab38907 
(Abcam) 
Mouse 
monoclonal 
MMP3 1:1000 Polyclonal 
rabbit anti- 
mouse (Dako 
Cytomation) 
54 KDa 
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Chapter 3: Characterisation of Models for the 
Evaluation of MMP10 Functionality in NSCLC 
3.1 Introduction 
Human tumour-derived cell lines represent an unlimited, self-replicating 
source of tumour cells that are free of contaminating stromal cells. 
Subsequently, they have been commonly used as in vitro tumour models to 
investigate the biology and genetics of cancers, including NSCLC (Prieels et 
al., 2006; Wistuba et al., 1999). Herein, three lung cancer cell lines (A549, 
H460 and H661) were chosen to represent two of the most common 
subtypes of NSCLC, adenocarcinomas (A549) and large cell carcinomas 
(H460 and H661).  
Matrix metalloproteinases are essential for the development of NSCLC 
tumours. They play a role in the tumours’ growth, angiogenesis, migration, 
and invasion. Since the vast majority of MMPs are implicated in cellular 
processes that are related to cancer progression, the evaluation of their 
expression and activity in NSCLC is important in terms of the diagnosis, 
prognosis and therapy of this disease. 
The high expression of several MMPs in NSCLC has been linked either with 
aggressive disease or poor therapeutic response. These include MMP9 
(Jumper et al., 2004), MMP7 (Liu et al., 2007; Roy et al., 2009), MMP1 
(Schütz et al., 2002; Su et al., 2005) and membrane-type MMPs, (MMP14, 
15 and 17) (Atkinson et al., 2007). By focusing only on one or a few MMPs, 
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the authors did not account for the complex interactions that took place 
between different MMPs. Data regarding the whole range of MMP expression 
in NSCLC would greatly assist in defining the exact roles of these MMPs in 
this disease. 
The tumour microenvironment is a highly complex mixture of tumour—
endothelial, stromal, and fibroblastic cells—signalling molecules and ECM 
(Hanahan and Weinberg, 2011; Visvader and Lindeman, 2008). The 
interaction between these components contributes to cancer progression as 
it allows for a diversity of regulatory cascades, resulting in the stimulation of 
various MMPs (Clark et al., 2008). It is important, therefore, to assess 
whether the expression patterns seen in the 2D cultures for MMP10 are 
maintained once cells are subjected to the microenvironment of the in vivo 
situation in the tumour xenografts. 
It is known that the gene expression of most secreted enzymes does not 
necessarily reflect the expression pattern of the corresponding protein due in 
part to the effects of post-translational regulation (de Sousa Abreu et al., 
2009; Lichtinghagen et al., 2002; Zhang et al., 2007). Results of genetic 
analysis need to be confirmed at the protein level using detection methods, 
such as Western blotting, ELISA and immunocytochemistry. All these 
methods, however, depend on antibody specificity, which has raised a 
considerable amount of debate recently (Mann, 2008). There are concerns 
that antibody companies do not sufficiently pre-evaluate their antibodies and, 
as a consequence, the market is full of invalidated antibodies and extra time 
needs to be taken for troubleshooting during method development (Mann, 
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2008; Marx, 2013). Another technology that can evaluate protein expression 
without using antibodies would be valuable. The use of proteomics mass 
spectrometry provides such a technique. 
The term proteomics refers to the large-scale study of proteins, mainly their 
structure and function (Chandramouli and Qian, 2009). Proteomics is the link 
between genes, proteins and disease. It has been extensively used in areas, 
such as drug discovery, diagnostics and molecular medicine. With many 
advantages offered by this analysis system, including quantitative 
measurement and the ability to detect the modification status of proteins 
(Mann, 2008), it has been increasingly used for determining the unique 
patterns of protein expression or of biomarkers associated with specific 
diseases. In general, there are two approaches for proteomic analysis that 
are currently in use. These include bottom-up and top-down (Bogdanov and 
Smith, 2005). The bottom-up approach, which is used in this research, 
involves breaking up chemically or enzymatically the parent protein into 
peptide fragments that are sufficiently small for the available instrumentation 
(Breuker et al., 2008). When peptide fragments that are unique to each 
protein are formed, they are usually analysed by peptide mass fingerprinting 
or by tandem mass spectrometry for peptide sequence tags to allow for 
protein recognition (Liu et al., 2011). In top-down proteomics, on the other 
hand, intact proteins are directly analysed into the mass spectrometer where 
it is subjected to gas-phase fragmentation (Breuker et al., 2008; Wehr, 2006). 
Since conventional protein detection techniques suffer from issues 
concerning antibody selectivity and cost and are time consuming, the 
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proteomics technique has recently emerged as highly valuable, especially for 
the rapid identification and quantitation of proteins in complex biological 
mixtures (Breuker et al., 2008). In particular, MMP10 is secreted from cells in 
low abundance and subsequently diluted even further in the cell culture 
medium or body fluid. It is difficult, therefore, to detect and analyse in the 
majority of biological samples and a highly accurate and sensitive 
methodology is important. The proteomics approach was employed in this 
research to attempt to detect secreted MMP10. 
3.1.1 Aims and Objectives 
The main aim of this chapter is to characterise MMP10 expression at the 
mRNA and protein levels in a panel of human NSCLC cell lines in order to 
assess their suitability as models for investigating MMP10 functionality.  
The specific objectives include the following: 
 Evaluation of the mRNA expression of a large panel of known MMPs 
in three human NSCLC cell lines (A549, H460 and H661) using semi-
quantitative PCR. 
 Investigation of MMP10 expression at both genetic and protein levels 
in a panel of NSCLC cell lines grown in vitro and as transplanted 
xenografts in vivo using semi-quantitative PCR and Western blotting. 
 Evaluate the mass spectrometric-based proteomics methodology for 
the detection of secreted MMP10 in cell-conditioned media.  
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3.2 Materials 
3.2.1 Cell Lines 
A549, H460, H661, Colo205 and HT-1080 cell lines were used in this 
chapter. Their origin and culturing details are described in section 2.1.1.1 and 
2.2.1, respectively. 
3.2.2 Proteomics 
All chemicals and solutions were stored at room temperature unless 
otherwise specified. High performance liquid chromatography (HPLC) grade 
acetonitrile, ammonium bicarbonate, water and trifluoroacetic acid (TFA) 
were bought from Sigma-Aldrich (Gillingham, UK). For proteolysis, 99.9% 
trypsin enzyme was purchased from Roche diagnostics GmbH (Mannheim, 
Germany). The LC Packings UltiMate 3000 capillary HPLC system used for 
the protein fractionation was obtained from Dionex (Surrey, U.K.). The matrix 
α-Cyano-4-hydroxycinnamic acid (CHCA), MTP AnchorChip 800/384 target 
plate and Peptide Standard II were all purchased from Bruker Daltonik 
(Bremen, Germany). 
3.3 Methods 
3.3.1 NSCLC Cells Growth Analysis 
The growth curve analysis of the NSCLC cell lines was performed as 
previously described in section 2.2.2. 
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3.3.2 RT-PCR Analysis 
Cells were screened for their expression of 22 MMPs (MMP1, 2, 3, 7, 8, 9, 
10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 23, 24, 25, 26 and 28) using RT-
PCR analysis as previously described in section 2.2.4. For normal mouse 
lung tissues, mouse MMP10 primers (F:5-AGGGACCAACTTATTCCTGG-3; 
R:5-AGAGTGGGCCAAAATGCTGA-3) and GAPDH primers (F:5- 
CGGTGCTGAGTATGTCGTGG-3; R:5- GTGTAGCCCAAGATGCCCTTC-3) 
were used. 
3.3.3 Western Blotting 
Samples were probed for MMP10 protein using the mouse monoclonal 
MMP10 antibody (ab49473, Abcam) and following the Western blotting 
procedure as described in section 2.2.6. 
3.3.4 Manual MALDI TOF-MS of Peptides 
3.3.4.1 Instrumentation 
Mass spectrometric analysis was performed using an UltraflexTM II Matrix-
assisted laser desorption/ionization time-of-flight mass spectrometer (MALDI-
TOF/TOF) (Bruker Daltonics, Bremen, Germany). This automated MS and 
MS/MS detection system with a 200Hz pulsed 337nm nitrogen laser is a high 
throughput identification tool for proteins and peptides. In this work, the mass 
spectra of all peptides were acquired following the trypsin digestion of 
proteins as described below. 
69 
3.3.4.2 SDS-PAGE. 
Cell culture supernatants from Colo205 and H661 cell lines were collected as 
previously described in section 2.2.6.2. This was followed by protein 
concentration determination as previously described in section 2.2.6.4. In 
addition, a recombinant human MMP10 was included to serve as positive 
control. These samples were then separated electrophoretically in a 10% 
polyacrylamide gel as described in section 2.2.6.5 
3.3.4.3 Staining of proteins using Coomassie Brilliant Blue 
dye 
Following gel electrophoresis, the proteins in the gel were visualised using 
Coomassie Brilliant Blue dye as follows: The gel was incubated with 50ml of 
the Coomassie Blue Reagent for one hour at room temperature with gentle 
agitation. The excess stain was then removed using a destaining solution 
containing 50% (v/v) methanol, 10% (v/v) acetic acid and 40% (v/v) water. 
The gel was then scanned and the image was kept for future reference.  
3.3.4.4 In-gel trypsin digestion and peptides extraction 
After visualization, bands in the stained gel corresponding to the molecular 
weight of MMP10 (54kDa) were excised, treated and subjected to digestion 
with trypsin according to the procedure of (Shevchenko et al., 1996). In 1.7ml 
microcentrifuge tubes, each gel piece was dehydrated in 100µl of acetonitrile 
for 15 minutes, with solvent removed. Then, the gel piece was rehydrated in 
10µl of 25mM ammonium bicarbonate for 15 minutes. These dehydration and 
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hydration steps were repeated three times before the gel was allowed to dry 
for 30 minutes at RT. For tryptic protein digestion, the dried gel piece was 
then resuspended in 20µl of 10ng/µl trypsin in 25mM ammonium bicarbonate 
and left at 28°C in a water bath for 18 hours. Upon completion of digestion, 
samples were centrifuged at 8500 g for 20 seconds and supernatants were 
collected. For full peptide extraction, gel pieces were covered with 100% 
acetonitrile for 15 minutes and were centrifuged and the supernatants were 
collected. The gel pieces were further extracted with 5ul of 25mM ammonium 
bicarbonate and 50ul of 100% acetonitrile for 10 and 15 min, respectively. 
These extractions with 25mM ammonium bicarbonate and 100% acetonitrile 
were repeated twice and supernatants were combined with the 
corresponding initial supernatants. Finally, supernatants containing peptides 
were lyophilised and stored at -20°C until MS analysis. 
3.3.4.5 Matrix solution preparation. 
A saturated matrix stock solution was prepared by dissolving 10mg of CHCA 
in 1ml of 30% acetonitrile and 0.1% trifluoroacetic acid. This mixture was 
vortexed for two minutes then sonicated for 30 minutes prior to storage at 
4°C for future use. Once needed, a fresh CHCA matrix working solution was 
prepared as the following: 120μl of matrix stock supernatant mixed with 
1.056ml ethanol-acetone (2:1), 12ul of 100mM ammonium phosphate and 
12μl of 10% TFA. 
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3.3.4.6 Manual analysis of gel digest. 
Following in gel-trypsin digestion, 0.5ul of peptide sample solution was then 
placed on each spot of an MTP AnchorChip 800/384 target plate previously 
coated with 1.2μL of  10mg/mL CHCA matrix.  Once air-dried, samples were 
covered with another layer of CHCA matrix (0.5μl). Finally, the peptide-matrix 
sandwich was allowed to dry before analysis in the mass spectrometer. For 
the calibration and testing of the MALDI-TOF MS, a Peptide Standard II, 
which is a mix of seven standard peptides with m/z ranging from 1046 to 
3147 (appendix 3), was applied between each group of four samples onto the 
target plate. Mass spectra were obtained using MALDI−TOF/TOF in 
reflectron mode in the mass range of 700-4000Da with 50-80% laser power. 
FlexControl version 3.0 software was used for data acquisition. 
3.3.4.7 nHPLC coupled to MALDI-MS/MS for protein 
identification (LC-MS/MS). 
3.3.4.7.1 Reverse phase nHPLC fractionation of modified 
peptides 
Nanoscale RP Liquid Chromatography was carried out for the fractionation of 
trypsin-digested peptides using an LC Packings UltiMate 3000 capillary 
HPLC system. Lyophilised peptides that were resuspended in 6.5μl of 10% 
acetonitrile containing 0.05% TFA were injected onto a (C18, 300μm × 5mm, 
5μm diameter, 100 Å PepMap pre-column) then washed with the mobile 
phase A for 3.5 minutes at a flow rate of 0.3µl/minute. At the same flow rate, 
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samples were subsequently transferred onto another 100 Å PepMap column 
with C18, 75μm x 15cm, 3μm diameter. 
3.3.4.7.2 nHPLC gradient conditions 
After applying the above-mentioned conditions, peptides in the aqueous 
mobile phase should bind to the stationary phase in the reverse phase 
nHPLC column. For the elution of peptides, mobile phase B, which contained 
80% acetonitrile and 0.05% TFA, was used in a linear gradient manner. 
Mobile phase B increased by 10% in six minutes followed by a linear 
increase from 10–40% over the next 75 minutes. Within 81 minutes, 100% of 
mobile phase B was used for five minutes. Once completed, 100% mobile 
phase A was used to re-equilibrate the column until the end of the run at 100 
minutes. Eluents were measured simultaneously at 280nm and 215nm 
wavelengths using a deuterium lamp and data was monitored on a computer 
connected to the system using the Hystar 3.2 software (Bruker Daltonics, 
Gmbh). 
3.3.4.7.3 Fraction collection and mass spectrum acquisition 
Around 75nL fractions were co-deposited with 1.2μL of saturated CHCA 
matrix using Proteineer FC fraction collector (Bruker Daltonics, Gmbh) onto 
the MTP AnchorChip 800/384 target plate. This fully automated robot was 
adjusted to load a well every 15 seconds using the Hystar 3.2 software. For 
the calibration and testing of the MALDI-TOF MS, a Peptide Standard II 
covering the mass range between 1046 to 3147 Da (Appendix 3) was applied 
between each group of four samples onto the target plate. For automated 
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MALDI-MS/MS analysis, 800 pulse of laser were fired for parent ion and 
1200 for the fragment ions in UltraflexTM II MALDI-TOF/TOF instrument.  
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3.4 Results 
3.4.1 NSCLC Cell Line Growth Kinetics 
To ensure that cells subjected to analyses in this research were in their log 
growth phase, growth curves were performed for the A549, H460 and H661 
cell lines. Figure 3.1 summarises the growth patterns of the cell lines 
following the initial seeding density of 1x104 cells/cm2. Data obtained was 
also used to calculate the doubling time for cells in their log growth phase. 
The H661 cell proliferation rate was the slowest amongst all the cell lines 
used with a doubling time of 25.2 hours. The H661 cells began their log 
growth phase at day one and entered the stationary phase at day seven. 
Although the A549 cells took the same time to enter the stationary phase 
compared to H661, their doubling time was 23 hours, indicating a faster 
growth rate. The growth rate of the H460 cells was the fastest, with a 
doubling time of 16.3 hours. Their plateau phase began at day five.  
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Figure 3.1. Growth curves for the NSCLC cell lines, A549, H460 and H661. Cells 
were seeded into 25 cm2 flasks at seeding concentrations of 1x104 cell/cm2. The 
number of cells was determined every other day for 11 days using a 
haemocytometer. Presented mean data was obtained from three independent 
experiments, (+/- S.D). 
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3.4.2 Genetic Expression 
3.4.2.1 Optimisation of the PCR conditions. 
The amount of cDNA and final concentration of primers for inclusion in the 
reaction mixture were optimised to ensure maximum possible efficiency and 
specificity for the semi-quantitative PCR. For the determination of the optimal 
cDNA amount, 1ng-20ng of cDNA from the three NSCLC cell lines (A549, 
H460 and H661) was used and evaluated to amplify the housekeeping 
GAPDH gene. The optimal cDNA amount was considered as the lowest that 
could yield consistent GAPDH gene bands from the various cDNA templates 
within the limits of detection, thus improving reproducibility. Using 5ng cDNA 
produced the most reproducible bands and was, therefore, chosen as the 
optimal cDNA amount for further analysis (Figure 3.2). In the same context, a 
range of primer concentrations (0.5µM- 5µM) were evaluated to amplify the 
GAPDH gene. As the lowest primer concentration that produced the maximal 
PCR product without excess primer was 0.5µM per 20µl reaction, it was 
chosen as the optimum primer concentration (Figure 3.3). 
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Figure 3.2. Identification of optimal cDNA concentration for RT-PCR 
analysis. A range of concentrations of cDNA was tested per 20 µl reactions 
to amplify the GAPDH gene in A549, H460 and H661 cell lines.  Negative 
control without cDNA was used to exclude genomic DNA contamination in all 
samples. Marker used is 1 kb plus DNA ladder from Invitrogen. The 5ng DNA 
was the minimum amount with the least variation among the different sample 
intensities, so this was chosen as the optimal DNA amount for PCR 
reactions. 
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Figure 3.3. Optimisation of GAPDH primer concentration for RT-PCR 
analysis. GAPDH gene was amplified in the presence of four different final 
primer concentrations (5µM- 2.5µM- 1µM- 0.5µM) using cDNA from the A549 
cell line. Among all primer concentrations that were tested, 0.5µM produced 
the maximum PCR product with no risk of primer dimer; hence, it was chosen 
as the optimal primer concentration for future PCR analysis. 
 
3.4.3 MMPs mRNA Level in NSCLC Cell Lines 
The expression profile of MMPs in human NSCLC reported in the literature is 
currently incomplete and needs to be further evaluated as previously 
discussed in the introduction (section 3.1). To fill the gap in our knowledge 
regarding MMP expression in NSCLC, the expression of 22 human MMPs 
was evaluated at the genetic level in a panel of NSCLC cell lines (A549, 
H460 and H661). In parallel, the HT-1080 fibrosarcoma cell line was used as 
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a universal positive control for MMPs because of its previously well 
characterised protease profile (Sugiura et al., 1998). The Colo205 colon 
adenocarcinoma cell line was also used as a negative control due to the 
overall weak expression of MMPs, which has been previously described 
(Atkinson et al., 2010). Semi-quantitative RT-PCR analysis was performed as 
described in section 2.2.4. Results are summarised in Figure 3.4 and 
appendix 4.   
Generally, diverse MMP expression profiles were observed for the NSCLC 
cell lines. Very high expression pattern was seen in the H661 cells, especially 
with MMP1, 2, 3, 9, 10, 11, 15, and 25. Lower expression patterns were also 
seen for the H460 and A549 cell lines, with most of the MMP evaluated as 
compared to the H661 cell line. 
In the three NSCLC cell lines evaluated, the overall high expression of 
MMP2, 3, 9, 10, 15, and 25 was observed. Matrix metalloproteinase 10 is of 
particular interest to this research because its expression has been 
correlated to poor clinical outcome in NSCLC (Frederick et al., 2008). 
Interestingly, the level of MMP10 mRNA in the H661 cell line was the highest 
compared to the remaining NSCLC cell lines. The MMP10 mRNA expression 
levels in the A549 and H460 cell lines were high and moderate, respectively.  
Unlike other MMPs, MMP14 was very low in all the cell lines tested, except 
for the HT-1080. Selected MMPs were as expected; they were highly 
expressed in the HT-1080 cell line, including MMP 1, 2, 3, 8, 9, 10, 13, 14 
and 16. In contrast, the expression levels of the majority of MMPs in Colo205 
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cells were low, especially MMP2, 9, 12, 14, 16 and 17, which were below the 
level of detection. 
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Figure 3.4. MMP10 mRNA expression is elevated in human NSCLC preclinical 
tumour models as measured by semi-quantitative RT-PCR. Other MMP were also 
tested to assess any possible interactions that took place between different 
MMPs. The HT-1080 and Colo205 cell lines were used as positive and negative 
controls, respectively. GAPDH was also used as a loading control. Results were 
semi-quantified by densitometry (appendix 4). Although it would be better to use a 
quantitative PCR for more reliable results, it could not been done within the 
constraints of this research.  
 MMP     A549    H460     H661   Colo205   HT-1080         MMP      A549    H460     H661   Colo205  HT-1080 
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3.4.4 MMP10 mRNA in Tumour Xenograft Tissue 
Following the analysis of MMP10 mRNA in a monolayer culture, 
subcutaneous tumour xenografts of A549 and H460 cells were subjected to 
semi-quantitative RT-PCR analysis to assess the impact of the tumour 
microenvironment on MMP10 expression. A mouse normal lung tissue was 
included in this analysis to give a baseline of the physiological MMP10 
expression, and HT-1080 xenografts which are known to highly express 
several MMPs, were used as a positive control. 
The MMP10 mRNA expression from the tissue extracts was significantly 
higher in the NSCLC xenografts compared to the normal mouse lung tissue 
(Figure 3.5). The MMP10 expression patterns in the A549 and H460 tissue 
xenografts were similar to those seen in the 2D cell culture. The elevated 
MMP10 expression in the A549 cells was the highest in both the 2D culture 
and tissue xenografts as compared to that of the H460, which showed 
moderate MMP10 level at both conditions. Collectively, this confirms an 
elevation in the MMP10 mRNA expression in the NSCLC tumour 
environment and supports the use of these human cell lines as MMP10 
models for future experiments. 
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Figure 3.5. High MMP10 expression in NSCLC subcutaneous tissue 
xenografts compared to mouse normal lung tissue. Data presented as a 
fold change of MMP10 mRNA expression. HT-1080 tissue xenograft was 
used as a positive control. Statistically significance was evaluated using 
student t test. * p<0.05. (n=3). For normal lung tissues, mouse PCR primers 
were used for MMP10 and GAPDH as desribed in section (3.3.2). For 
xenograft tissues, human specific PCR primers were used as described in 
table 2.2 (section 2.2.4.5) 
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3.4.5 In Vitro and In Vivo MMP10 Protein Expression 
Following the analysis of the MMP10 gene expression at the transcriptional 
level, MMP10 protein levels were also assessed in the NSCLC cells and 
xenograft tissues using Western blotting as described in section 2.2.6. For 
immunoblotting experiments, the specificity of antibodies is critical for 
accurate results. Thus, all antibodies were initially validated before use in this 
research. 
3.4.5.1 Confirmation of antibody specificity 
It is well known that there is a high resemblance between MMP3 and MMP10 
in terms of structure and substrate specificity (Murphy and Nagase, 2008). It 
was essential, therefore, to confirm the specificity of the antibody to MMP10 
but not MMP3 protein and vice versa for MMP3. Initially, several 
commercially available MMP3 and MMP10 antibodies were tested against 
cell lysates. From this, only two demonstrated potential for specifically 
detecting their relevant protein. The specificity of both MMP10 (ab49473) and 
MMP3 (ab38907) antibodies was further evaluated against the recombinant 
human MMP3 and MMP10 proteins. 
Figure 3.6 showed that MMP10 antibody (ab49473) produced a clear band 
corresponding to MMP10 protein, with no cross reactivity observed against 
MMP3. In contrast, MMP3 antibody (ab38907) cross-reacted with the MMP10 
protein. Despite further testing the MMP3 antibodies, there was a failure to 
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discriminate between the two proteins tested. Based on these findings, the 
ab49473 antibody was chosen as the antibody of choice for MMP10 
detection, whereas it was not possible within the constraints of the project to 
identify an MMP3-specific antibody. 
 
“MMP10” Ab (ab49473) antibody “MMP3” Ab (ab38907) antibody 
 
 
 
 
 
Figure 3.6. Confirmation of antibody specificity. Immunoblots probed with 
ab49473 (left panel) and ab38907 (right panel) antibodies were tested for 
their specificity towards human MMP3 and MMP10 purified proteins. As it 
does not cross react with MMP3, Ab49473 was chosen as the antibody of 
choice for MMP10. The ab38907 antibody cross-reacted with the MMP10 
protein, indicating a lack of specificity.    
 
 
3.4.5.2 MMP10 protein expression in NSCLC cell lines and 
xenograft tissue. 
To assess whether the expression results at the protein level match those at 
the gene level, the expression of MMP10 protein was analysed using the 
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MMP10 validated antibody (ab49473). For both pro and active forms, MMP10 
protein expression analysis was carried out by Western blotting with both cell 
and tissue extracts. 
For NSCLC cells, pro MMP10 protein was highly expressed in both the A549 
and H460 cells (Figure 3.7), which was consistent with the expression 
analysis at the mRNA level. Unexpectedly, a moderate pro MMP10 protein 
expression was observed in the H661 cells, which differed from what was 
seen at the gene level. For all cell lines evaluated, active MMP10 protein was 
below detection levels and could not be observed. 
For xenograft tissue, MMP10 proteins were significantly higher in the NSCLC 
xenografts when compared to mouse normal lung tissue (Figure 3.8). This is 
consistent with the results seen at the gene level, supporting elevated 
MMP10 in NSCLC at the transcriptional and translational levels. 
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Figure 3.7. MMP10 protein levels in a panel of NSCLC cell lines 
using Western blotting. Levels of MMP10 protein in the A549 and 
H460 were high compared to those in the H661 cell line. (β-actin) 
was used as internal control. Semi-quantification of results was 
performed using the densitometry tool of Quantity One software. 
The statistical difference was assessed using Student's t-test. * 
p<0.05. (n=3). 
 
 
 
 
 
 
* * 
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Figure 3.8. Significantly higher MMP10 protein expression observed in 
NSCLC subcutaneous xenografts compared to normal lung tissue. 
Although bands at 54 KDa correspond to proMMP10 can be clearly 
seen, the gel could not differentiate well between pro and active forms of 
MMP10 protein. Therefore, activation by APMA is required to confirm 
whether the bands seen at ≈ 44 KDa are the active form of MMP10 or 
just glycosylated pro MMP10. Recombinant MMP10 with predicted 
molecular mass for pro and active forms (52 and 43 KDa, respectively) 
was used as a positive control, but only the pro form evident. 
 
3.4.6 Detection of Secreted MMP10 Using MALDI-TOF-MS 
Due to the low level of secreted MMP10 in most tissues, the use of more 
sensitive methodology than the traditional Western blotting would be 
essential for secreted MMP10 detection. The MALDI-MS detection system 
has recently proven to be a powerful procedure. Subsequently, it was used to 
detect secreted MMP10 protein in this research. The secreted MMP10 was 
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high in the Colo205 cell line but low in the H661 as suggested by Western 
blotting (Figure 3.9A). These cell lines therefore were used to evaluate the 
sensitivity range of the MALDI-MS system. Recombinant MMP10 was also 
used as a positive control. A blank containing PBS (alone) was run parallel to 
it as negative control. The protocol involves separating the complex protein 
mixture using SDS-PAGE followed by Coomassie Blue protein staining 
(Figure 3.9B). The latter was carried out to locate the protein of interest prior 
to gel excision. After trypsin digestion, the resulting fragments of all samples 
were assessed using manual MALDI-MS analysis. 
Only two dominant significant signals with m/z of 992.39 and 1463.62 were 
found in the mass spectra of the peptides generated from the recombinant 
human MMP10 (Figure 3.10). For the 992.39 signal, a peptide sequence was 
identified using MS/MS analysis as K.GNEFWAIR.G, which was specifically 
related to MMP10 (located in hemopexin-like2 domain). Conversely, 1463.62 
signal was identified as K.VWEEVTPLTFSR.L, which was related to both the 
MMP3 and MMP10 (located in catalytic domain in both enzymes). In 
contrast, MMP10 in conditioned media from both the Colo205 and H661 was 
below the detection level at this stage as no dominant signals were observed 
(Figure 3.10). This was attributed to mixture complexity, wherein the signal of 
interest was suppressed by other strong signals. To overcome this, peptide 
fragments were further fractionated using Nanoscale RP Liquid 
Chromatography, then subjected to automated MALDI-MS/MS analysis. 
Unfortunately, MMP10 was again below the detection level in the conditioned 
media evaluated (Appendix 5). Given the time and financial constraints, this 
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methodology was not pursued further. For the remaining studies, secreted 
MMP10 protein levels were measured using Western blotting. 
 
A 
 
                            
B 
 
 
            
Figure 3.9. Evaluation of the secreted MMP10 level in the Colo205 and 
H661 cell lines. Western blotting of the conditioned media from the 
Colo205 and H661 cells for 24 hours using (ab49473) MMP10 antibody 
(A). The same samples were subjected to the SDS-PAGE Coomassie 
Blue protein staining procedures (B). 120ng of recombinant MMP10 
was used as positive control to locate the potential bands for MMP10. 
Red squares point to potential MMP10 bands where gels were excised. 
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Figure 3.10. Mass spectra of blank (negative control), Colo205 and H661 
cell conditioned media and recombinant MMP10 (positive control). Two 
dominant significant signals with m/z of 992.39 and 1463.62 were 
generated from the recombinant human MMP10 (arrows). Secreted 
MMP10 from both Colo205 and H661 was below the detection level with 
no dominant signals observed. The MMP10 was used as a positive control 
and the arrows point to dominant peptides signal for MMP10. 
Recombinant MMP10  
         H661 
                   COLO205 
                        Blank 
          H661 
          COLO205 
          Blank 
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3.4.7 Comparison of Protein and mRNA Expression Detected 
for MMP10 in the NSCLC Cell Lines 
Table 3.1 summarises the RT-PCR and Western blotting results for MMP10 
expression in both the cell and tissue extracts. As can be seen, for the A549 
and H460 cell lines, a consistency between the mRNA and protein levels of 
MMP10 was observed in both the cells and tissue xenografts. However, high 
MMP10 mRNA expression in the H661 cell line did not correlate with its 
protein levels, showing low MMP10 expression. As a consequence, only the 
A549 and H460 cells were selected for further MMP10 studies. 
 
Table 3.1. Summary of MMP10 Expression in the NSCLC cell lines 
(A549, H460 and H661) in both the 2D culture and Tissue 
Xenografts. The mRNA and protein levels of MMP10 were graded 
from zero to five according to their band intensities. Each + 
represents approximately 1.3 band intensity as semi-quantified 
using Quantity One software for RT-PCR and Western blotting 
results. Levels of active MMP10 protein in cells grown in 2D culture 
were below the detection level of the Western blotting. ND: not 
detected, NA: not available. NCA: needs confirmation by APMA. 
Cell 
Lines 
MMP10 Expression 
Cells Tissue Xenografts 
 mRNA Protein mRNA Protein 
  Pro Active  Pro Active 
A549 ++++ +++ ND +++++ +++ NCA 
H460 +++ +++ ND +++ +++ NCA 
H661 +++++ + ND NA NA 
 
93 
3.4 Discussion 
Matrix metalloproteinase is known to be involved in cancer growth, spread, 
invasion and angiogenesis. The identification of proteolytic enzyme 
expression, especially MMPs, in human cancers is critical in understanding 
the characteristics of individual cancer types (Atkinson et al., 2007; López-
Otín and Overall, 2002). The expression profile of MMPs in human NSCLC 
as reported in the literature is currently incomplete and does not account for 
the significant interactions between the different MMPs that take place during 
their involvement in the several processes related to cancer development. 
The complete profile of MMP expression and activity in NSCLC could 
increase the understanding about their role in the disease. To achieve this 
using in vitro studies, preclinical models that precisely characterise MMP in 
the human NSCLC are needed to be established first. Three human tumour 
NSCLC cell lines (A549, H460 and H661) were chosen as representatives of 
two of the most common subtypes of NSCLC—adenocarcinomas and large 
cell carcinomas—and were screened for their expression of 22 MMPs in this 
chapter using semi-quantitative PCR. 
During the screening of MMP mRNA expression in the NSCLC cell lines, the 
HT-1080 cell line was used as a positive control for MMP expression. Due to 
the high expression of multiple MMPs, this cell line was previously used in 
several studies focusing on MMP expression and activity—for example, 
MMP2, MMP9 and MMP14 (Upadhyay et al., 1999); MMP3 (Kamio et al., 
2010) and MMP2, MMP 14 and MMP16 (Atkinson et al., 2010). In agreement 
with most of these studies, HT-1080 cells demonstrated a high expression of 
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MMP3, 14, 16, 2, and 9 in this study. However, H661 demonstrated a more 
diverse and generally higher expression of MMPs than even HT-1080 and 
thus would itself be a good cell line to select as a positive control in similar 
studies. 
The Colo205 colorectal cancer cell line was used as a negative control for 
MMP expression. The use of this particular cell line was based on its overall 
negative expression of MMP that was previously observed (Atkinson et al., 
2010). While their result was produced using the more sensitive real-time 
PCR, a higher expression pattern of MMPs in the Colo205 was detected in 
the current study using standard PCR. The expression of MMP3, 8, 10, 24, 
25, 26 and 28 was below the detection level in the reported research; 
however, it is observable in this study. The discrepancy between the data 
may be due to the different reference genes or internal controls used to 
normalise the results, which can adversely influence the uniformity of the 
results (Zhang et al., 2007). Other contributing factors might be the variation 
in cancer cell lines, culture conditions, passages number and cell density, all 
of which have been reported to influence the in vitro expression of several 
MMPs (Hagemann et al., 2010; Rossi et al., 1995; Trog et al., 2006). Thus, 
caution should be exercised when relying on MMP expression data from a 
single source or experiment. 
Due to the potential for variation of the MMP expression results, it was 
necessary to characterise MMP expression in a panel of NSCLC cell lines to 
assess their suitability for further studies. As was expected, the MMP 
expression in the NSCLC cell lines evaluated was not consistent with the 
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only report in the literature using the same three cell lines (Atkinson et al., 
2010). Despite this variation, high mRNA expression for MMP2, 3, 9, 10, 15, 
and 25 were detected in the A549, H460 and H661 cell lines, with extremes 
observed in the H661 cells in both the reported and current study. It’s worth 
noticing that the reported study used a quantitative real time PCR, whereas 
the current study used semi-quantitative PCR. Therefore, caution was 
required when comparing the data due to the variation in detection sensitivity. 
Overall, this high level of MMP expression in the NSCLC cell lines observed 
in this and the reported study support the potential roles of these MMPs in 
NSCLC tumour development. Furthermore, these MMPs may serve as 
potential therapeutic targets to be exploited in NSCLC. 
Matrix metalloproteinase 10 is a specific interest to this study because its 
expression has been correlated to poor clinical outcome in NSCLC (Frederick 
et al., 2008). Data in the present study indicated a diverse profile for MMP10 
in the panel of the NSCLC cell lines evaluated, with very strong, high and 
moderate levels of MMP10 expression detected in the H661, A549 and H460 
cell lines, respectively. These findings slightly differ from those of Atkinson et 
al. (2010), which showed high expression of MMP10 mRNA in the H661 cell 
line and low expression in the A549 and H460 cell lines (Atkinson et al., 
2010). In addition, differences were also seen in a study where MMP10 
mRNA was evaluated in a glioblastoma cell line (Hagemann et al., 2010). It 
was seen that MMP10 expression varied with passage in culture. In 
particular, MMP10 levels were initially high, with a decrease seen by passage 
five and very low or below levels of detection at passage 15 (Hagemann et 
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al., 2010). Although in this study no such relationship was observed, all cell 
lines were only used up to passage eight as a precaution. 
In the case of NSCLC xenograft tissues, MMP10 mRNA expression from the 
A549 and H460 tissue extracts was significantly higher compared to the 
normal mouse lung tissue. Unfortunately, H661 xenograft tissue could not be 
included as it had not been grown as a tumour xenograft in these 
laboratories. Despite this, the data generated from NSCLC xenograft tissues 
used (A549 and H460) showed a consistent MMP10 mRNA expression in 
both xenografts and 2D cell culture, confirming the expression of MMP10 in 
the NSCLC cell lines evaluated. 
Although MMP10 mRNA expression levels are detected in the NSCLC cell 
lines (A549, H460 and H661), RT-PCR analysis alone is insufficient to 
correctly indicate levels of MMP10 protein due to the effects of the post-
translational regulation of the enzymes, such as phosphorylation. Therefore, 
Western blotting was used to address MMP10 protein expression in these 
cells. This indicated inconsistencies between gene and protein expression, 
particularly in the case of the H661 cells. A low to moderate pro-MMP10 
protein level was observed in contrast to its mRNA, which showed very high 
MMP10 expression. There are a few possible reasons for this conflict, 
including differences in mRNA and protein turnover rates and different 
posttranslational regulation and modifications (Fu et al., 2007). A potential 
mechanism by which H661 shows such discrepancies between mRNA and 
gene expression while the other two cells lines are consistent in both mRNA 
and protein expression is through their respective p53 statuses. p53 is a key 
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regulator of the mTOR pathway (Feng, 2010), which is implicated in the 
MMP10 released in stromal cells (Reikvam et al., 2013). In the published 
study, the inhibition of the PI3K/mTOR pathway results in an increase in 
MMP10 release by stromal cells. It is interesting to note there is non-
functional P53 in H661 (Stuschke et al., 2002), unlike in the H460 and A549 
cells, but more studies would be required to make a link  with changes in 
MMP10 levels observed in the current study. Although conflicting results 
were seen for the H661, the results for the other NSCLC cell lines evaluated 
(A549 and H460) for MMP10 expression at the transcriptional and 
translational levels were consistent and generally supported the elevated 
MMP10 in these cell lines. Therefore these cell lines were selected for further 
MMP10 studies in the project. A good candidate for further investigation 
would be to demonstrate the suggested mechanism of the non-functional p53 
that is negatively affecting MMP10 protein expression in the H661 cells.   
Following the evaluation of MMP10 protein level at 2D cell culture, selected 
NSCLC xenograft tissues (A549 and H460) were included to assess the 
influence of tumour microenvironment on MMP10 expression. Pro MMP10 
was successfully detected with bands at the right size (54 KDa). Although 
bands at the right size of active MMP10 (44 KDa) were seen, caution was 
taken to consider them active MMP10 as they could be glycosylated pro 
MMP10. A confirmation step is required that involves an activation by amino-
phenyl mercuric acetate (APMA) to ensure these bands corresponding to the 
active MMP10. 
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Matrix metalloproteinase 10 is a low abundance secretory protein that is 
difficult to detect in the majority of the biological samples. Such an obstacle 
has consequently hampered the elucidation of the roles of MMP10 in 
cancers, including NSCLC. One procedure that has proven useful in protein 
detection is the MALDI-MS detection system, which was utilised to detect 
secreted MMP10 in this research. 
In an attempt to evaluate the MALDI-MS detection system to measure 
secreted MMP10 protein, conditioned media from the Colo205 and H661 
cells, as well as recombinant MMP10 protein, were used as sources of 
MMP10 in the current study. The signature peptide for MMP10 was detected 
in the recombinant MMP10 digest fragments but not in the Colo205 and 
H661 conditioned cell media, representing limited success in secreted 
MMP10 detection in biological samples. This limited success could be 
explained by the proteomic complexity of biological samples, specifically the 
dynamic range of proteins (Corthals et al., 2000), with low abundance 
proteins being masked by high abundance proteins. In addition to this, 
protein loss at the various stages of the sample processing in MALDI-MS 
could greatly impact the detection of low abundance protein, such as 
MMP10. 
While the MALDI-MS detection system has been frequently used to detect 
endogenous MMP substrates (Butler et al., 2010; Starr et al., 2012; Vaisar et 
al., 2009), the identification of the cellular MMP enzymes themselves in 
human cells by this method is rare. The few studies that have had success in 
MMP identification by this method have had to utilise protein enrichment 
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methods. The MMPs identified include MMP14 (Shuo et al., 2012) and 
MMP9 (Ries et al., 2007). Based on this, immunoprecipitation of MMP10 in 
cell conditioned media was attempted in this research using magnetic beads 
and MMP10 antibody (Ab49473) prior to the proteomics work, but 
unfortunately this was unsuccessful. The potential for MMP degradation by 
other proteases present in the biological samples and the need to maintain 
their structural integrity by an optimised buffer could add to the difficulties 
encountered in MMP detection by the MALDI approach (Grasso et al., 2006). 
Overall, the identification of MMP10 by the MALDI-MS system was 
demonstrated for purified recombinant protein. Detection in complex 
biological samples remains elusive and is hindered by the factors discussed 
above, as well as by instrument sensitivity. 
In conclusion, screening MMP expression in NSCLC cell lines (A549, H460 
and H661) at the genetic level reveals that these cells constitutively express 
a wide variety of MMPs, including MMP2, 3, 9, 15 and 25, and the focus of 
this project, MMP10, which has been shown to support tumour development 
and contribute to poor clinical outcome. In this study, MMP10 demonstrates a 
stronger expression in the A549 and H460 tissue xenografts compared to 
mouse normal lung tissue at both the genetic and protein levels. The 
confirmed high expression of MMP10 in the NSCLC cells, coupled with 
evidence of selective expression by tumour cells, suggests that MMP10 is a 
potential target for therapeutic intervention in NSCLC. However, further 
investigation is needed to elucidate its roles in NSCLC. Based on the mRNA 
and protein levels of MMP10, the NSCLC cell lines (A549 and H460) 
100 
presented themselves as good models for the evaluation of MMP10 
functionality in further experiments. The H661 cells were not chosen due to 
inconsistency in results on MMP10 in the gene and protein levels. 
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Chapter 4: Development of In Vitro MMP10 
Expressing Models for the Evaluation of the Role of 
MMP10 in NSCLC 
4.1 Introduction 
The use of a relevant preclinical model that precisely characterises the 
patterns of MMP10 expression in human NSCLC is essential for a better 
understanding of the roles of MMP10 in the disease. It has previously been 
reported that MMP10 is up-regulated in NSCLC, where it is strongly linked to 
poor clinical outcome (Batra et al., 2012; Cho et al., 2003; Frederick et al., 
2008; Gill et al., 2004; Zhang et al., 2007). Based on this, well characterised 
models with a range of expression levels (from high expression to represent 
the more aggressive NSCLC to little or no expression to act as normal 
controls) would be useful for the investigation of the involvement of MMP10 
in NSCLC. 
Two NSCLC cell lines (A549 and H460) have been identified as good 
potential models based on their mRNA and protein levels of MMP10 in the 
previous chapter. However, levels are still relatively low in these cell lines 
compared to those seen clinically; hence, there is a requirement for cell lines 
that can be engineered to overexpress MMP10 to a more clinically-relevant 
level. 
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Several transfection methods have been used to knock down or over express 
MMP10 in preclinical studies. For MMP10 overexpression, methods involving 
cloning a sequence-verified human MMP10 cDNA into an expressing vector, 
which is then inserted into cells by either chemical-based transfection (e.g. 
lipofection) or non-chemical methods (such as electroporation and viral 
transduction), have proved to be efficient. It was reported that human MMP10 
cloned into pBICEP2 vector and transfected into oral carcinoma cells by 
lipofection using FuGENE 6HD, resulted in a marked MMP10 expression 
(Deraz et al., 2011). In another study where pCMV6-Entry vector and 
electroporation were used to transfect HeLa cells, successful MMP10 
overexpression was achieved (Zhang et al., 2014a). On the other hand, 
silencing MMP10 in the literature is generally achieved by harnessing the 
endogenous RNA interference (RNAi) mechanisms through introducing into 
the cell an MMP10 specific short interfering RNA (siRNA) for transient effect 
or short hairpin RNA for a stable one, followed by the same transfection 
methods described above (Deraz et al., 2011; Zhang et al., 2014a). 
Recently, MMP10 expression has been shown to be repressed in vivo by the 
class II histone deacetylase HDAC7 (Chang et al., 2006) (previously 
described in general introduction section 1.6.2), with the silencing of HDAC7 
leading to an increase in MMP10 expression. This relationship will be 
investigated here as an alternative strategy to produce MMP10 
overexpressing cell lines. 
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4.1.2 Aims and Objectives 
The aim of this chapter is to develop a functionally active MMP10 
overexpression model to investigate the consequences of high MMP10 in 
NSCLC tumour vasculature.  
This will be achieved by the following objectives: 
1- Development and characterisation of a functionally overexpressing 
MMP10 cell line either: 
a) By MMP10 overexpression in the H460 cells or  
b) Using HDAC7 silencing to mediate the induction of MMP10 in the NSCLC 
cell lines. 
2- Evaluation of the effects of functional MMP10 expression on vascular 
formation using a tube formation assay (Zhang et al., 2014a). 
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4.2. Materials and Methods 
4.2.1 Materials 
Opti-MEM® Reduced Serum Medium and Lipofectamine® RNAiMAX reagent, 
HDAC7A Pre-designed siRNA (ID:108707) and Silencer® Select Negative 
Control No. 1 siRNA (cat. 4390843) were purchased from Life Technologies 
Ltd (Paisley, UK). Polybrene was purchased from Sigma-Aldrich (Gillingham, 
UK). For cell selection, antibiotics, including G418 and puromycin, were also 
obtained from Sigma-Aldrich (Gillingham, UK). For immunohistochemical 
analysis, Harris’ Haematoxylin and Scott’s Tap Water were purchased from 
Sigma-Aldrich (Gillingham, UK). The CD34 antibody MA1-22646 used for 
immunostaining was obtained from Fisher Scientific (Loughborough, UK). 
The Vectashield Kit was purchased from Vector Laboratory Ltd 
(Peterborough, UK) for slide mounting. For 2D angiogenesis model analysis, 
the immortalised human umbilical vein endothelial cells (HUVEC-Cs) were 
obtained from the ATCC (Middlesex, UK) (Hoshi and Mckeehan, 1984; Jaffe 
et al., 1973). Microvascular endothelial cell growth medium-2 BulletKit EGM®-
2MV was bought from Lonza (Slough, UK). Amicon Ultra-15 centrifuged filter 
device, Ilomastat (GM6001) and In Vitro Angiogenesis Assay Kit were 
purchased from Millipore (Watford, UK). The polystyrene eight-well 
chambered cover glasses (Lab-TekTM) were bought from Fisher Scientific 
(Loughborough, UK). For PCR and Western blotting materials, refer to 
sections 2.1.2 and 2.1.3, respectively. 
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4.2.2 Methods 
4.2.2.1 Cell line nomenclature 
Transduced H460 cells with Short Hairpin HDAC7 (shHDAC7) and non-
targeting control (shNT) are termed ‘H460-shHDAC7’ and ‘H460-shNT’ 
respectively, while those genetically modified with mouse MMP10 expressing 
vector are termed ‘H460-clone2’. The H460-clone2 cells were a kind gift from 
Dr. Jason Gill (Durham University) who transfected them with this vector that 
was designed as described by (Madlener and Werner, 1997) (see section 
4.2.2.4.1). The A549 and H460 cells that have been transiently transfected 
using HDAC7 siRNA are termed ‘A549-siRNA’ and ‘H460-siRNA’, 
respectively. The immortalised human umbilical vein endothelial cells 
(HUVEC-Cs) isolated using an enzymatic technique described in (Eccles et 
al., 2008), were a kind gift from Dr Anne Graham (Bradford University). 
4.2.2.2 Cell line maintenance and culture conditions 
All cell lines used in this chapter were routinely maintained and cultured in 
complete RPMI-1640 as described in section 2.2.1 apart from HUVEC-Cs, 
which were cultured as described below.  
4.2.2.2.1 Culture of HUVEC-Cs 
The immortalised HUVEC-Cs were grown as monolayer cultures in EGM-
2MV medium supplemented with optimal concentrations of EGF, VEGF, IGF-
1, bFGF, hydrocortisone, ascorbic acid and 5% FBS. Cells were incubated at 
37°C in a humidified atmosphere of 5% CO2 and 95% air and media was 
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changed every other day. Before 80% confluence was achieved, cells were 
detached using 0.25% trypsin-EDTA, as previously described in section 
2.2.1. The resulting cells were resuspended in fresh, complete EGM-2MV 
medium and were either passaged or collected for further experimentation. 
4.2.2.3  Evaluation of cytotoxicity using the MTT assay 
4.2.2.3.1 Validity of the MTT Assay for H460 cells 
To ensure that the cell number correlates with the MTT absorbance readings, 
the linear relationship between cell viability and absorbance was established 
for the H460 cells using the MTT assay (Mosmann, 1983). Cells were grown, 
harvested and counted as described in section 2.2.1. Serial dilutions of cell 
suspensions (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and 5 x104 cells/ well) were 
prepared and seeded onto 96 well plates. Wells without cells but with media 
added acted as a blank. The plates were then centrifuged to allow cells to 
settle onto the bottom and supernatant was removed. Following the addition 
of the MTT solution, absorbance was read as described below in section 
4.2.2.3.3. To demonstrate the linear relationship, the mean absorbance was 
plotted against the cell number and a trend line was drawn.  
4.2.2.3.2 Optimisation of cell seeding densities for the MTT 
assay 
To optimise the H460 cell seeding density for use in the MTT assay, such 
that the cells would be in the log phase of their growth cycle during the 
experiments, growth curves of the H460 cells at several different seeding 
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densities were set up. Five different cell concentrations (one, three, 10, 30, 
and 100) x103 cells/ml in a final volume of 180 µl were seeded onto a 96-well 
plate in hextuplicate, leaving control wells where no cells were added.  Plates 
were then incubated for one, two, three, four or five days. Following the 
addition of the MTT solution, absorbance representing cells viability was read 
as described below in section 4.2.2.3.3. Data from three experiments were 
averaged and plotted against time. 
4.2.2.3.3 MTT Assay  
The impact of two selection antibiotics, G418 and puromycin, and the 
transfection reagent lipofectamine RNAiMAX on cell number was measured 
using the MTT assay. Briefly, cells were seeded at 1.8x103 cells per well into 
96-well culture plates. Wells without cells but with media added acted as a 
blank control. All wells received 180µl fresh complete medium. The plate was 
incubated overnight at 37°C in a 5% CO2 and 95% air humidified atmosphere 
to allow cells to adhere. The next day, cells were treated with compounds of 
interest at the required concentration in 200uL fresh, complete medium. 
Control wells that received no drug but contained cells were also included for 
comparison. The plate was incubated for a further 96 hours in the same 
conditions described above. The media were then replaced with fresh 
medium containing 500µg/mL MTT and plates were incubated for a further 
four hours at 37°C. The medium was subsequently removed and the 
resulting crystals were dissolved in 150μL DMSO. Absorbance was 
measured on a microplate reader at 540nm and were averaged and the 
mean blank absorbance was subtracted to provide an adjusted absorbance 
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reading. To assess growth inhibition, the relative proportion of live cells to 
untreated control was calculated as follows: % cell survival = [adjusted mean 
treated group absorbance / adjusted mean control group absorbance] x 100.  
A graph of concentration against percentage cell survival was then plotted. 
This assay was conducted in triplicate unless otherwise stated. 
4.2.2.4  Generation of stable MMP10 expressing cells 
4.2.2.4.1 MMP10 expressing clones 
The human H460 cells transfected with a mouse MMP10 expressing vector 
designed as described (Madlener and Werner, 1997) were a kind gift from Dr 
Jason Gill (Durham University). Since these cells initially were generated for 
another project to assess in vivo the consequences of MMP10 
overexpression in tumours on the adjacent normal vasculature, the use of 
mouse vector in human cells could be justified. The cells were cultured prior 
to the selection of stable transfectants using G418 antibiotic as described 
below in section 4.2.2.4.4. 
4.2.2.4.2 Stable HDAC7 silencing using shRNA lentiviral 
particles 
Histone deacetylase 7 was silenced in the H460 cells using a Short Hairpin 
RNA (shRNA) lentiviral transduction system. Lentiviral particles targeting the 
HDAC7 gene, prepared by MISSION shHDAC7 plasmids DNA (Sigma) 
according to the manufacturer’s protocol, was a kind gift from Dr Andriana 
Margariti (Queen’s University Belfast). A full detail of the procedure is 
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reported by Margariti et al. (Margariti et al., 2010). A control of the shRNA 
lentiviral vector that does not target any known genes (shNT) was also 
prepared in parallel for comparison. For lentiviral infection, H460 cells were 
seeded in a T75 flask at 60% confluence and allowed to attach overnight. 
The next day cells were incubated with shHDAC7 or shNT (1x107 
transduction units per ml) in RPMI complete media supplemented with 
10μg/ml of polybrene for 24 hours. Medium containing lentiviral particles was 
replaced with fresh medium, then the cells were incubated for another 48 
hours before being selected. 
4.2.2.4.3 Optimisation of antibiotic concentration for selection 
The MMP10 expression and the shRNA lentiviral vectors were designed to 
encode G418 and puromycin antibiotic resistance genes, respectively. These 
antibiotics therefore were used to select stable transfectants for this study. To 
ensure that the optimal antibiotic concentration was used during selection, a 
growth inhibition assay based MTT for wild type H460 was performed as 
described in section 4.2.2.3.3. G418 (100, 200, 400, 800, and 1600µg/mL) 
and puromycin (0.125, 0.25, 0.5, 1, 2, 4, and 8 µg/ml) were tested and cell 
viability was assessed daily. For G418, H460-clone2 cells were also included 
to evaluate their resistance as compared to the wild type, consequently 
confirming the presence and functionality of the vector inside the cells. The 
minimum concentration of G418 and puromycin that resulted in total cell 
death within three to four days and one to four days respectively, was 
considered the optimal antibiotic concentration for generating stable 
transfectants. The specific time period for the antibiotics was selected 
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according to their onset mode of action. Experiments were performed in 
triplicates, then data was averaged and plotted as percentage cell survival 
against time. 
4.2.2.4.4 Selection of stable transfectant 
H460-clone2 cells were incubated with complete RPMI media containing the 
optimal concentration of G418 for 13 days. In the case of lentiviral 
transduction, H460-shHDAC7 and H460-shNT were incubated with complete 
RPMI media supplemented with optimal puromycin concentration for seven 
days. During the incubation period, the medium was replaced every two days 
and the cells were monitored daily. Surviving cells were subjected to RT-PCR 
and Western blotting analysis to confirm successful transfection. 
4.2.2.4.5 Verification of stably transfected H460 cells 
Following cell selection, PCR analysis to confirm the specificity of the vectors 
was performed as previously described in section 2.2.4. For H460-clone2 
cells, mouse MMP10 primers (F:5-AGGGACCAACTTATTCCTGG-3; R:5-
CAGTATGTGTGTCACCGTCC-3 according to Van et al (Van Themsche et 
al., 2004) were used to amplify MMP10 mRNA.  
Histone deacetylase 7 and the MMP10 protein levels in transfected cells 
were evaluated using Western blotting as described in section 2.2.6. The 
monoclonal MMP10 antibody (ab49473) was confirmed to cross react with 
murine MMP10 protein before being used for the verification of H460-clone2 
cells. 
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4.2.2.5 Immunohistochemistry 
To assess the consequences of MMP10 overexpression on NSCLC tumour 
vasculature, immunohistochemical (IHC) analysis of CD34 protein was 
performed using tumour xenografts of wild type H460 and those engineered 
to express MMP10 (H460-clone2). The CD34 protein is a human 
hematopoietic and endothelial progenitor cell antigen that is expressed in all 
types of endothelium (Folkman, 1995), and its antibody has been validated to 
stain the capillary endothelium (Fina et al., 1990). For immunohistochemistry, 
formalin-fixed, 5μm thick paraffin-embedded tissue sections were provided 
by Beryl Cronin of the Institute of Cancer Therapeutics. All incubations were 
carried out at room temperature unless otherwise stated.  Following heating 
at 60°C for 20 minutes, sections were de-waxed in xylene and rehydrated in 
distilled water. The dewaxed hydrated sections were then incubated in 1% 
hydrogen peroxide for 30 minutes to extinguish endogenous peroxidase 
activity. For antigen retrieval, section were completely immersed in 0.1mM 
citrate buffer (pH 6.0) and heated in a microwave for five minutes. Slides 
were allowed to cool in citrate buffer for 30 minute before being washed with 
PBS for 10 minutes. Non-specific binding of primary antibody with sections 
was blocked through the incubation of the latter with 10% normal rabbit 
serum (Vector) diluted in PBS for 30 minutes. Sections were subsequently 
immunostained with 100µl of primary anti-CD34 antibody at 1:2000 ratio in 
PBS for two hours. A negative control that received no primary antibody 
treatment was also included. After washing excess antibody with water and 
PBS for 10 minutes, sections were dried and incubated for one hour with 
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biotinylated rabbit anti-rat secondary antibody diluted as 1:100 in PBS. 
Following a further wash with water and PBS, sections were incubated for 30 
minutes with ABC reagent (Vector) and developed in DAB. Developed 
sections were then counterstained in Harris’ Haematoxylin solution for 20 
minutes before being incubated for two minutes with Scott’s Tap water as 
blueing reagent. Sections were dehydrated and cleared using ascending 
concentrations of ethanol (70%, 80% and 100%), 50% xylene/ethanol and 
100% xylene. Slides were then mounted using DPX mounting medium. 
4.2.2.5.1 Semi-quantitative analysis of immunohistochemistry 
To assess the microvessel density for microscopic sections, vessels and 
capillaries identified by positive staining for CD34 and appropriate 
morphology were manually counted using a grid overlay method. The 
intersection of visibly interconnected brown-staining endothelial cells with a 
spot on the grid was counted. Ten representative equal size fields were 
counted per slide and the mean number was calculated. The values reported 
herein are averaged of the three independent slides per sample set. The 
observation was done at 40X objective magnification using a Leica DMLS 
microscope connected to JVC digital ½ inch CCD video camera. 
4.2.2.6 In vitro 2-D angiogenesis model 
Matrix metalloproteinase 10 protein can exist in both pro and active forms; 
hence, measuring enzyme activity is essential to ensure the presence of 
active MMP10. As there is no specific MMP10 activity assay available to 
date, the well-known angiogenic role of MMP10 can be used as a functional 
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marker where the amounts of angiogenesis seen should be relative to the 
amounts of MMP10 present. Thus, an in vitro angiogenesis assay was used 
here to assess the functionality of MMP10 protein in the wild-type and 
engineered cell lines. 
4.2.2.6.1 Characterisation of HUVEC growth 
Human umbilical vein endothelial cells cultures were used in the in vitro 
angiogenesis assay for this research to mimic the behaviour of vascular 
endothelial cells in vivo (Boisen et al., 2010; Staton et al., 2009). Growth 
curves were constructed to characterise their growth pattern as described in 
section 2.2.2. 
4.2.2.6.2 Optimisation of HUVEC-Cs seeding density for the 
tube formation assay. 
As the proper seeding density of endothelial cells is crucial for any tube 
formation assays, HUVEC-Cs were seeded in an eight-well chamber coated 
with ECMatrixTM at four different seeding densities: 1 x 104, 2 x 104, 3 x 104 
and 4 x 104 cells/well as described below. After 24 hours of incubation, tube 
formation was inspected using the LumaScope 500 at 40x magnification. 
4.2.2.6.3 In vitro angiogenesis assay 
The in vitro angiogenesis assay kit (Millipore) was adopted for use in these 
studies. The polystyrene eight-chambered cover glasses was used instead of 
the recommended 96-well culture plate in order to provide sufficient growth 
space and improve captured image quality. Briefly, ECMatrixTM was thawed 
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overnight on ice and all the components kept at 4°C before and during the 
assay to avoid premature solidification of the ECMatrixTM. In a cold sterile 
microcentrifuge tube, ECMatrixTM was diluted in a 1:9 ratio with 10x Diluent 
Buffer. Approximately 170μL of this mixture was transferred to each well of 
polystyrene eight-chambered cover glasses. The plate was then incubated at 
37°C for at least one hour to allow the matrix solution to solidify. HUVEC-Cs, 
which were maintained in EGM-2 complete medium, were seeded on the 
ECMatrixTM polymerised layer at a density of 4 x 104 cells in 210µl EGM-2 
complete medium per well. This was followed by the addition of concentrated 
conditioned media from different samples. For the impact of MMP10 on 
angiogenesis studies, recombinant MMP10 (equivalent to 0.25, 2.5 and 
25nM) was added at this stage. A positive control received no conditioned 
media and a negative control treated with 25uM broad spectrum MMPs 
inhibitor (GM6001) was also included. The cells were subsequently incubated 
in a humidified atmosphere of 5% CO2 and 95% air at 37°C for 18 hours. 
Once incubation was completed, tube formation under bright-field illumination 
was monitored in situ using a LumaScope 500 (EtalumaInc, Carlsbad, USA) 
at 20x or 40x objective lens magnification, with images captured digitally 
through a CMOS Sensor camera and processed using LumaView 500 
software (EtalumaInc, Carlsbad, USA).   
4.2.2.6.4 Quantification of HUVEC tube formation 
During the complex multistep processes of angiogenesis at the molecular 
level, activated endothelial cells form capillary tubes sprouting into the 
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stromal space in a branching pattern. Counting the number of branch points 
of these tubes should reflect the extent of angiogenesis. 
To measure the tube-like structure area following the performance of the 
angiogenesis assay, the number of branch points formed by HUVEC-Cs after 
24 hours incubation per well were counted. All sample values were 
normalised to the corresponding control (non-treated). Consequently, the 
relative number of branching points was determined. The values of the three 
independent experiments were then averaged and presented in a bar graph. 
Statistical differences were assessed using Student's t test.  
4.2.2.7  siRNA Silencing of HDAC7 in NSCLC cell lines 
For efficient transient HDAC7 silencing, optimisation was performed as 
described below. 
4.2.2.7.1 siRNA-gene knockdown 
Approximately 5x105 cells/well were seeded and grown overnight with 
complete RPMI media in a six-well plate. The next day, media were removed 
and cells were incubated for four hours with 1mL Optimum media containing 
the indicated concentration of siRNA and lipofectamine RNAiMAX. A control 
with non-targeting siRNA and mock transfection was included to assess any 
potential effect of the transfection reagents on the cells. Cell growth condition 
was then normalised by the addition of 0.5mL 3X RPMI feed media, 
supplemented with 30% FCS, 6% L-Glutamine and 3% sodium pyruvate. The 
cells were then further incubated for 48 hours to recover and their condition 
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was monitored daily. Once the incubation period was completed, cells were 
harvested, counted and subjected to RT-PCR analysis as described above in 
section 2.2.4. For data analysis, HDAC7 mRNA expression level was 
determined and the ratio of HDAC7 gene knockdown was calculated as 
residual HDAC7 expression compared to the non-targeting siRNA control. 
4.2.2.7.2 Optimisation of siRNA concentration for 
transfection. 
To determine the optimal siRNA concentration for a successful transfection, a 
titration of HDAC7-siRNA concentrations (25nM, 50nM, 100nM, and 200nM) 
was tested for HDAC7 silencing in the H460 cell line. This optimisation was 
performed for 48 hours using 0.5% v/v Lipofectamine and following the 
protocol described above. 
4.2.2.7.3 Optimisation of Lipofectamine RNAiMAX 
concentration. 
To ensure efficient exogenous siRNA uptake by cells during the transfection, 
concentration of the transfection reagent was optimised. Several 
concentrations of Lipofectamine RNAiMAX (0.18, 0.26, 0.34, 0.42 and 0.5% 
v/v) were evaluated for HDAC7 silencing in the H460 cells. This optimisation 
was performed using the optimal 50nM HDAC7 siRNA and following the 
protocol described in section 4.2.2.7.1.  
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4.2.2.7.3.1 Evaluation of Lipofectamine toxicity 
Lipofectamine RNAiMAX toxicity on the H460 cells was measured by MTT 
assay as described in section 4.2.2.3.3. Cells were treated with serial 
dilutions of Lipofectamine RNAiMAX, including 0.18, 0.26, 0.34, 0.42, 0.5 and 
0.58% v/v. Data from the total three separate experiments were then plotted 
as percentage of cell survival against Lipofectamine RNAiMAX 
concentrations. 
4.2.2.7.4 Optimisation of post-transfection incubation period 
The induction and duration of HDAC7 silencing were examined to choose the 
most suitable post-transfection periods for future experiment. By following the 
protocol described in section 4.2.2.7.1, the H460 cells were transfected in 
triplicates with the optimal 50nM HDAC7 siRNA and 0.5% v/v Lipofectamine 
then incubated for different post transfection periods, including 24, 48, and 72 
hours. 
4.2.2.7.5 Transient HDAC7 Gene Knockdown 
By following the protocol described in section 4.2.2.7.1, transient HDAC7 
knockdown was performed in the A549 and H460 cells using the identified 
optimal siRNA transfection conditions, 50nM HDAC7-siRNA, 0.5% v/v 
Lipofectamine RNAiMAX, and 24-72 hour post incubation periods. 
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4.3 Results 
4.3.1 Optimisation of the MTT Assay for Use with H460 Cells 
Initial day zero studies confirmed the linear relationship between the H460 
cell number and absorbance using the MTT assay (Figure 4.1). The growth 
pattern of the H460 cells generated from five cell seeding densities in a 96-
well plate was then evaluated using the MTT assay. Three cell seeding 
concentrations (1x104, 3x104 and 10x104 cell/ml) showed a clear exponential 
phase of growth; however, the stationary phase corresponding to the cell 
seeding concentrations of 3x104 and 10x104 cell/ml roughly began at day 
four and day three, respectively (Figure 4.2). Taking into consideration the 
fact that incubation periods may extend up to five days, the optimal seeding 
concentration for the H460 cells to be used in further assays was 1x104 
cells/ml. 
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Figure 4.1. Relationship between the number of H460 cells and MTT 
absorbance readings. A linear relationship with an R2 value of 0.976 was 
established between the number of H460 cells and MTT absorbance, 
supporting suitability of MTT assay. Cells were seeded at various 
densities ranging from 0.5x104 to 5.0x104 cells/well. Absorbance readings 
at 540nm, representing the number of viable cells at day zero, were then 
assessed using the MTT assay.  
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Figure 4.2. Growth kinetics of the H460 cells cultured in 96-well plates. The 
growth curve analysis was performed using a titration of the cell seeding 
densities. For each time point, absorbance representing cell viability was 
read at 540nm following the addition of MTT solution as described in 
section 4.2.2.3.3. Data from the three experiments were averaged and 
plotted against time. Based on growth patterns, 1x104 cells/ml in a final 
volume of 180ul is the optimal cell seeding density identified for future 
growth inhibition assay. 
 
4.3.2 H460-Clone2 as an MMP10 Preclinical Model 
To elucidate the exact consequence of the high MMP10 overexpression seen 
in NSCLC tumour development, engineered models with MMP10 
overexpression are a useful tool. One such model has previously been 
developed in this laboratory by overexpressing MMP10 in the H460 cells 
(H460-clone2) and it is utilised in these studies. 
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4.3.2.1 Determination of ideal antibiotic concentration for 
H460-clone2 selection. 
Stable transfectants of H460-clone2 were selected using G418 antibiotic. It 
was necessary to first optimise the antibiotic concentration to use.  
It is clear from the results shown in Figure 4.3A that the minimum 
concentration of G418 required to kill 100% of the wild-type H460 cells within 
three to four days is 800ug/ml. This was chosen as the optimum 
concentration of G418 for selection. When this dose was applied to H460-
clone2, significant resistance to G418 was seen (Figure 4.3 B), indicating the 
presence and functionality of the vector inside the majority of the transfected 
cells and confirming the suitability of this dose. 
4.3.2.2 Evaluation of MMP10 in H460-clone2 at mRNA and 
protein levels. 
Following the H460-clone2 selection, MMP10 induction was assessed at the 
transcriptional level using RT-PCR analysis. As expected, higher expression 
of murine MMP10 mRNA was observed in transfectant H460-clone2 as 
compared to the wild type, confirming the functionality and specificity of the 
vector. This gave the confidence to proceed to the verification at the protein 
level using Western blotting. 
The Western blotting results showed that the H460-clone2 has significantly 
higher pro MMP10 protein than the wild-type H460 cells, indicating MMP10 
overexpression even at the translational level (Figure 4.4).  
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Figure 4.3. Cytotoxicity profile of G418 antibiotic on wild-type and H460-
clone2 cells. A range of G418 concentrations were tested to determine the 
optimum concentration for the selection (A). The minimum concentration 
that resulted in total cell death within three to four days is 800ug/ml, 
therefore it was chosen as the optimal concentration. In contrast, a 
significant resistance was observed for H460-clone2 cells when they were 
exposed to this similar dose of G418 (B). The induction of resistance in 
H460-clone2 supports the presence and functionality of the vector. Data 
shown represent the average of the three experiments and * p<0.05 by the 
student t test. 
 
* 
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Figure 4.4. Verification of MMP10 induction in transfected H460-
clone2 cells. A single band corresponding to mouse MMP10 
mRNA was observed with H460-clone2 following RT-PCR analysis 
(A). MMP10 protein was significantly higher in H460-clone2 
compared to the wild type as suggested by Western blotting (B). 
Recombinant MMP10 with predicted molecular mass for pro 
MMP10 52 KDa was used as a positive control. * p<0.05. 
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4.3.3 In Vitro Angiogenesis Assay 
4.3.3.1 HUVEC-C growth curve 
To assess the HUVEC-C growth characteristics for future studies on 
vasculature, a growth curve analysis was performed as described in section 
2.2.2. As shown in Figure 4.5, for the cell concentration applied, HUVEC-Cs 
log growth phase began at day one with doubling time calculated as 36.6 
hours. The log phase lasted for six days, then cells entered the stationary 
phase approximately at day seven. This data was used to ensure HUVEC-Cs 
subjected to future analysis were in the log growth phase. 
 
 
Figure 4.5. Growth pattern of HUVEC-Cs. The cells were seeded into 25 
cm2 flasks at seeding concentrations of 1x104 cell/ml. The number of cells 
were determined every other day for 11 days using a haemocytometer, 
then plotted against time. Error bars were obtained from three 
independent experiments. 
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4.3.4.2 Confirming the presence of secreted MMP10 in 
concentrated conditioned media of NSCLC. 
Since MMP10 is a low abundance secreted protein, a centrifuge filtration 
method for concentrating the conditioned media from cells was utilised prior 
to Western blotting to confirm the secretion of MMP10 from the NSCLC cell 
lines in the panel (described in section 2.2.6.2). The Western blotting results 
in Figure 4.6 generally showed a low level of secreted pro-MMP10 protein 
(54KDa) in conditioned media from the A549 and H460 cell lines. The 
secreted pro-MMP10 from the H661 cell line was below the detection level of 
Western blotting and could not be observed at this stage. However, when 
conditioned media was concentrated (10-fold concentration) using the 
centrifuge filtration method to improve the detection level by Western blotting, 
secreted pro-MMP10 from H661 cells was observed, indicating a very low 
level in this cell line. Although active MMP10 protein (44 KDa) in all the 
samples tested was below the detection level of Western blotting and could 
not be observed, it was assumed that this method successfully concentrated 
both forms of MMP10 as the membrane cut-off was 30 KDa. Together, data 
confirmed the secretion of MMP10 from the panel of the NSCLC cell lines 
evaluated, although at low levels compared to the cellular levels of MMP10. 
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Figure 4.6. Confirming the secretion of MMP10 in a panel of NSCLC cell 
lines. Evaluation of secreted MMP10 in conditioned medium from A549, 
H460 and H661 cells by Western blotting showed weak bands 
corresponding to pro-MMP10 of A549 and H460 cells, whereas no band in 
the case of the H661 cells. When conditioned media were concentrated, 
pro-MMP10 in the H661, as well as in other cells, was successfully seen. 
Despite concentrating the conditioned media, active MMP10 was below 
the detection level and could not be seen. 
 
4.3.4.3 Validation of angiogenesis assay 
Prior to using the in vitro angiogenesis assay for assessing the functionality 
of MMP10 protein, it was important to validate it first by evaluating the effect 
of MMP10 addition on the tube formation of HUVEC-Cs. To achieve this, 
cells were treated with ascending recombinant MMP10 concentrations and 
assessed for their ability to form tube-like structures using branching point 
counts. The data show that adding increasing amounts of MMP10 protein 
resulted in an increase in angiogenesis in a dose dependent manner (Figure 
4.7). Significantly higher angiogenesis with 25nM MMP10 was observed 
Pro-MMP10 (54 KDa) in 
conditioned media 
Pro-MMP10 (54 KDa) in 
concentrated conditioned 
media 
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compared to control. Inhibiting the activity of MMP10 clearly reduced the 
angiogenesis, as demonstrated when GM6001 was used. 
In addition, for further validation and evaluation of whether this assay is 
suitable for assessing the effects of MMP10 in cell-conditioned media, 
HUVEC-C cells were treated with concentrated conditioned media from the 
NSCLC cells in the panel and data was compared to the Western blotting 
results. As would be expected, results in Figure 4.8 showed an induction of 
angiogenesis due to MMP10 and other potential angiogenic factors secreted 
by the NSCLC cells with the angiogenesis capacity consistent with the 
MMP10 levels detected by Western blotting (Chapter 3, Figure 3.7). For the 
A549 and H460 cells, a marked induction in angiogenesis capacity due to 
secreted MMP10 was almost identical to the high MMP10 level detected by 
Western blotting in these cell lines. For the H661, no significant effect on 
angiogenesis capacity was observed, corresponding to low MMP10 protein 
by Western blotting. Overall, these data confirm suitability and validate this 
assay. 
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Figure 4.7. Induction of angiogenesis by MMP10 using an in vitro 
angiogenesis assay. HUVEC-Cs were treated with several concentrations 
of MMP10 then assessed for their angiogenic ability. Representative 
image for each sample was taken by LumaScope 500 at 20x 
magnification (A). Results quantification using branching point count (B). 
Arrows point to branching point. * p<0.05. (n=3). 
* 
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Figure 4.8. Induction of angiogenesis due to concentrated conditioned 
media from NSCLC cells. HUVEC-Cs were exposed to concentrated 
conditioned media from the A549, H460 and H661 cell lines, and then 
assessed for their angiogenic ability. Representative image for each 
sample was taken by LumaScope 500 at 20x magnification (A). 
Results quantification using branching point count (B). * p<0.05. (n=3). 
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4.3.4.4 In vitro angiogenesis assay for H460-clone2. 
Since MMP10 overexpression was observed at both the genetic and protein 
levels for the H460-clone2 cells, it was conceivable that they might have 
potential as an MMP10 NSCLC preclinical model. This overexpression of 
MMP10 however was not associated with phenotype changes; therefore, the 
functionality of the protein being secreted has to be demonstrated.  
As an increase in the functional secreted MMP10 results in increased 
angiogenesis, the angiogenic capacity of the H460-clone2 was evaluated 
using the in vitro angiogenesis assay. The wild type H460 was also included 
for comparison. As would be predicted, the angiogenesis capacity seen for 
the wild type H460 concentrated conditioned media was significantly higher 
than for the control. In contrast, no marked increase in angiogenesis was 
observed for the H460-clone2 cells when compared to the control (Figure 
4.9). While high angiogenesis capacity was observed with the H460 
concentrated conditioned medium, the addition of 25µm of GM6001 (broad 
MMP inhibitor) clearly decreased it, indicating that the effect seen was MMP 
related (Figure 4.9). Overall, this suggests that the MMP10 being 
overexpressed in the conditioned media of the H460-clone2 cells is inactive, 
certainly in an in vitro setting. 
4.3.4 Confirmation of the Lack of Functional Activity of the 
H460-clone2 MMP10 
To see if growing the cells in a more supportive environment in vivo would 
enhance MMP10 activity in the H460-clone2 cells, sections of tumour taken 
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from a previous in vivo study conducted to assess the consequence of 
MMP10 overexpression on tumour growth were evaluated for evidence of 
angiogenesis. 
Although the semi-quantitative analysis of CD34 immunolabelling 
demonstrated a slight reduction in the vascular density of H460-clone2 
xenografts compared to the wild type, there was statistically no significant 
difference between the two types of tumours (Figure 4.10). This provides 
further evidence that the elevated MMP10 levels seen in the H460-clone2 
cells were non-functional. At this stage, it was decided not to make further 
use of the H460-clone 2 as an MMP10 overexpressing model. 
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Figure 4.9. An in vitro angiogenesis functional assay for the transfected 
H460-clone2 cells and their wild type. Tube formation by HUVEC-Cs 
following exposure to H460 (wild type) concentrated conditioned media 
was higher than that of the H460-clone2, suggesting that MMP10 being 
secreted is not functional. Non-treated HUVEC-Cs were used as a 
control. HUVEC-Cs exposed to the H460 concentrated culture medium 
containing 25µm of GM6001 (broad MMP inhibitor) was included to 
ensure that the effect was MMPs related. Representative image for 
each sample was taken by LumaScope 500 at 20x magnification (A). 
Results quantification using branching point count (B).  * p<0.05. (n=3). 
* 
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Figure 4.10. Semi-quantification of microvessel density. For each 
sample, three sections were stained using CD34, then counted as 
previously described in section 4.2.2.5.1. Representative images of 
successfully labelled blood vessels, which are included in the count 
(A). Bars represent 100µm length. Averaged data from three separate 
analyses were presented (B). Interestingly, no statistical difference in 
the number of blood vessels between the wild type and MMP10 
transfected (H460-clone2) was observed using Student's t-test. 
 
 
P.value =0.15 
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4.3.5 Lentiviral Transduction Mediates Stable HDAC7 in H460 
Cells 
Due to the failure of the direct transfection of MMP10 to generate a 
functionally overexpressing MMP10 preclinical model, another approach was 
tried. From the literature, it is known that HDAC7 silencing increases MMP10 
expression in endothelial cells (Chang et al., 2006). To investigate whether 
this correlation also occurred in the NSCLC cells, HDAC7 was silenced 
permanently in the H460 cells by transcriptional stable gene silencing using 
the shRNA lentiviral transduction system as described in section 4.2.2.4.2. 
4.3.5.1. Optimisation of puromycin concentration for H460-
shHDAC7 cell selection. 
To ensure that only stable transfectants were used for analysis, H460-
shHDAC7 cells were selected using puromycin antibiotic. The ideal 
concentration to use for the selection was determined using a growth 
inhibition assay for the H460 cell line as described in section 4.2.2.4.3.  
From the results shown in Figure 4.11, the minimum concentration of 
puromycin required to kill 100% of the H460 wild type cells within one to four 
days was 1ug/ml. This was chosen as the optimum concentration of 
puromycin for selection. 
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Figure 4.11. Optimising appropriate puromycin concentration for the 
selection of lentiviral-HDAC7 transduced cells. The H460 wild type cells 
were exposed to various concentrations of puromycin for one, two, three 
and four days. Cell growth was measured using the MTT assay and the 
percentage of viable cells was determined. The puromycin concentration of 
1 µg/ml was chosen for the selection as it was the lowest one that resulted 
in almost total cell death between one to four days incubation. (n=3). 
 
4.3.5.2 Optimisation of HDAC7 and MMP10 primers for RT-
PCR analysis. 
In terms of investigating the possible relationship between HDAC7 and 
MMP10 at the genetic level, primer concentration for both genes was 
optimised to ensure maximum accuracy and efficiency. A range of primer 
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concentrations (0.5µM- 5µM) for HDAC7 and MMP10 was tested using the 
A549 cDNA as template. As the lowest primer concentration that produced 
the maximal single PCR product without excess primer was 0.5µM per 20µl 
reaction, it was chosen as the optimum primer concentration for the future 
PCR for HDAC7 and MMP10 genes (Figure 4.12). 
 
Gene Name Primer Concentrations 
HDAC7 
   
MMP10 
  
 
 
 
 
 
 
Figure 4.12. Optimization of HDAC7 and MMP10 primers concentration. 
HDAC7 and MMP10 genes were amplified in the presence of four different 
final primer concentrations using 5ul cDNA extracted from the A549 cell line. 
Maximal single PCR products without too much waste or primer excess were 
observed at 0.5µM. Optimum primer concentration identified was 0.5µM per 
reaction. 
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4.3.5.3 Impact of stable HDAC7 silencing on MMP3 and 
MMP10  expression in the H460 cells. 
Following lentivirus infection, cells were verified at the transcriptional level for 
the expression of HDAC7 to ensure successful silencing. RT-PCR analysis 
demonstrated a significant HDAC7 gene knockdown in H460-shHDAC7 
compared to the H460-shNT cells (Figure 4.13, A and B). Further evaluation 
of the long term impact of this knockdown on MMP expression was 
performed. Interestingly, HDAC7 silencing resulted in no change on MMP10 
expression in H460 cells as shown in Figure 4.13, A and D. In addition, a 
significant elevation of MMP3 expression was observed as a result of HDAC7 
down-regulation in these cells (Figure 4.13, A and C).  
The effect of HDAC7 silencing on MMP3 and MMP10 observed at the 
transcriptional level should also be confirmed at protein level. However, an 
MMP3 antibody that does not cross-react with the closely-structured MMP10 
protein could not be identified (See 3.4.5.1). As a consequence, protein 
analysis was limited to MMP10 only using the validated MMP10 antibody as 
confirmed in section 3.4.5.1. Similar to mRNA levels, marked HDAC7 protein 
silencing was achieved, but did not cause any change to the MMP10 protein 
levels (Figure 4.14). Although the long-term investigation did not reveal an 
MMP10 expression model, it demonstrated for the first time potential 
negative correlations at the transcriptional level between HDAC7 and MMP3 
in the H460 cell line.  
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Figure 4.14. Verification of HDAC7 silencing at protein level and the 
evaluation of its impact on MMP10. Although a marked HDAC7 
knockdown was achieved, no marked change in MMP10 expression was 
detected using Western blotting. Immunoblot images were shown in (A) 
and semi-quantification of results for H460-shNT and H460-shHDAC7 
was presented in (B). A positive control (NIH3T3 whole cell lysate) for 
HDAC7 was used in compliance with the antibody supplier 
recommendations. β-actin was used as loading control. Data shown 
represents means ± SD of three different experiments.* p<0.05. For 
HDAC7 blot full image, see appendix 6. 
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4.3.6 Transient Transfection Studies 
Since no stable MMP10 overexpressing model was identified, the next step was 
to try and develop a transient MMP10 model to be used for insight 
investigations. Transient gene impact studies based on RNA transfection have 
several advantages over the long term studies. Most importantly, there will be 
no risk of integration into the host genome, thereby causing relatively minimal 
cell stress (Kim and Eberwine, 2010; Yamamoto et al., 2009). 
4.3.6.1 Optimising of siRNA knockdown conditions using 
HDAC7 siRNA. 
Low transfection efficiency is the most common cause of unsuccessful siRNA 
gene knockdown experiments. To ensure high levels of transfection efficiency 
with minimal impact on cell viability, protocol optimisation was performed to 
choose the appropriate concentrations of siRNA and the transfection reagent to 
be used in the transfection procedure. The post transfection period was also 
optimised to ensure high-throughput gene silencing. 
4.3.6.2 Optimising appropriate siRNA concentration for the 
transfection of the H460 cell line. 
Optimisation of siRNA concentration on the H460 cells was performed using 
several concentrations of HDAC7-siRNA as described in section 4.2.2.7.2. A 
marked HDAC7 knockdown was achieved from as low as 25nM siRNA. 
Increasing the siRNA concentration from 25nM to 200nM did not improve the 
HDAC7 knockdown. Despite minor differences in HDAC7 knockdown capability 
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between 25nM and 50nM siRNA concentrations, 50nM was chosen as the 
optimal siRNA concentration, taking into consideration that results of this 
optimisation may be applied to other cells that are more difficult to transfect in 
future analysis (Figure 4.15). 
4.3.6.3 Optimisation of a Lipofectamine RNAiMAX 
concentration for H460 transfection. 
Optimising the concentration of the transfection reagent (Lipofectamine) is 
important for a successful siRNA delivery into cells. An ideal concentration of 
the transfection reagent is one that can yield a marked target gene silencing 
without significant cell mortality. To achieve this, the optimal concentration of 
50nM HDAC7 siRNA and a range of Lipofectamine RNAiMAX concentrations 
(0.18, 0.26, 0.34, 0.42 and 0.5% v/v) were tested for H460 cell transfection at 
two time points. Lipofectamine RNAiMAX concentration of 0.5% v/v shows the 
highest transfection efficiency achieved with approximately 90% and 75% gene 
silencing for 24 and 48 hours post-transfection periods respectively (Figure 
4.16). 
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Figure 4.15. Optimisation of HDAC7 siRNA concentration.  A range of 
HDAC7 siRNA concentrations were tested to transfect H460 cells with 
0.5% v/v Lipofectamine for 48 hours. HDAC7 knockdown was 
evaluated using RT-PCR analysis (A). Results were semi-quantified by 
densitometric tool of Quantity One software (B). Controls of non-
targeting siRNA and mock transfection were used for comparison. 
Despite minor differences in the HDAC7 knockdown capability 
between 25nM and 50nM siRNA concentrations, 50nM was chosen as 
the optimal siRNA concentration, taking into account the possible use 
of other cells that are more difficult to transfect in future analysis. Data 
shown represents the mean ± standard deviation of the three different 
experiments. * p<0.05 
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Figure 4.16. Identification of optimal Lipofectamine concentration for H460 
cells transfection. Among the concentrations tested, the use of 0.5% v/v 
Lipofectamine RNAiMAX concentration results in the highest transfection 
efficiency achieved for both 24 and 48 hours. As such, this was chosen as the 
optimal concentration. The RT-PCR was performed for HDAC7 and GAPDH 
genes, followed by semi-quantification of the results by densitometry. Data 
shown represents the mean ± standard deviation of the three different 
experiments. * p<0.05. 
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4.3.6.3.1 Evaluation of Lipofectamine toxicity on H460 cells. 
To evaluate whether the identified optimal concentration of Lipofectamine 
RNAiMAX has an impact on cell health, toxicity on the H460 cells was 
measured by MTT assay as described in section 4.2.2.3.3. Despite a minor 
reduction in cell viability observed in 0.58% v/v concentration, this analysis 
generally revealed no marked differences in viability between treated and non-
treated cells as shown in Figure 4.17. As it demonstrates no considerable 
increase in toxicity, Lipofectamine concentration of 0.5% v/v was chosen as 
optimal for future experiments. 
4.3.6.4 Duration of transient HDAC7 knockdown by siRNA 
transfection. 
H460 cells were transfected in a six-well plate using the optimal transfection 
conditions identified (50nM HDAC7-siRNA and 0.5% v/v lipofectamine/well) for 
three post-transfection periods (24, 48, and 72 hours). Histone deacetylase 7 
silencing was induced at as little as 24 hours post-transfection and continued 
over the next 48 hours (Figure 4.18). Results of the semi-quantification revealed 
that there was no marked difference in the gene silencing for the three time 
points tested, suggesting a constant inhibitory effect. Based on this, it was 
decided to choose 48 and 72 hours as the optimal post transfection periods for 
the analysis of the HDAC7 gene silencing effects. 
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Figure 4.17. Evaluation of Lipofectamine toxicity on H460 cells using 
growth inhibition-based MTT assay. By following the procedure described 
in section 4.2.2.7.3.1, no marked reduction in cell viability was observed 
with Lipofectamine concentrations from 0.18 to 0.5% v/v. As it shows no 
considerable increase in toxicity, Lipofectamine concentration of 0.5% v/v 
was chosen as the optimal Lipofectamine concentration for future 
experiments. Data shown represents the means ± SD of the three 
different experiments. 
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Figure 4.18. Duration of transient HDAC7 knockdown in H460 cells. A 
reduction in HDAC7 expression achieved at 24, 48 and 72 hours post 
transfection as indicated by RT-PCR analysis (A). Results shown above 
were semi-quantified using densitometric tool of Quantity one software (B). 
No obvious effect was seen with  non-targeting siRNA or mock transfection. 
Although there was no marked difference in gene silencing within the time 
frame used, the 48 and 72 hours were chosen as the optimal post 
transfection periods for future experiment. Data shown represent the 
average of triplicate experiments. * p<0.05. 
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4.3.7 siRNA Mediates Silencing of HDAC7 in H460 Cells 
Following the optimisation of the transfection conditions (50nM siRNA-HDAC7 
and 0.5% v/v lipofectamine), a significant transient HDAC7 knockdown was 
achieved, and these cells were used for the study of the short term impact of 
HDAC7 silencing. 
4.3.7.1 Impact of HDAC7 silencing on MMPs in H460 cells 
While it has been demonstrated in other cell types that transient HDAC7 
knockdown leads to the modulation of not only MMP10, but other 
endoproteases, such as MMP14 and MMP13 (Ha et al., 2008; Higashiyama et 
al., 2010) as well, this has not been reported for NSCLC cell lines. Therefore, 
this was evaluated here by assessing the mRNA levels of 22 MMPs in 
transiently HDAC7-silenced H460 cells. 
Among the evaluated MMPs, results in Figure 4.19 show that HDAC7 silencing 
resulted in a marked induction of MMP3 mRNA expression, confirming that a 
negative correlation exists between HDAC7 and MMP3 in the H460 cell line. A 
slight decrease of MMP15 expression caused by this silencing was also 
observed. Matrix metalloproteinase 14 mRNA expression was below the 
detection level of this analysis. Similar to the long term impact studies, no effect 
on MMP10 mRNA expression was detected due to HDAC7 silencing. This 
suggests that the relationship between MMP10 and HDAC7, as seen in other 
studies, might be cell type specific. 
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Figure 4.19. Impact of HDAC7 transfection on 22 MMPs mRNA expression using 
RT-PCR analysis. The HDAC7 silencing in the H460 cells results in a marked 
increase of MMP3 expression. Since most MMPs are mainly expressed in the 
HT-1080 cell line, it was used as a positive control. GAPDH was also used as a 
loading control. S.siRNA: scrambled siRNA; mock.T: mock transfection; HDAC7-
s: HDAC7-siRNA 
 
MMP    S.siRNA   Mock T.   HDAC7.s   HT-1080         MMP   S.siRNA    Mock T.  HDAC7.s   HT-1080 
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4.3.7.2 Lack of effects of HDAC7 silencing on MMP3 and MMP10 
induction in A549 cells. 
To address whether the reverse correlation observed for HDAC7 and MMP3 in 
the H460 cells is cell type specific, transient HDAC7 silencing in the A549 cells 
was performed. Although significant HDAC7 silencing was achieved in the A549 
cells following the transfection procedure, no marked MMP3 induction was 
observed (Figure 4.20) unlike for the H460 cells. Thus, the relationship 
observed between HDAC7 and MMP3 might be cell type specific. 
To confirm the absence of a relationship between HDAC7 and MMP10 in 
NSCLC, the impact of HDAC7 down-regulation on MMP10 expression in the 
A549 cells was also evaluated. Similar to H460 cells, no effect on MMP10 
mRNA expression was observed due to HDAC7 silencing (Figure 4.20), 
suggesting no relationship between HDAC7 and MMP10 in terms of NSCLC.  
 
 
 
 
 
 
 
 
150 
A 
Gene 
 
 
HDAC7 
 
MMP10 
 
MMP3 
 
GAPDH 
 
 
 
 
 
B 
 
Figure 4.20. No effect on MMP3 and MMP10 mRNA following a significant 
HDAC7 silencing in the A549 cells. RT-PCR analysis was used to evaluate 
HDAC7, MMP3, MMP10 and GAPDH genes (A). Results of semi-
quantification using densitometry with Quantity One software (B). GAPDH and 
HT-1080 cells were used as internal and positive controls, repectively.* 
p<0.05. 
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4.3.7.3 Impact of HDAC7 silencing on NSCLC cell growth. 
To evaluate the influence of HDAC7 knockdown on the growth of NSCLC cells, 
a comparison in proliferation rate was made between the HDAC7 transfected 
cells (A549-siRNA and H460-siRNA) and their corresponding controls. 
Following the optimal transfection procedure, HDAC7 silencing was verified by 
RT-PCR analysis and cells were counted throughout the next five days. 
As has been shown, a marked HDAC7 silencing was successfully achieved in 
both the A549 and H460 cells as suggested by the RT-PCR. However, HDAC7 
silencing results in a marked reduction of the H460 cell numbers (Figure 4.21a), 
while no effect was observed in the case of A549 (Figure 4.21 b). This suggests 
that a diversity between A549 and H460 in terms of HDAC7 function might 
exist. 
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Figure 4.21. Impact of HDAC7 silencing on NSCLC cell growth. The 
growth curves of H460 (A) and A549 (B) cell lines during four days 
incubation following HDAC7 silencing was drawn based on manual cell 
count. A negative impact on the proliferation of H460 cells was 
observed due to HDAC7 silencing. However, no effect was detected 
on A549 cell growth. Data shown represent three separate 
experiments. Statistical significance was evaluated using Students t-
test . * p<0.05. 
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4.4 Discussion 
Overexpressing models are important in elucidating the function of specific 
proteins. Several MMP overexpressing preclinical models have been useful in 
assessing their roles in tumour progression. An MMP12 overexpressing model 
has shown MMP12 to play a key role in myelopoiesis modulation, immune 
suppression and lung tumourigenesis (Qu et al., 2011). Similarly, an MMP14 
overexpressing model has shown MMP14 to be important in cell migration, this 
being via EGFR transactivation (Langlois et al., 2007). In human glioma, using 
an overexpressing model, MMP26 has been shown to promote cell invasion 
both in vitro and in vivo (Deng et al., 2010). As such, developing an MMP10 
overexpressing preclinical model for NSCLC is important to elucidate the 
functions of MMP10 in this cancer. 
Since the H460-clone2 cell line was previously engineered in this laboratory to 
overexpress MMP10, it was decided to confirm MMP10 levels in this model 
initially. The relative resistance to the selection marker (G418) observed in the 
H460-clone2 over the wild type is an early evidence of the presence and 
functionality of the MMP10 vector used. At the verification of the H460-clone2 
by RT-PCR, a band at ≈700 bp was linked to mouse MMP10 mRNA. However, 
it has to be considered that the lack of band in the corresponding control (H460-
wild type) could be due to the use of mouse primers on human cells. Initially, 
this vector was designed based on the findings described by (Madlener and 
Werner, 1997), and the right size for the mouse mRNA was calculated using 
their reported sequence in a blast search. Although the main focus of the 
present study is human MMP10, the use of a vector encoding mouse MMP10 
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should not compromise the results, as most MMP members, including MMP10, 
share the same sequence among the majority of vertebrates (Jackson et al., 
2010).  
The induction of angiogenesis was used as an indication for secreted MMP10 
functionality in the present study. H460-clone2 did not cause any increase in 
both the tube formation capacity of HUVEC-Cs in vitro and the tumour 
microvessels density in vivo, indicating a lack of functional MMP10 in these 
cells. While the in vitro angiogenesis assay was validated to assess MMP10 
functionality using recombinant MMP10 protein, the conditioned media from 
cells contain not only MMP10 but thousands of proteins that can influence the 
tube formation of HUVEC-Cs. To ensure the effect seen in this study on 
HUVEC-Cs, angiogenesis capacity was MMP-related, cells treated with the 
broad spectrum metalloprotease inhibitor (GM6001) was used as negative 
control. GM6001 has been shown to markedly decrease in vitro angiogenesis in 
several studies (Galardy et al., 1994; Koike et al., 2003; Witte et al., 1998). In 
accordance, the angiogenesis capacity was reduced when the HUVEC-Cs were 
exposed to the recommended concentration of GM6001 in the current study, 
indicating that the effects seen were related to MMP. As no specific MMP10 
inhibitor is currently available and no MMP10-negative cell line was identified in 
this study, the use of a broad spectrum MMP inhibitor was the only option. 
Despite this, the lack of angiogenesis potential of H460 clone 2 could be due to 
the influence of the vector cloning on other angiogenic factors, thereby affecting 
the tube formation results. In addition, suitable control with non-targeting vector 
(empty vector) was not included to exclude the influence of transfection process 
on the cell behaviour which could be the case here. A better methodology would 
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be to set a comparison between the H460-clone2 and a proper empty-vector 
control, as well as including a confirmed specific MMP10 inhibitor, if this 
becomes available in the future. Overall, taking all these factors into 
consideration, caution was considered when interpreting the results of the 
angiogenesis assay regarding the H460-clone2. The results observed in the 
H460-clone2 cells of low angiogenesis potential in vitro and the absence of 
microvessels density induction in vivo indicated that the elevated MMP10 in 
these cells was not functional. Thus, they were not used for further analysis and 
another approach was taken to generate MMP10 overexpressing cells. 
It has been reported that class II HDAC, HDAC7, represses MMP10 in the 
developing vasculature in vivo, suggesting a relationship between HDAC7 and 
MMP10 in endothelial cells (Chang et al., 2006). Such a relationship was 
observed in another study, confirming that the repression of MMP10 expression 
is dependent on HDAC7 activity or expression (Ha et al., 2008). Therefore, 
HDAC7 was silenced in the H460 cells in the current study to generate a 
functionally overexpressing MMP10 NSCLC preclinical model. While a 
significant HDAC7 knockdown (60%) was better achieved in the H460-
shHDAC7 cells compared to control, more efficient HDAC7 gene silencing was 
expected (not less than 80%) as a lentiviral transduction system was used 
(Karnabi et al., 2009; Karra and Dahm, 2010; Yu et al., 2013). Several factors 
related to the gene of interest or the lentivirus itself could be the reasoning for 
this observation. For example, it was found that the virus integration site in the 
genome is critical for controlling the transcription of the gene of interest (Park, 
2007). As a consequence, little gene silencing or gene expressing might be due 
to the viral integration into inactive heterochromatin. Another example is the 
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involvement of histone deacetylation process in the lentiviral transgene 
capability, which was reported in embryonic stem cells (Ma et al., 2003), and 
this could be evidenced here. Further studies reveal that determining the 
integration site of lentivirus on the DNA is based on histone function (Wang et 
al., 2007). As such, silencing HDAC7 might result in low histone deacetylation, 
thereby influencing the efficiency of lentiviral transduction. 
In contrast to the reported relationship between HDAC7 and MMP10, the 
HDAC7 knockdown did not induce MMP10 mRNA expression in the NSCLC cell 
lines (A549 and H460) in this study. Inconsistent with this finding, HDAC7 
silencing in human HepG2 hepatocellular carcinoma cell line reportedly induces 
the down-regulation of MMP10 expression (Zhang and Wang, 2010). While 
these data reinforce that the modulation of MMP10 by HDAC7 silencing may be 
cell type specific, further work is required to confirm this finding. 
It is important also to remember that silencing HDAC7 was reported to not only 
affect MMP10 but also to modulate other several genes in the endothelial cells, 
such as platelet-derived growth factor–β (PDGF-β), its receptor (PDGFR-β) 
(Mottet et al., 2007), MMP13 (Higashiyama et al., 2010), FGF1, retinoic acid 
receptor, gamma (RAR-γ) and TIMP1 (Chang et al., 2006; Mottet et al., 2007). 
Owing to the observations that HDAC7 is a major gene transcriptional regulator, 
the impact of transient HDAC7 silencing on the expression of other MMP-family 
members in the H460 cells was also evaluated. Out of all the MMPs tested, a 
significant induction in expression was observed for MMP3, suggesting a 
correlation between HDAC7 and MMP3 in these cells. The current study seems 
to be the first to report such a correlation at the genetic level between HDAC7 
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and MMP3 in the context of NSCLC. Confirming the potential of this relationship 
at the translational level was required, but was unachievable in this study 
because a specific MMP3 antibody could not be identified. Given further time, 
an appropriate antibody may be identified, which may make this achievable. 
Nonetheless, this still remains as a hypothesis that needs to be further 
investigated. 
To ascertain whether the effects of HDAC7 silencing on MMP3 mRNA 
expression was specific to the H460 cell line, the impact of transient HDAC7 
knockdown on MMP3 mRNA expression in the A549 cells was evaluated. No 
marked induction in MMP3 expression was seen with the A549 in contrast to 
the H460 cells, supporting the hypothesis that the HDAC7-MMP3 relationship 
might be cell type specific. Indeed, it was reported that the effects of the HDAC 
down-regulation on MMP expression might be cell type specific. Evidence of 
this is in the observation that trichostatin A, a class I and II HDAC inhibitor, 
suppressed MMP2 expression in mouse 3T3 fibroblasts, but not in human HT-
1080 fibrosarcoma cells (Ailenberg and Silverman, 2002; Ailenberg and 
Silverman, 2003). 
In explaining the relation between HDAC7 and MMP3 observed in this study, c-
Myc, a key regulatory gene that encodes the transcriptional factor c-Myc, which 
is implicated in many cancer types, appears to be key. c-Myc silencing has 
been shown to result in a reduction in both MMP1 and MMP3 expression, thus 
importantly, c-Myc expression induces MMP3 expression (Pap et al., 2004). 
Although HDAC7 activity has been reported as dependent on its interaction with 
class I HDAC3 (Fischle et al., 2001), HDAC3 silencing with or without HDAC7 
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silencing has been shown to have no influence on c-Myc expression. This 
would suggest that the relationship observed in this study between HDAC7 and 
MMP3 is most likely occurring due to the dependent signalling events of c-Myc, 
without the involvement of HDAC3.  
While assessing the impact of transient HDAC7 silencing on the growth of 
NSCLC cells, a reduction in the cell viability of H460, but not A549, was 
observed, supporting a diversity between these cell lines in terms of HDAC7 
function. The lack of effect seen with the A549 cells is different from findings of 
another study where HDAC7 knockdown resulted in cell cycle arrest in HCT116, 
MCF-7 and HH cancer cell lines, supporting HDAC7 silencing-induced cell cycle 
arrest as a common feature in several cancer cells (Chen et al., 2009; Zhu et 
al., 2011). While several pathways might be involved due to the roles of HDAC7 
in cancer cellular proliferation (Clocchiatti et al., 2011), the growth reduction 
seen here can be attributed to the resulting MMP3 overexpression or the 
reduction in MMP15 expression in response to the HDAC7 silencing. Since 
these gene results were based on semi-quantitative PCR, further validation 
using quantitative PCR is required. In the meantime, a possible mechanism for 
the growth inhibitory effect is the stimulation of cell apoptosis caused by MMP15 
reduction, with strong evidence regarding MMP-15 as an anti-apoptotic factor in 
HeLa cells (Abraham et al., 2005). Another mechanism could be due to the 
stimulation of cell apoptosis caused by MMP3 expression, with close correlation 
reported between MMP3 and cell apoptosis (Liu et al., 2013). In addition, it has 
been reported that HDAC7 silencing resulted in a decrease in the growth of 
HeLa cells and this effect was due to a mechanism involving c-Myc protein (Zhu 
et al., 2011). Collectively, these data support the growth regulatory function of 
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HDAC7, probably through MMP15 anti-apoptotic activity or a mechanism 
involving the c-Myc and MMP3, a relationship evidenced earlier in this research. 
Recombinant MMP10 protein increased the tube formation capacity of HUVEC-
Cs in a dose dependent manner, supporting the proangiogenic role of MMP10. 
Likewise, MMP10 in the A549 and H460 cells induced the in vitro tube 
formation, indicating an induction in angiogenesis in NSCLC tumours caused in 
part by MMP10. These findings are extensively discussed in the general 
discussion section of this research. 
In conclusion, MMP10 in the established H460-clone2 was not functional, 
highlighting the importance of assessing the enzyme functionality in preclinical 
models before conducting MMP-related studies. In terms of the relationship 
between HDAC7 and MMP10, HDAC7 silencing did not increase MMP10 
expression, but it did increase MMP3 expression at the gene level in the H460 
cell line. 
While a preclinical model with high and functional MMP10 could not be 
identified, the involvement of MMP10 to induce angiogenesis in vitro was 
observed to be significant. Overall, the induction of angiogenesis due to strong 
MMP10 expression in NSCLC cells seen herein, coupled with the expression 
and activity of MMP10 in the NSCLC clinical samples reported in the literature, 
support the potential of MMP10 as a target for therapeutic intervention in 
NSCLC. 
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Chapter 5: Identification of MMP Substrates and MMP-
Activated Prodrugs Specifically Cleaved by MMP10 
5.1 Introduction 
In the development of MMP-targeted TAPs, therapeutic drugs (‘effector’) are 
attached to an MMP substrate peptide (‘trigger’) to control the selectivity and 
specificity of the effector (Vartak and Gemeinhart, 2007). Ideally, the peptide 
should only be cleaved by a specific MMP, resulting in the activation of the 
drug. The cleavage of the peptide by other enzymes (either proteases or other 
MMP) can lead to premature activation and systemic side effects of the 
prodrugs (Chau et al., 2006a; Chau et al., 2006b). Since the substrate peptide 
is the key for TAP specificity, enzyme-substrate cleavage studies should be 
conducted to ensure the high specificity of MMP towards the selected peptides.  
Based on the findings of several studies focusing on MMP substrate 
specificities (Deng et al., 2000; Nagase and Fields, 1996; Netzel-Arnett et al., 
1991; Turk et al., 2001), several MMP- targeted TAP were rationally designed in 
the last decade. For example, two doxorubicin prodrugs have been reported to 
demonstrate promising efficacy after selective activation by MMP2, 9, and 14 
(Albright et al., 2005; Lee et al., 2006). Another TAP, the colchicine derivative 
ICT2588, has been designed and proven to be selectively activated by MMP14 
(Atkinson et al., 2010).  
In terms of MMP10, there is no specific MMP10 TAP that has been developed 
to date in spite of its expression and activity in several cancers, including 
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NSCLC. One reason is the incomplete data about MMP10 synthetic substrate 
specificity, which is in part due to the high similarity between MMP3 and 
MMP10. 
At protein level, the resemblance between stromelysins (MMP3, MMP10 and 
MMP11) has become a major issue for studies focusing on an enzyme member 
of this MMP subgroup. Despite the similar domain structure of MMP11 to other 
stromelysins, it is readily distinguished due to the differences in enzymatic 
activity, size and amino acid sequence (Barrett et al., 2004). Matrix 
metalloproteinase 3 and MMP10 are, however, similar in nearly every aspect, 
including the primary domain structure. They have 78% identical overall amino 
acid sequence and 86% similarity in terms of catalytic domain. They both have 
no affinity for interstitial collagen and they cleave the same extracellular matrix 
molecules. They also both contribute in the activation of other pro MMPs 
(Bertini et al., 2004; Kucukguven and Khalil, 2013). In contrast, the most 
obvious differences that have so far been observed between MMP3 and 
MMP10 are in their differential pH optimum activity against synthetic substrates 
and their patterns of expression in tissues (Barrett et al., 2004). For maximum 
activity, optimum pH for MMP3 was 5.5–6.0 while it was 7.5–8.0 for MMP10 
(Gunja-Smith et al., 1989; Harrison et al., 1992). Although traditional Western 
blotting can be used to distinguish between MMP3 and MMP10, it highly 
depends on selective antibody reactivity and does not measure protein activity. 
Thus, there is still a need for further studies on structure activity relationship for 
complete discrimination between MMP3 and MMP10 proteins.    
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5.1.1 Aims and Objectives 
The main aim of this chapter is to identify MMP10-specific cleavable sequences 
that could be incorporated into an MMP10-targeted TAP. 
The objectives are: 
 To evaluate through in vitro cleavage studies, if commercially available, 
known MMP substrates can be used to differentiate between MMP10 
and MMP3 cleavage using a mass spectrometry approach.  
 In addition, MMP activated TAP candidates designed in-house will be 
assessed for their ability to be cleaved specifically by MMP10 and 
MMP3, again using a mass spectrometry approach. 
This approach should result in the identification of a potential candidate 
sequence that could be utilised in a TAP. 
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5.2 Materials and Methods 
5.2.1 Materials 
Analytical grade chemicals for activity buffer, including APMA, Tris, NaCl, CaCl2 
and Brij 35, were bought from Sigma-Aldrich (Gillingham, UK). As, were formic 
acid (FA) and polypropylene auto sampler vials. HPLC grade methanol and 
triple distilled water were obtained from Fisher Scientific (Loughborough, UK). 
All novel compound used were provided in-house by the chemistry department 
at the Institute of Cancer Therapeutics (Bradford, UK). Full recombinant human 
MMP10 and MMP3 catalytic domain proteins were purchased from R and D 
systems (Abingdon, UK) and Calbiochem (Nottingham, UK), respectively. A 
panel of commercially available MMP substrates, cat. Number 444215, 444220, 
444228, 444230, 444258 and 444259, were obtained from Calibochem 
(Nottingham, UK). The sequence of these substrates is listed in Table 5.1. The 
MMP3 substrate (cat. number M-2105) and MMPs substrate (cat. number M-
1895) were purchased from Bachem (Bubendorf, Switzerland). Commercially 
unavailable peptides were custom-made at Peptide Protein Research Ltd 
(Hampshire, UK). 
5.2.2 Methods 
5.2.2.1 Enzyme activation 
Matrix metalloproteinase 10 recombinant pro enzyme was pre-activated with 
freshly made 1mM APMA prior to being used for any activity studies. An 
appropriate amount of APMA was dissolved in dimethyl sulfoxide to give 
100mM concentration. The APMA solution was further diluted to 1mM using an 
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activity buffer that contains 50mM Tris; 0.15M NaCl; 5.0mM CaCl2; 0.05% Brij 
35 and a pH adjusted to 7.5. For activation, four parts of this 1mM APMA was 
then mixed with one part of MMP10 pro-enzyme and incubated at 37°C for 
three hours. Successful activation was confirmed by SDS-PAGE with a band 
corresponding to 44 KDa (Figure 5.1).  
5.2.2.2 Liquid chromatography (LC) 
5.2.2.2.1 High performance liquid chromatography coupled with 
mass spectrometry (LC-MS) 
Sample analysis was carried out using high performance liquid chromatography 
(HPLC) reverse-phase separation and MS detection system. Drugs and 
metabolites were separated on a C18 HIRPB Hichrom column with 5µm silica 
particle size and 250mm x 4.6mm inner diameter. Subsequently, a waters 2695 
autosampler, waters 2996 photodiode array detector and Micromass ZMD 
single quadrupole electrospray with Masslynx software (Waters) was used for 
spectral and mass to charge the analysis of the peaks of interests. 
5.2.2.2.2 HPLC running conditions 
To ensure maximum resolution, mobile phase A (MPA) (90% HPLC grade 
water, 10% MeOH and 0.1% formic acid) and mobile phase B (MPB) (10% 
HPLC grade water, 90% MeOH and 0.1% formic acid) were used in an optimal 
gradient manner. An initial ratio of 90% MPA and 10% MPB was changed to 
100% MPB over 18 minutes. The later ratio was held for seven minutes until 
minute 25. Then, the ratio was changed again to 90% MPA and 10% MPB and 
kept constant until the end of the running time. All mobile phase solvents were 
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degassed before pumping onto the system using vacuum filtration through a 
0.45µm pore nylon filter membrane. During the running time, the mobile phase 
was delivered at a flow-rate of 1 mL/min. The scanning range of photodiode 
array detector was set between 200-400nm. The volume of injected sample was 
10µL and total running time for each was 40 minutes. 
5.2.2.3 In vitro MMPs-substrate cleavage study 
Active MMP10 and MMP3 were tested to determine their ability to cleave 
commercially available MMP substrates. A list of these substrates with their 
sequence, molecular weight and catalogue number are in Table 5.1. 
For analysis, 200ng active recombinant MMP3 or MMP10 proteins were 
incubated with 50µM of each substrate in the activity buffer at 37°C for 18 
hours. For special circumstances where cleavage rate is evaluated, several 
time points at zero, 30, 60, 120 and 240 minutes were used.  Once incubation 
was completed, sample reactions were terminated by the addition of 100% 
Methanol in a ratio of 1:4. In parallel, substrates in the activity buffer were 
incubated for the same corresponding time point to serve as a negative control. 
5.2.2.3.1 HPLC analysis of substrate cleavage 
The same method was used as in section 5.2.2.2. 
5.2.2.3.2 LC-MS analysis for MMPs-substrate cleavage study 
Mass spectrometry was used in a positive mode under optimum conditions. 
These include desolvation gas flow 650I/hr, cone gas flow 30I/hr, desolvation 
temperature 200°C, source block temperature 100°C, sample cone 30V, RF 
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lens 0.20V, extraction cone 5V and capillary 3.00kV. A full spectrum scan 
ranging from 300-900m/z was used to detect parent substrates and their 
metabolite as either singularly or double positive charged ions. Selected ion 
recording (SIR) for substrates and their possible metabolites were also used for 
maximum possible sensitivity. 
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Table 5.1. MMP Substrates Used with Full Details of Sequence. Dpa: N3-(2,4-
dinitrophenyl)-L-2,3-diaminopropionyl; Bz: Benzyl; DNP: 2,4-Dinitrophenol ; 
MCA: (7-methoxycoumarin-4-yl)acetyl; DANSYL: 5-dimethylamino-1-
naphthalenesulfonyl; p-OMeBz: S-para-methoxybenzyl 
 
Trade Name Catalogue 
Number 
Substrate Sequence Molar 
Mass 
Supplier 
MMP-2/ MMP-9 
Substrate I  
444215 DNP-Pro-Leu-Gly-Met-Trp-Ser-Arg-OH 1012.1 Calibochem 
(UK) 
MMP-3 
Substrate I, 
Fluorogenic 
444220 DNP-Pro-Tyr-Ala-Tyr-Trp-Met-Arg-OH 1152.3 
MMP-7 
Substrate I, 
Fluorogenic 
444228 DNP-Arg-Pro-Leu-Ala-Leu-Trp-Arg-Ser-OH 1164.3 
MMP-8 
Substrate I, 
Fluorogenic 
444230 DNP-Pro-Leu-Ala-Tyr-Trp-Ala-Arg-OH 1042.1 
MMP-14 
Substrate I, 
Fluorogenic 
444258 MCA-Pro-Leu-Ala-Cys(p-OMeBz)-Trp-Ala-
Arg(Dpa)-NH2  
 
1403.5 
MMP-14 
Substrate II, 
Fluorogenic 
444259 DANSYL-Pro-Leu-Ala-Cys(p-OMeBz)-Trp-
Ala-Arg-NH2  
1168.4 
MMP-3 
substrate 
M-2105 
 
Mca-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-
Lys(Dnp)-NH₂ 
1656.8  
Bachem 
(Switzerland) Trifluoroacetate 
salt 
M-1895 Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-
NH₂ 
1093.1 
Part of 
Proteoglycan 
protein (ABD1) 
Designed 
according to 
(Nguyen et 
al., 1993) 
His-Asp-Arg-Ala-IIe-His-IIe-Gln-Ala-Glu-
Asn-Gly-Pro-His-Leu-Leu-Val-Glu-Ala-Glu 
2249.4 Synthesised 
by Peptide 
Protein 
Research Ltd 
(UK) 
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5.2.2.4 Activation of MMP Targeted TAPs by MMP10 and MMP3 
5.2.2.4.1 MMPs targeted TAPs 
A panel of MMP-targeted TAPs developed in-house at the ICT—ICT2588 
(Atkinson et al., 2010), ICT3019, ICT3120, ICT3115, ICT3198 and ICT3146— 
were used to evaluate the ability and selectivity of MMP3 and MMP10 to 
activate these prodrugs in vitro. The sequence of these prodrugs is listed in 
Table 5.2. 
5.2.2.4.2 MMP-targeted compounds activation study 
For analysis, 200ng of active recombinant MMP3 or MMP10 protein were 
incubated with 50µM of each compound in the activity buffer at 37°C for 18 
hours. The long incubation time was to ensure maximum accumulation of 
reaction products. Once completed, sample reactions were terminated by the 
addition of 100% MeOH in a ratio of 1:4. In parallel, compounds alone in the 
activity buffer were incubated for the same time point to serve as a negative 
control. In addition, MMP3 and MMP10 enzymes were incubated with MMPs 
substrate (444228), known to be cleaved by both to serve as enzyme positive 
control. 
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Table 5.2. Illustration of MMPs Targeted TAPs Used with 
Their Sequence. MB2 refers to amino colchicine. FITC: 
Flouroisothiocyanate; ph: 2-methoxy-6-nitrophenyl 
Prodrug 
Conjugate Sequence 
ICT2588 FITC -βAla-Arg-Ser-Cit-Gly-Hof-Tyr-Leu-Tyr- MB2 
ICT3120 ph  -βAla-Leu-Tyr-Hof-Gly-Cit-Ser-Arg-Tyr- MB2 
ICT3146 ph -βAla-Leu-Ala-Hof-Gly-Arg-Ser-Arg-Tyr- MB2 
ICT3115 FITC-βAla-Arg-Ser-Cit-Gly-Hof-βAla-Leu-Tyr- MB2 
ICT3019 FITC -βAla-Arg-Ser-Arg-Gly-Hof-Tyr-Leu-Tyr- MB2 
ICT3198 Sugar -βAla-Arg-Ser-Cit-Gly-Hof-Tyr-Leu-Tyr- MB2 
 
5.2.2.4.3 HPLC analysis 
The same method was described in section 5.2.2.2 
5.2.2.4.4 LC-MS analysis for the activation of MMPs-targeted 
compounds by MMP3 and MMP10 
Mass spectrometry was set at the same parameters previously described in 
section 5.2.2.3.2. However, following a full scan ranging from 400-1000m/z, 
selected ion recording (SIR) was used for compounds of interest and their 
possible metabolites as illustrated in Table 5.3. 
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Table 5.3. SIR for Compounds and Their Possible Metabolites 
Used in Mass Spectrometry 
Compound 
Name 
Molecular 
Weight 
SIR (m/z) 
ICT2588 1901.7 952.8 - 639.9 - 824.5 
ICT3146 1613.7 842.49 - 808.8 - 791.45 
ICT3198 1804.8 999.4 - 904.4 - 824.4 - 501.2 
ICT3120 1706.7 855.3 - 590 - 548 - 791 
ICT3115 1809.75 906.8 - 661.32 - 732.5-893.4 
ICT3019 1900.79 952.3 - 662.3 - 985.4- 548.6 
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5.3 Results 
5.3.1 Differentiation between MMP3 and MMP10  
5.3.1.1 Full length versus activated MMP10  
In this research, catalytically active MMP3 enzyme was compared to the 
MMP10 enzyme. According to the manufacturer (R and D Systems), 
recombinant MMP10 was supplied as pro (52 KDa) and active (43 KDa) forms. 
To confirm this, 150ng of the product was subjected to Western blotting using 
the monoclonal MMP10 antibody. The results show that the recombinant protein 
contains mainly pro MMP10 with a clear band at 52 KDa (Figure 5.1). In terms 
of enzyme activity, a comparison of cleavage efficiency was made between pre-
activated and non-activated recombinant MMP10 product using the 444228 
MMP substrate (Figure 5.2). No marked difference in cleavage efficiency should 
be detected if the activation of the recombinant protein is not necessary. 
However, the cleavage of the pre-activated MMP10 was more efficient than the 
non-activated with 46.5% of the parent remaining after 18 hours of incubation, 
supporting the earlier Western blot results. Therefore, MMP10 enzyme 
activation of this product was carried out for future cleavage studies. 
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Figure 5.1. Validation of recombinant MMP10 using Western blotting. 
120ng of the product produced a large band that correspond to the 
size of pro MMP10 (inactive form) (A). Activated product was run in 
parallel to locate the active form band (B). The recombinanat MMP10 
tested was supplied as a mixture of pro and active forms. These data 
suggest that the product contains mainly pro MMP10 and that pre-
activation is necessary for activity studies. 
 
 
 
KDa 
 
 
 (A)    (B) 
 Pro form (54 KDa) 
 Active form (44 KDa) 
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Figure 5.2. Figure demonstrating the comparison between the non-
activated and pre-activated recombinant MMP10 product to cleave the 
444228 MMP substrate. Analysis of the peak area show that 46.5% of the 
substrate remained after 18 hours of incubation with the non-activated 
MMP10 product (A), whereas there was only 2.5% with the pre-activated 
one (B). HPLC trace of metabolite separated at retention time (RET) of 
12.9 minutes using diode array detection at wavelength 360nm and the 
substrate eluted at RET. 15.0 minutes. 
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5.3.1.2 MMPs-substrate cleavage study for peptides selectively 
cleaved by MMP10 
To build the foundations for a rationally designed MMP10-activated TAP, a 
peptide sequence that is specifically cleaved by MMP10 needs to be identified. 
A major problem occurring in the exploitation of MMP10 in therapy is the 
existence of the closely structured MMP3. To identify peptide sequences that 
can distinguish between these two closely structured enzymes, substrate 
cleavage studies were carried out. A panel of MMP substrates was tested 
against MMP3 and MMP10 using a mass spectrometry approach. These 
substrates are illustrated in Table 5.1. 
No cleavage was detected by both enzymes with substrate M-1895 under the 
experimental condition described in section 5.2.2.3. However, substrates 
444215, 444220, 444228, 444230, 444258, 444259 and ABD1 were all cleaved 
by both enzymes in the same position following 18 hours of incubation at 37°C 
as shown in Figures 5.3–5.11. Results summarised in Table 5.4 show the 
difficulty of differentiating between these two enzymes. Despite this, such 
information is valuable to provide the structural basis for future rational drug 
design. 
The initial aim of this chapter was to find a unique substrate that can distinguish 
between MMP3 and MMP10. Substrates 444258 (Figure 5.4) and 444259 
(Figure 5.11) showed different cleavage capacities by MMP3 despite their 
similarity, providing a basis for the further investigation of these particular 
substrates. 
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Figure 5.3. Figure to demonstrate that no metabolite was detected after 
18 hours of incubation of the substrate (1895) with MMP10 (A) or MMP3 
(B). For both enzymes, HPLC trace of the substrate (1895) eluted at 
RET. 15.30 minutes and was detected at a wavelength of 360nm. The 
444228 substrate was used as +ve control to show activity in both 
enzymes (C). 
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Figure 5.4. Figure demonstrates that substrate 444258 is cleaved in the 
same position by MMP10 (A) and MMP3 (B). For both enzymes, the 
HPLC trace of potential metabolite separated at RET. of 12.47 minutes 
using detection at wavelength 360nm and the parent substrate was 
eluted at RET. 18.47 minutes. 
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Figure 5.5. Figure demonstrates that substrate 444215 is cleaved in the 
same position by MMP10 (A) and MMP3 (B). For both enzymes, the 
HPLC trace of the potential metabolite separated at RET. of 13.42 
minutes using detection at 360nm and the parent substrate was eluted at 
RET. 15.40 minutes. 
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Figure 5.6. Figure demonstrates that substrate 444220 is cleaved in the 
same position by MMP10 (A) and MMP3 (B). For both enzymes, the 
HPLC trace of the potential metabolite separated at RET. of 10.31 
minutes using detection at wavelength 360nm and the parent substrate 
was eluted at RET. 13.60 minutes. 
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Figure 5.7. Figure demonstrates that substrate 444228 is cleaved in the 
same position by MMP10 (A) and MMP3 (B). For both enzymes, the HPLC 
trace of the potential metabolite separated at RET. of 11.95 minutes using 
detection at wavelength 360nm and the parent substrate was eluted at 
RET. 13.72 minutes. 
 
 
   Substrate standard 
t=0 
 
  t=18 hours 
Metabolite  
m/z=622.5
+1 Parent for the substrate 
m/z=583.3
+2 
Parent for the substrate 
m/z=583.3
+2 
Substrate standard 
t=0 
 
t=18 hours 
Metabolite  
m/z=622.5
+1 
180 
 
 
A 
 
 
 
B 
 
Figure 5.8. Figure to demonstrate that substrate 444230 is cleaved in the 
same position by MMP10 (A) and MMP3 (B). For both enzymes, the HPLC 
trace of the potential metabolite separated at RET. of 13.71 minutes using 
detection at wavelength 360nm and the parent substrate was eluted at 
RET. 15.15 minutes. Un refers to unknown. 
 
Metabolite  
m/z=466.5
+1 
Parent for the substrate 
m/z=522.2
+2 
t=0 
 
 
t=18 hours 
   Substrate standard 
Parent for the substrate 
m/z=522.2
+2 
    t=0 
 
Substrate standard  
 
   t=18 hours 
Metabolite  
m/z=466.5
+1 
Un
 
181 
 
 
 
A 
 
 
 
 
B 
 
Figure 5.9. Figure demonstrating that the M-2105 substrate is cleaved in 
the same position by MMP10 (A) and MMP3 (B). The HPLC trace of the 
potential metabolites by MMP10 and MMP3 separated at RET. 14.05 and 
14.08 minutes using detection at wavelength 360nm, respectively. The 
parent substrate was eluted at RET. 14.37 minutes. 
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Figure 5.10. Figure demonstrates that ABD1 substrate is cleaved in the 
same position by MMP10 (A) and MMP3 (B). For both enzymes evaluated, 
total ion chromatogram (TIC) scanning following reverse phase LC 
separation shows metabolite at RET. 5.16 minutes and this was identified 
at m/z=560.5 using as SIR in specific [ES+1]. The parent substrate was 
eluted at RET. 11.14 minutes. 
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Figure 5.11. Figure demonstrates that substrate 444259 is cleavage after 
18 hours of incubation with MMP10 (A) or MMP3 (B). A complete cleavage 
was observed by MMP3 but not MMP10. For both enzymes, the HPLC 
trace of the parent substrate was eluted at RET. 19.40 minutes and was 
detected at wavelength 360nm.  
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Table 5.4. Illustration of MMP-Substrate in In Vitro Cleavage Studies. Red 
lightning points to the cleavage position by both MMP3 and MMP10. 
Trade Name Catalogue 
Number 
Peptide Sequence 
Trifluoroacetate 
salt 
M-1895 Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 
MMP-2/MMP-9 
Substrate I  
444215 DNP-Pro-Leu-Gly---Met-Trp-Ser-Arg-OH 
MMP-3 Substrate 
I, Fluorogenic 
444220 DNP-Pro-Tyr-Ala---Tyr-Trp-Met-Arg-OH 
MMP-7 Substrate 
I, Fluorogenic 
444228 DNP-Arg-Pro-Leu-Ala---Leu-Trp-Arg-Ser-OH 
MMP-8 Substrate 
I, Fluorogenic 
444230 DNP-Pro-Leu-Ala---Tyr-Trp-Ala-Arg-OH 
MMP-14 
Substrate I, 
Fluorogenic 
444258 MCA-Pro-Leu-Ala-Cys---(p-OMeBz)-Trp-Ala-
Arg(Dpa)-NH2  
MMP-14 
Substrate II, 
Fluorogenic 
444259 DANSYL-Pro-Leu-Ala-Cys ---(p-OMeBz)-Trp-
Ala-Arg-NH2  
MMP-3 substrate M-2105 
 
Mca-Arg-Pro-Lys-Pro-Tyr-Ala---Nva-Trp-Met-
Lys(Dnp)-NH₂ 
Part of 
Proteoglycan 
protein 
ABD1 His-Asp-Arg-Ala-IIe-His-IIe-Gln-Ala-Glu-Asn-
Gly-Pro-His-Leu---Leu-Val-Glu-Ala-Glu 
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5.3.1.3 Structure Activity Relationship Study of 444258 and 
444259 Substrates 
The 444258 substrate has almost the same structure as the 444259 substrate; 
however, these differ due to slight modifications, such as the replacement of the 
MCA and Dpa groups at the peptide terminals with a DANSYL group and 
hydrogen atom, respectively. These minor changes unpredictably made the 
substrate more susceptible to cleavage by MMPs. For the 444258 substrate, a 
partial cleavage was detected after incubation with MMP3 or MMP10 for 18 
hours at 37°C, indicating a slow cleavage rate (Figure 5.4). In contrast, a 
complete cleavage was observed in the case of MMP3 with 444259 substrate 
under the same experimental conditions (Figure 5.11). For further insight, a 
half-life evaluation study of 444259 substrate after incubation with MMP3 and 
MMP10 enzymes was carried out. The half-life of the 444259 substrate after 
being incubated with MMP3 was 25.6 minutes (Figure 5.12), with initial 
cleavage detected as soon as 10 minutes. In contrast, the same substrate with 
MMP10 was very stable under the same experimental conditions. This peptide 
sequence represents a validated tool to differentiate in vitro between MMP3 and 
MMP10 activity as long as incubation time is less than four hours, paving the 
way for rational drug design. 
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Figure 5.12. Figure demonstrates the half-life time evaluation of the 
444259 substrate within four hours of incubation with MMP10 (A) or MMP3 
(B). Under our experimental conditions, this substrate was differentially 
cleaved by MMP3 with t0.5=25.6 minutes, whereas no cleave by MMP10 
was detected at this time range. The straight line regression equation 
shown above was used to calculate the half-life of the substrate. 
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5.3.2 Activation of MMP-Targeted Compounds by MMP10 and 
MMP3 
To build the basis for the studies evaluating MMP10 as a prodrug activator and 
ensure high selectivity, a panel of novel MMP-targeted TAPs developed in-
house at the ICT, ICT2588, ICT3019, ICT3120, ICT3115, ICT3198 and 
ICT3146, were incubated with pure MMP3 or MMP10 as described in section 
5.2.2.4.2. These compounds were chosen with respect to their similarity to the 
reference compound ICT2588 to guide this primary structure activity 
relationship (SAR) study. MMP-substrate 444228, known to be cleaved by both 
enzymes, was used in parallel in each experiment to ensure enzyme 
functionality. Results from this are presented in Figures 5.13-5.18 and 
summarized in Table 5.5. The numbers in bold below refers to a prodrug result 
that is listed in the table. 
The initial SAR began with ICT2588, which was cleaved by MMP3 but not 
MMP10 at the Hof-Tyr bond (1). Completely reversing the peptide sequence 
(ICT3120) causes no effect on enzymes selectivity with cleavage at Arg-Tyr 
bond by MMP3 only (2). Keeping this sequence constant and replacing cytosine 
with arginine and the tyrosine with alanine in the side chain of the amino acid 
residues (ICT3146) resulted in same selectivity and the cleavage shifted to Arg-
Ser bond, indicating that the above positions are not crucial for guiding 
enzymes selectivity (3). 
Further SAR efforts based on ICT2588 involves replacing tyrosine with B-
alanine in the amino acid side chain (ICT3115), which resulted in the prevention 
of the compound being activated by both MMP3 and MMP10, suggesting a vital 
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site for both enzymes activity (4). In the same context, the replacement of 
cytosine in ICT2588 with arginine at the amino acids chain (ICT3019) results in 
selectivity identical to the ICT2588 and the cleavage shifted toward the 
carboxylic end at the Tyr-Leu bond, indicating important position in terms of 
specificity but not the selectivity (5). Most of these tested compounds were 
capped at the N-termini with FITC or Ph moieties to avoid pre-activation or 
aminopeptidase degradation. To evaluate whether the N-terminal capping type 
can affect the behaviour of the tested enzymes and whether this position can 
serve as a starting point for further modifications, the FITC end cap of the 
ICT2588 was replaced with a simple sugar end cap to give the ICT3198 
compound. This surprisingly resulted in a decrease in selectivity as the 
compound was cleaved by both MMP3 and MMP10 at the same bond, Gly-Hof 
(6). These valuable findings represent a foundation for further studies to exploit 
MMP10 or MMP3’s tremendous proteolytic activity as prodrug activators. 
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Figure 5.13. Figure demonstrating the comparison between MMP10 (A) 
and MMP3 (B) to activate the ICT2588 prodrug. Using detection at 
wavelength 360nm, no HPLC trace of potential metabolite was detected 
with MMP10, whereas metabolite separated at RET. of 15.00 minutes 
was detected in the case of MMP3. The prodrug was eluted at RET. of 
16.79 minutes. Refer to Figure 5.19 for the positive controls of both 
enzymes. 
Parent for ICT2588 
m/z=952.8
+2 
  t=18 hours 
 
 
   t=0 
  ICT2588 standard 
Parent for ICT2588 
m/z=952.8
+2 
       t=18 hours 
 
 t=0  
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+1
 
Unknown
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Figure 5.14. Figure demonstrating the comparison between MMP10 (A) 
and MMP3 (B) to activate the ICT3019 prodrug. Using detection at 
wavelength 360nm, no HPLC trace of the potential metabolite was 
detected with MMP10, whereas metabolite separated at RET. of 14.80 
minutes was detected in the case of MMP3. The prodrug was eluted at 
RET. of 16.23 minutes. Refer to Figure 5.19 for the positive controls of 
both enzymes. 
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Figure 5.15. Figure demonstrating the comparison between MMP10 (A) 
and MMP3 (B) to activate the ICT3115 prodrug. Using detection at 
wavelength 360nm, no HPLC trace of potential metabolite was detected 
with MMP10 and MMP3. The prodrug was eluted at RET. of 16.64 
minutes. Refer to Figure 5.19 for the positive controls of both enzymes. 
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Figure 5.16. Figure demonstrating the comparison between MMP10 (A) 
and MMP3 (B) to activate the ICT3120 prodrug. Using detection at 
wavelength 360nm, no HPLC trace of potential metabolite was detected 
with MMP10, whereas metabolite separated at RET. of 12.16 minutes was 
detected in the case of MMP3. The prodrug was eluted at RET. of 17.44 
minutes. Refer to Figure 5.19 for the positive controls of both enzymes. 
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Figure 5.17. Figure demonstrating the comparison between MMP10 (A) 
and MMP3 (B) to activate the ICT3198 prodrug. Using diode array 
detection at wavelength 360nm, the HPLC trace of the potential metabolite 
by both enzymes separated at RET. of 15.14 minutes was detected. The 
prodrug was eluted at RET. of 16.07 minutes. Refer to Figure 5.19 for the 
positive controls of both enzymes. 
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Figure 5.18. Figure demonstrating the comparison between MMP10 (A) 
and MMP3 (B) to activate the ICT3146 prodrug. Using detection at 
wavelength 360nm, no HPLC trace of the potential metabolite was 
detected with MMP10, whereas metabolite separated at RET. of 12.09 
minutes was detected in the case of MMP3. The prodrug was eluted at 
RET. of 16.61 minutes. Refer to Figure 5.19 for the positive controls of both 
enzymes. 
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Figure 5.19. Figure to demonstrate substrate 444228 is cleaved by 
MMP10 (A), and MMP3 enzymes (B). As positive control, this experiment 
was performed in parallel to activation studies to ensure activity in both 
enzymes. HPLC trace of potential metabolites by MMP10 and MMP3 
separated at RET. 12.77 minutes using detection at wavelength 360nm. 
The parent substrate was eluted at RET. 14.82 minutes.  
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Table 5.5. Summary of the in vitro cleavage profile of peptide-colchicine 
conjugates by MMP3 and MMP10. MB2 refers to amino colchicine. Red 
colour indicates site of modification, whereas the blue thunder sign indicates 
potential cleavage site.  
NO Prodrug Conjugate Sequence 
Cleave by: 
MMP
3 
MMP
10 
1 ICT2588 FITC-βAla-Arg-Ser-Cit-Gly-Hof-Tyr-Leu-Tyr-MB2   
2 ICT3120 ph -βAla-Leu-Tyr-Hof-Gly-Cit-Ser-Arg-Tyr- MB2   
3 ICT3146 ph -βAla-Leu-Ala-Hof-Gly-Arg-Ser-Arg-Tyr- MB2   
4 ICT3115 FITC-βAla-Arg-Ser-Cit-Gly-Hof-βAla-Leu-Tyr-MB2   
5 ICT3019 FITC-βAla-Arg-Ser-Arg-Gly-Hof-Tyr-Leu-Tyr-MB2   
6 ICT3198 Sugar-βAla-Arg-Ser-Cit-Gly-Hof-Tyr-Leu-Tyr-MB2   
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5.4 Discussion 
In the development of MMP-targeted TAPs, a fundamental step is incorporating 
a substrate peptide (‘trigger’) to derive the specificity of the prodrugs (Atkinson 
et al., 2008). Therefore, the identification of a specific peptide sequence for 
MMP activation is critical, as it could determine the future prospects of MMP-
activated TAPs. In the literature, there is currently a lack of data about MMP 
substrate specificities for several MMPs, including MMP10, the main focus of 
this research. The aim of the work in this chapter is to identify an MMP10-
specific cleavable sequence to incorporate into an MMP10-targeted TAP. A 
major obstacle for targeting MMP10 is the presence of the highly similar MMP3. 
To improve specificity in targeting MMP10, the selected peptide should have a 
high affinity to MMP10 as compared to MMP3. 
The activity of the enzyme needs to be addressed prior to performing the 
enzyme-substrate cleavage studies. While the precise enzymatic activity for 
MMP3 and MMP10 recombinant proteins could not be measured within the 
constraints of the current project, it was sufficient at this stage using the 444228 
substrate, which is known to be cleaved by both enzymes, as a marker for their 
activity to be qualitatively evaluated. This assay was unexpectedly able to 
provide an idea about the cleavage efficiency of MMP10. The recombinant 
MMP10 was supplied as a mixture of both the pro and active forms. The 
comparison in the cleavage efficiency of recombinant MMP10 between the non-
activated and the APMA pre-activated version using the 444228 substrate has 
revealed a higher efficiency (a faster cleavage rate) of the fully activated than 
the non-activated MMP10 protein. This indicates that the 444228 substrate-
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enzyme cleavage assay successfully provided an accurate and a semi-
quantitative evaluation for the MMP10 enzymatic activity. 
Only one study in the literature has offered a peptide that could distinguish 
between MMP3 and MMP10 (Nguyen et al., 1993). In the reported study, 
human cartilage link protein with amino acid sequence, shown in Figure 5.20, 
was cleaved by MMP10 in two different sites compared to MMP3. The MMP3 
and MMP10 cleaved between His'6 and Ile"7 and MMP10 specifically cleaved 
between Leu25 and Leu26. The part of the cartilage protein that exhibited 
resistance to the cleaving by the MMP3 has brought the attention of this 
research. It could provide a key for amino acid sequences to distinguish 
between the two closely structured MMP3 and MMP10. Based on this, a 
peptide of similar amino acid sequence was synthesised and tested with MMP3 
and MMP10 in this research. Interestingly, the synthetic substrate was cleaved 
in the same position by both enzymes, indicating a lack of specificity. This 
discrepancy between the results may be attributed to the differences in assay 
conditions and tools of study. For example, the incubation time, concentrations, 
buffers and recombinant MMP enzyme sensitivity of the detection system used 
can greatly influence the results. 
 
1                                         10                                          20                                            30 
D H L S D N Y T L D H D R A I H I Q A E N G P H L L V E A E…. 
 
                                                        MMP3 and                       MMP10 
                                                        MMP10 
Figure 5.20. Amino acid sequence of the N-terminal of human cartilage link 
protein and cleavage sites by MMP3 and MMP10. D:Asp; H:His; L: leu; S: ser; 
N:Asn; Y:Tyr; T:Thr; R:Arg; A:Ala; I:Ile; Q: Gln; E:Glu; G:Gly; P:Pro; V:Val. 
Arrows refer to the cleavage generated in vitro by the enzymes as indicated 
above. Figure was adapted from (Nguyen et al., 1993) with slight modification. 
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As the only MMP10 specific substrate sequence reported in the literature was 
found to be unreliable in terms of absolute specificity, a panel of synthetic MMP-
sensitive substrates were screened in this research. The screening of synthetic 
substrates against enzymes, such as MMP10, can provide insight into the 
enzyme’s behaviour and specificity toward different substrates, resulting in the 
identification of a unique substrate for the enzyme. As previously discussed 
(section 1.8.2.1), SAR studies have been conducted on several MMPs, leading 
to the identification of structural features within the substrates that are either 
necessary for cleavage by all MMPs or relatively specific for a  few MMP 
members (Deng et al., 2000; Nagase and Fields, 1996; Netzel-Arnett et al., 
1991; Turk et al., 2001; Vartak and Gemeinhart, 2007). For example, if the 
sequence analogue of the substrate is defined as “--A3--A2--A1=A1’--A2’--A3’--
”, where A is any specific amino acid and = is the cleavage site (Vartak and 
Gemeinhart, 2007), an MMP substrate should typically have small amino acids 
at (A1), hydrophobic amino acids at (A1’ and A2), proline at (A3) and 
hydrophobic or basic amino acids at (A2’). Special substrate features identified 
to date for MMPs, including MMP1, MMP2 and MMP9, require small residues at 
(A3’); MMP3, 7 and 14 prefer methionine at the same position; MMP2, MMP3 
and MMP7 favour glutamic acid at A1. It is worth noticing that MMPs have a 
diverse tolerance for both aromatic amino acids at (A1) and the hydrophobic  
amino acid residues at (A2) (Vartak and Gemeinhart, 2007). The data from this 
chapter suggests that the substrate structural features for MMP3 and MMP10 
are consistent with the general criteria for MMP substrates, except that 
hydrophobic amino acids at (A1’) were not found to be essential for selectivity 
as demonstrated in the insertion of a polar tyrosine residue at (A1’) in the 
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444220 and 444230 substrates. Although the intention was to develop an 
MMP10 substrate, the detailed amino acid sequence was not identified, due 
probably to the small scale screening of MMP substrates and the high 
resemblance between MMP3 and MMP10. Results of this study provide the 
foundation for future studies necessary to create a profile of the MMP10 
substrate specificity. This will, in the future, result in the identification of MMP10-
specific cleavable peptide sequences. 
The in vitro cleavage studies for MMP substrates are a valuable tool to measure 
the affinity of individual MMPs to the selected linker peptides. It is desirable that 
the linker is rapidly cleaved once it encounters the specific MMP (Vartak and 
Gemeinhart, 2007). Data in the present study showed that MMP3 has higher 
affinity to the 444259 substrate in vitro than MMP10, supporting the 444259 
substrate as a validated tool for differentiating in vitro the MMP3 and MMP10 
activity. However, the behaviour of enzymes toward a substrate during the in 
vitro experiments can differ significantly in the more complex in vivo 
environment, where proteins and mediators are present at relevant 
concentrations (Overall and Blobel, 2007). Although in this research, MMP3 
cleaved the 444259 substrate in vitro at a faster rate than the MMP10 and no 
other substrate showed the potential to distinguish between the two enzymes, it 
remains difficult to know whether the same happens in vivo. Therefore, a careful 
consideration is necessary when interpreting the in vitro experiment results and 
further confirmation in an in vivo setting is required. 
The MMP-activatable prodrug ICT2588 has demonstrated great promise as an 
antitumour therapy, with a marked capacity to reduce HT-1080 fibrosarcoma 
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tumour xenografts with a low systemic toxicity. It involves the peptide conjugate 
(βAla-Arg-Ser-Cit-Gly-Hof-Tyr-Leu-Tyr) linked to azademethylcolchicine. It was 
initially introduced as being selectively activated by MT-MMPs (Atkinson et al., 
2010). This claim was supported by extensive enzyme-cleavage in vitro studies 
using recombinant proteins for all the MT-MMPs and for MMP1, 2, 10, 12, and 
13. With the MMP3 enzyme not included in their evaluation, data of the present 
study unpredictably demonstrated cleavage of the ICT2588 prodrug by MMP3. 
Such finding probably allows the questioning of the selectivity of the ICT2588 
prodrug, especially with evidence of it being slightly cleaved by MMP2 as well 
(Atkinson et al., 2010). In this regard, it has become increasingly acceptable 
that most peptide substrates in general are cleaved at certain conditions by 
various MMPs with only two to ten fold selectivity (Vartak and Gemeinhart, 
2007), which could be the same case with the ICT2588. Thus, the design of the 
optimal peptide sequences to exhibit selective cleavage by specific MMPs has 
been proven difficult. 
Continuing to identify the key structural features of the substrates that would 
allow the targeting of MMP10 specifically, SAR studies based on the ICT2588 
prodrug and using MMP3 and MMP10 enzymes were also conducted in this 
research. If the sequence analogue of the ICT2588 is defined as                                         
‘FITC-P1-P2-P3-P4-P5-P6-P7-P8-P9-amino colchicine’, where P is any specific 
amino acid, the addition of arginine at P4 (ICT3019) resulted in no effect on 
both enzymes’ specificity. In addition, the use of β-alanine at the P7 site 
(ICT3115) led to the inhibition of the activation by MMP3, indicating a vital site 
for MMP3 specificity. Interestingly, the replacement of FITC at the N-terminal 
with a sugar residue as end-cap surprisingly allows the activation by MMP10, as 
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demonstrated with ICT3198. This sudden change in affinity of the MMP10 
enzyme to the peptide substrate in ICT3198 might be due to the removal of the 
influence of the FITC residue, which has been reported to often compete with 
the substrate on the enzyme active site under certain conditions (Yang et al., 
2000). 
In conclusion, proper validation of commercial enzymes is critical prior to the 
conduction of the in vitro substrate-enzyme cleavage studies, as exemplified 
here with the recombinant MMP10. This should improve confidence and 
enhance the reliability of results. Cleavage studies in vitro reveal that the 
differentiation between closely related MMP3 and MMP10 can be successfully 
detected if cleavage rates are carefully monitored with the 444259 substrate 
using specific reaction conditions described in this study (Section 5.2.2.3). 
While a peptide sequence specific to MMP3 was uncovered, sequences specific 
to MMP10 to incorporate into a TAP were more elusive. The data provided 
herein is essential for building the foundation to achieve this goal. Developing a 
substrate specific to MMP10 (as with other MMPs) still remains a challenge.  
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Chapter 6: General Discussion 
As previously described, MMPs are heavily implicated in the tumourigenicity of 
most cancers, in part through ECM degradation, which directly facilitates tumour 
invasion and metastasis or through their involvement in the release of several 
bioactive molecules that are known to contribute to the phenotypic evolution of 
cancer (Overall and Dean, 2006). Since MMPs are key players in cancer 
development, the evaluation of their expression, activity and localisation in 
human cancers is essential in terms of diagnosis, prognosis and therapy. 
In NSCLC, there is still a need to identify new molecular targets that can be 
either targeted for novel therapeutics or exploited to improve the tumour-
delivery of the current chemotherapeutics, thereby minimising systemic toxicity. 
Among MMPs, MMP10 has the most potential to be a good candidate as a 
target, given its expression, activity and its correlation to poor clinical outcome 
in NSCLC (Frederick et al., 2008). The main aims of this project were to 
investigate the role of MMP10 in the tumour microenvironment of NSCLC and to 
contribute to the evaluation of MMP10 as a target for therapeutic intervention. 
It is worth noticing that the heterogeneous tumour microenvironment might 
contain other sources of MMP10 as well as tumour cells, such as tumour-
associated epithelial, stromal and immune cells (Justilien et al., 2012). In fact, 
MMP10 has also been detected in normal cells such as  bone marrow-derived 
macrophages as evidenced in a recent study (Murray et al., 2013). However, 
the rate of secreting MMP10 between stromal and tumour cells is different. Low 
levels of MMP10 in the lung epithelium have been reported in vivo compared to 
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those when oncogenic Kras is activated in tumour cells (Regala et al., 2009). 
Hence, tumour cells are the main source of MMP10 in tumour tissue, despite 
potential other sources. 
In the literature, numerous studies have reported elevated expression of 
MMP10 in a wide range of tumour types (Gill et al., 2004; Mathew et al., 2002; 
Miyata et al., 2007; Rodriguez et al., 2008). Matrix metalloproteinase 10 
expression has been linked to the progression of several cancers, including 
lymphoma, lung and head and neck cancers (Deraz et al., 2011; Frederick et 
al., 2008; Van Themsche et al., 2004). In NSCLC, MMP10 demonstrates 
elevated expression in both primary and secondary tumours, an observation 
that is independent of tumour status (Cho et al., 2003; Gill et al., 2004; Muller et 
al., 1991). In relation to this, MMP10 is also expressed in the early stages of 
NSCLC tumour development, rather than just tumour invasion and metastasis 
(Frederick et al., 2008; Justilien et al., 2012). In accordance with most studies 
concerning MMP10 expression in NSCLC, generally high MMP10 expression at 
the gene and protein levels were observed in the two NSCLC cell lines, A549 
and H460. Owing to this, these cell lines were selected for use in the present 
study to evaluate the role of MMP10 in NSCLC. While the intention was to 
engineer the above cell lines to overexpress MMP10 to the expression levels 
observed clinically, this goal could not be achieved within the time scale of this 
project. Thus, the development of functional MMP10 overexpressing models in 
vitro as a future work of this project is a priority as it can provide insight 
regarding the roles of MMP10 in NSCLC tumour development and progression. 
205 
The results of the mRNA expression analysis in the above NSCLC cell lines 
showed high expression for MMP10. An identical observation was seen for the 
structurally similar MMP3 in these cell lines, suggesting the importance of these 
enzymes in these cells. Despite their structural similarity (Bertini et al., 2004; 
Kucukguven and Khalil, 2013), a study reveals that the use of recombinant 
active MMP10 but not MMP3 improves the transformation of NSCLC cells 
(Frederick et al., 2008), suggesting that MMP3 and MMP10 have different non-
overlapping functions in NSCLC development. This difference in functions 
between these enzymes may be applicable to the regulatory mechanisms of 
their expression. An induction in the mRNA levels of MMP3 but not MMP10 was 
shown in this study to be due to HDAC7 silencing in the H460 cells. 
Confirmation of this finding at the translational level is required but was not 
attempted in this study due to the unavailability of any MMP3 specific antibody. 
Experience showed that several commercially available MMP ‘specific’ 
antibodies actually cross-reacted between these MMPs, requiring extreme 
caution when selecting an antibody for the studies. Future work in this research 
will involve further screening of other MMP3 antibodies to identify one that could 
distinguish between MMP3 and MMP10. Although it has been reported that 
immunolocalisation can be used to distinguish between the these enzymes 
based on their differences in cellular synthesis and localisation (Bord et al., 
1998; Saghizadeh et al., 2001), this has to be questioned since this technique 
still relies on antibody specificity. 
At the protein level, the elevated expression of MMP10 correlated with the 
angiogenic potential in the NSCLC cell lines, suggesting a strong relationship 
between MMP10 protein level and functional activity in NSCLC. A similar 
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correlation has also been seen between the immunohistochemical expression 
of MMP10 and the more aggressive human clinical bladder tumours (Zhang et 
al., 2014a). In relation to this but at the gene level, a significant correlation in the 
NSCLC clinical samples has been observed between the MMP10 gene 
expression and tumour progression, invasiveness and metastasis (Baty et al., 
2010). With respect to the differences between gene expression and the 
corresponding protein expression, the studies reported here support an 
association between the functional activity and levels of MMP10 mRNA and 
protein in the NSCLC clinical specimens. Since there is a consistency in results 
between the reported clinical studies and the present study, this supports the 
findings of this in vitro study in terms of its relevance to the clinical situation. 
Although MMP10 enzymatic activity was not measured because no 
experimentally validated MMP10-specific fluorescent substrate is available to 
date, the angiogenesis assay was alternatively used as indicative for MMP10 
functional activity in the present study, owing to the high involvement of MMP10 
in angiogenesis (Zhang et al., 2014a). The suitability of the angiogenesis assay 
was demonstrated using purified MMP10. The relationship between the 
expression and activity of the MMP10 seen in the current study indicates an 
important role for this enzyme in the NSCLC angiogenesis and its association 
with tumour development. To address the exact role of MMP10 in angiogenesis 
of NSCLC tumour, an in vivo model where MMP10 is silenced is needed to 
study the impact on the progression of tumour vasculature using a validated 
immunostaining technique for visualisation of blood vessels. Such an in vivo 
model could even be used to address the role of MMP10 in other phenotypic 
evolutions of cancer such as invasion. A link between MMP10 and  invasion has 
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already been reported for macrophages (Deraz et al., 2011; Murray et al., 
2013). 
To assess the impact of the tumour microenvironment on MMP10 expression, a 
comparison of MMP10 mRNA levels between 2D monolayer culture and tumour 
xenografts was made in this study. Tumours are dependent on the 
microenvironment-generated growth factors and cytokines that are known to 
transcriptionally up-regulate MMPs (Stamenkovic, 2000). However, the elevated 
MMP10 expression patterns in the NSCLC tumour xenografts in vivo were 
consistent with those seen in the monolayer culture in vitro, indicating a minor 
influence of the tumour microenvironment on MMP10 mRNA expression. While 
a solid tumour is a heterogeneous mixture of tumour and ‘normal’ stromal and 
endothelial cells, taking into account post-translational modifications, these 
results indicate that the MMP10 secretion observed originated directly from the 
tumour cells. This idea has been reported in several previous studies for 
MMP10 (Impola et al., 2004; Muller et al., 1991; Nakamura et al., 1998), and it 
might explain why MMP10 protein in the NSCLC tissues were found to be highly 
expressed independently of tumour grade, stage, histological type, or lymph 
node status (Gill et al., 2004). Although data of the current study provide a clear 
evidence of MMP10 expression mainly in tumour cells, there might be certain 
levels of MMP10 coming from stromal cells, therefore caution should be 
considered when interpreting these data. 
While the tumour microenvironment had little influence on MMP10 mRNA 
expression as shown by similar mRNA expression in cells and xenograft 
tissues, in contrast, a higher expression level of pro- and active-MMP10 
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proteins were observed in the tissue xenografts compared to cells. This pattern 
of MMP10 protein expression is consistent with a previous observation (Mishra 
et al., 2012), which showed that very low levels of MMP10 protein were 
detected in the cells grown in 2D culture, but significantly higher levels when the 
same cells were xenografted. Taken together, these findings suggest that the 
tumour microenvironment has a minor influence on MMP10 mRNA, but can 
markedly increase the MMP10 protein level through indirect mechanisms that 
could be related to the post-translational modifications. This also highlights that 
studies evaluating the levels and functions of MMP10 protein should be 
focussed on in vivo systems, which would take into account many other stimuli 
unavailable in the current in vitro system.  
While MMP10 expression has been widely reported to be linked to invasion and 
the metastatic potential of cancer cells, its role in angiogenesis is not fully 
understood (Deraz et al., 2011; Justilien et al., 2012; Zhang et al., 2014b). 
Vascular integrity is currently recognised to be maintained by tight junctions 
between adjacent endothelial and smooth muscle cells, as well as pericytes that 
possess a crucial role in stabilisation of the vessel wall (Ribatti et al., 2011). It is 
also recognised that the upregulation of MMPs presumably degrades these 
junctional complexes, facilitating the detachment and migration of endothelial 
cells into the surrounding tissues (Rundhaug, 2005; Saunders et al., 2005), a 
process that involve MMP10. However, once endothelial cells reach their 
destination, MMPs, including MMP10 are down-regulated to allow for the 
formation of the junctional complex and consequently blood vessel formation 
(Chang et al., 2006; Rundhaug, 2005; Yoon et al., 2003). There are several 
studies supporting the involvement of MMP10 in angiogenesis (Chang et al., 
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2006; Ha et al., 2008; Heo et al., 2010). One of these studies has reported an 
angiogenic role of MMP10 in the context of tumour progression (Zhang et al., 
2014a). In this current study, an induction of angiogenesis due to secreted 
MMP10 was observed in two NSCLC cell lines (A549 and H460), indicating that 
MMP10 could facilitate angiogenesis in the NSCLC tumours. However, this 
induction of angiogenesis may not be directly due to the cleavage activity of 
MMP10. It could be the consequence of the downstream effects of MMP10 on 
the MMP signalling cascade, leading to the secretion and activation of several 
angiogenic proteins, and thereby facilitating angiogenesis. In this context, it has 
been reported that MMP10 expression can up-regulate many key angiogenic 
proteins in tumour cells, indirectly facilitating angiogenesis. For example, MMP9 
and hypoxia-inducible factor 1-alpha proteins confirmed to be expressed in 
response to MMP10 overexpression in engineered HeLa cells, are implicated in 
angiogenesis (Zhang et al., 2014a). Furthermore, the down-regulation of 
MMP10 in HUVEC-Cs results in the reduction of VEGF-induced vessel 
formation in vivo and capillary tube formation in vitro, suggesting a link between 
MMP10 and VEGF expression (Heo et al., 2010). Thus, the MMP10 induced 
angiogenesis seen in the current study may not be exclusively due to MMP10-
ECM degradation, but to the up-regulation of other key angiogenic stimulators 
as a result of MMP10 expression.  
For further understanding and to underlie the mechanism by which MMP10 
expression facilitates the angiogenesis, it is important to identify all potential 
matrix substrates or molecules that are cleaved by MMP10 when it is activated. 
In this regard, immunoprecipitation and Western blotting could be utilised to 
determine the complexes formed with MMP10 when in its active state, as this 
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may delineate specific pathways for MMP10-related tumour progression. 
Another approach has recently been proven to be powerful procedure in the 
identification of the substrates of proteases with broad or unknown specificity, is 
terminal amine isotopic labeling of substrates (TAILS) (Kleifeld et al., 2010). The 
success of this tandem mass spectrometry based approach is exemplified with 
the discovery that galectin-1 is cleaved by MMP-11 in human breast cancer 
cells (Kleifeld et al., 2010). Another interesting example was when this strategy 
helped in identifying that a disintegrin and metalloproteinase with 
thrombospondin motifs ADAMTS-like protein 1 (ADAMTSL1) is a direct MMP10 
substrate (Schlage et al., 2014). As such, this strategy could be used in the 
future of this project to address the role of MMP10 in several hallmaks of 
NSCLC tumour development such as angiogenesis, migration and invasion. 
In contrast to the majority of studies (including this research) suggesting 
MMP10 as a facilitator of angiogenesis, a few key studies in this field have 
shown MMP10 up-regulation in HUVEC-Cs to be associated with both the 
inhibition of the tube formation capacity and capillary tube regression (Chang et 
al., 2006; Saunders et al., 2005). The apparent contradiction regarding the role 
of MMP10 in angiogenesis might have arisen from the differences in study 
design. Most studies did not take into account the fact that MMP10 can lead to 
the modulation of several endoproteases that could be pro- and anti-angiogenic. 
Another reason is that the function of MMP10 and other proteases in vascular 
development is believed to be temporal (Stetler-Stevenson, 1999). In addition, it 
has been demonstrated that both the absence or excess of proteolytic activity 
can negatively impact angiogenesis (Devy et al., 2002). Consequently, to 
exhibit the angiogenic phenotype, MMP10 activity towards endothelial cells 
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needs to be at the right time and right place. Therefore, to understand the exact 
role of MMP10 in angiogenesis, studies should first elucidate where, when and 
how MMP10 is involved, as well as reveal potential relationships between 
MMP10 and all other MMPs. Such goals cannot be achieved using the transient 
or stable gene expression systems used in the current study. Future work on 
this project should involve inducible transgenic systems, such as a tetracycline 
transactivator (tTA) or ‘Tet- Off’ and reverse tetracycline transactivator (rtTA) or 
‘Tet-On], that would be used to produce a temporal control of MMP10 
expression to mimic its activity during angiogenesis in NSCLC. 
It is known that nearly all MMPs are synthesised as zymogens and secreted 
instantly, either extracellularly or to the cell membrane. An exception is MMP8 
and MMP9, which are synthesised and stored in cytoplasmic granules of 
neutrophils prior to secretion when neutrophils are activated (Jackson et al., 
2010; Sternlicht and Werb, 2001). In solid tumours, MMP10 has been reported 
to be secreted mainly by the tumour cells following synthesis (Impola et al., 
2004; Muller et al., 1991; Nakamura et al., 1998). In the present study, levels of 
MMP10 in the conditioned media from the NSCLC cell lines were consistent 
with those in the whole cell lysates, suggesting a similarity between intracellular 
and extracellular MMP10 levels. This finding supports a scenario similar to that 
of MMP8 and MMP9 but within tumour cells. As such, it is conceivable to 
assume that in tumour cells, MMP10 might be stored in granules in the cell 
cytoplasm prior to their secretion when required. This assumption is supported 
by the immunohistochemical observations of low levels of extracellular MMP10 
protein compared to cytoplasmic MMP10 in NSCLC clinical tissues (Gill et al., 
2004). Further support of this was reported in another study where MMP10 was 
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mainly detected in the cancer cell cytoplasm in prostate clinical tissues (Maruta 
et al., 2010). However, there are currently no studies specifically comparing the 
intracellular and extracellular levels of MMP10; therefore, this observation 
needs further investigation. Since confirming this observation might further 
support MMP10 as a target for therapeutic intervention, future work on this 
project would involve immunohistochemistry studies utilising a tumour cell-
specific membrane marker, as well as MMP10 antibody. This will allow 
differentiation between intracellular and extracellular MMP10 protein levels, 
making it possible to evaluate where MMP10 is mainly localised in the tumour 
microenvironment. 
A major aim of this research is to evaluate MMP10 as a target for therapeutic 
intervention in NSCLC. The observation that it could be a major contributor in 
tumour development due to several factors: expression in the NSCLC cell lines; 
the existence of a relationship between the expression and the activity of 
MMP10; secretion mainly by tumour cells; and its involvement in facilitating 
angiogenesis, all support the idea that MMP10 could offer a novel therapeutic 
target for intervention in NSCLC. In support of this, evidence shows that 
silencing MMP10 expression suppresses the enhanced self-renewal and 
tumourigenic properties of lung cancer cells (with stem cell-like characteristics) 
(Batra et al., 2012; Justilien et al., 2012). Moreover, genetic loss of MMP10 has 
been shown to suppress tumourigenesis and tumour growth in the mouse 
models of oncogenic Kras-mediated lung adenocarcinoma (Batra et al., 2012; 
Regala et al., 2011). Taken together with the reported findings that MMP10 is 
highly expressed in the majority of the NSCLC clinical specimens (Gill et al., 
2004) and its expression being associated with poor prognosis (Frederick et al., 
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2008), this further supports MMP10 as a potential target for therapeutic 
intervention in this disease. 
Targeting MMP with non-selective inhibitors has not been successful (Choi et 
al., 2012; Coussens et al., 2002). However, identifying specific MMP10-
inhibitors may be a better approach for the future if the physiological roles of 
MMP10 are fully revealed. An alternative strategy for the use of elevated 
MMP10 expression and proteolytic activity in the NSCLC tumours is to use this 
to improve drug delivery at the tumour sites, an approach called tumour-
activated prodrugs (TAP). Tumour-activated prodrugs that utilise MMP10 would 
restrict the pharmacological effect to the tumour tissue, thereby lowering 
systemic toxicity and allowing for a wider therapeutic margin (Albright et al., 
2005; Atkinson et al., 2008). The key to the robustness of this approach is to 
completely rely on the enzyme activity, which can be inhibited due to the 
influence of the natural regulators of the MMP function, the TIMPs (Ikenaka et 
al., 2003). Four homologous mammalian TIMPs have been identified (Brew et 
al., 2000; Curran et al., 2001; Gomez et al., 1997), with evidence of overlapping 
inhibitory specificity among them (Nagase and Brew, 2002). However, only 
TIMP1 was reported to inhibit MMP10 in a stochiometric manner (Nicholson et 
al., 1989; Windsor et al., 1993). Since TIMPs were not included in this study, 
there was no way to assess their influence on MMP10 in the context of NSCLC. 
Nonetheless, it remains a place of further investigation to ensure that levels of 
TIMPs, especially TIMP1 in the NSCLC tumours, does not negatively impact the 
potential to use the endopeptidase activity of MMP10 in the development of 
TAPs. 
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The ultimate goal of cancer chemotherapeutic development is to increase drug 
targeting to the tumour with consequential diminution of systemic toxicities. The 
TAP approach has the potential to achieve this goal by selectively delivering 
chemotherapeutics to the tumour tissue (Atkinson et al., 2010) through the 
exploitation of the difference in the expression of selected MMPs between the 
tumour and normal tissues. The use of selected MMPs as prodrug activating 
enzymes has resulted in promising selectivity and anti-tumour efficacy, as 
exemplified with ICT2588 using MMP14 (Atkinson et al., 2010). As such, 
MMP10, in particular, might be a good candidate as a prodrug activator in 
NSCLC, given its selective high expression and activity in tumours and its ability 
to endopeptidase-cleave short peptide sequences. 
A primary step for targeting individual MMPs to improve drug delivery is the 
identification of a unique peptide (trigger) that is specific for the enzyme of 
interest. One way to achieve this goal is to fully elucidate the physiological MMP 
substrates that would provide the amino acid sequence essential for developing 
a peptide conjugate specific for that MMP. However, such a strategy has been 
proven to be quite challenging due to the significant overlap in the MMP 
substrate’s specificity in natural physiological substrates, a very few examples 
of which are listed in Table 6.1. Due to the MMP activity on a wide range of 
substrates, identifying unique, MMP-specific peptide conjugates for each MMP 
is challenging, thereby restraining the development of MMP-targeted prodrugs. 
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Table 6.1. Examples of Significant Overlap in MMP Substrate Specificity. 
Most natural MMP substrates are cleaved by numerous MMPs. 
Consequently, identifying a specific peptide sequence for individual MMP has 
become a challenge. 
MMP Natural MMP Substrate 
MMP1, 2, 8 and 13  collagen I (degradation) (Vartak and Gemeinhart, 
2007). 
MMP2, 3, 7, 10 and 11  Fibronectin (degradation) (Vartak and Gemeinhart, 
2007). 
MMP14 and 16  proMMP-2 (activation) (Nagase and Fields, 1996). 
MMP2 and 9  TGF β1 and TGF β2 (Activation) (McCawley and 
Matrisian, 2001). 
MMP1, 3 and 7  Tumour necrosis factor alpha (release of the cell 
surface) (Stamenkovic, 2003). 
 
In addition to the general overlap in specificity between MMPs, a particular 
obstacle in targeting MMP10 is the presence of the closely structured MMP3. In 
this context, there is a lack of data in the literature regarding MMP10 substrate 
specificities. In an attempt to identify peptide sequences that can distinguish 
between these two closely structured enzymes, MMP-substrate cleavage 
studies were carried out in this study. The data showed that MMP3 has higher 
affinity to the synthetic substrate 444259 than MMP10, representing a validated 
tool to differentiate in vitro between MMP3 and MMP10 activity. It is important to 
evaluate whether this is mirrored in vivo, given the enormous number of endo- 
and exopeptidases present in the living tissues relative to in vitro systems. The 
sequence of this peptide can also provide a source of insight regarding the 
structural relationship of peptide/protein selectivity between MMP3 and MMP10. 
Substrate 444259 therefore should be used as a starting point for further SAR 
studies to create a profile regarding MMP10-substrate specificity to identify an 
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MMP10-specific cleavable peptide sequence. Identification of such a specific 
peptide sequence for MMP10 is critical as it will determine the future prospects 
of MMP10 as a prodrug activator. Such an approach has led to the identification 
of a specific peptide sequence incorporated into the ICT2588, an MMP14 
selective TAP poised to enter clinical trials in 2015 (Loadman, Falconer and 
Patterson, personal communication). 
6.1 Overall Summary 
The main aim of this project is to evaluate the potential of MMP10 as a target 
for therapeutic intervention. In a series of preclinical experiments, MMP10 was 
shown to be highly expressed in the NSCLC cell lines and that high levels of 
MMP10 contribute to tumour development, in part by the induction of 
angiogenesis. Together, these findings, with the expression and activity of 
MMP10 in the NSCLC clinical samples that were reported in the literature, 
support MMP10 as a target candidate for therapeutic intervention in NSCLC. 
While specific targeting of MMP10 with an inhibitor might be elusive at the 
moment due to the un-elucidated physiological functions of MMP10, as well as 
the unavailability of MMP10 specific inhibitors, the selective high MMP10 
expression and proteolytic activity in tumours could be harnessed to activate 
antitumour prodrugs in NSCLC. The current research is the first to attempt to 
develop specific MMP10 activatable prodrugs. The data generated herein will 
provide the foundations necessary to successfully achieve such a goal in the 
future. This project has also highlighted the importance of assessing enzyme 
functionality in preclinical models before conducting MMP-related studies. 
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Appendices 
Appendix 1. TAE Buffer (10X) Recipe 
 
Components  
Tris-base (pH 7.6) 242g 
Glacial acetic acid 57.1ml 
0.5M sodium EDTA  100ml 
Distilled water Up to 1 litre 
 
245 
Appendix 2. Preparation of 10% Separating and 5% Stacking 
Gels 
Appendix 2. Recipe for 10% Separating and 5% Stacking Gels 
 30% acrylamide/ 
Bisacrylamide mix 
solution 
1.5M Tris 
(pH 8.8) 
1M Tris 
(pH 6.8) 
10% 
SDS 
distilled 
H2O 
10% 
AP 
TEMED 
10% separating 
gel (10ml) 
3.3ml 2.5ml 0 100ul 4ml 100ul 4ul 
5% stacking gel 
(3ml) 
0.5ml 0 0.38ml 30ul 2.1ml 30ul 3ul 
AP: Ammonium Persulfate 
TEMED: Tetramethylethylenediamine 
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Appendix 3. Illustration of the Contents of Peptide Calibration 
Standard Mixture for MALDI/MS 
Appendix 3. Illustration of the Contents of Peptide Calibration 
Standard Mixture for MALDI/MS 
Peptide standard 
Mass to mono charge ratio (m/z) 
Angiotensin II 1046.5418 
Angiotensin I 1296.6848 
Substance P 1347.7354 
Bombesin 1619.8223 
ACTH clip 1-17 2093.0862 
ACTH clip 18-39 2465.1983 
Somatostatin 28 3147.4710 
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Appendix 5. Supplementary Data for MALDI-MS Analysis 
 
 
A 
 
 
 
 
 
B 
MMP10 
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MMP3 
 
Appendix 5. Supplementary Data for MALDI-MS Analysis. (A) List of 
proteins identified in samples analysed by LC MALDI. (B) The location and 
sequence ID of the dominant peptide signals detected. Selective MMP10 
peptide is in red and the one found in both MMP3 and10 is in blue. 
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Appendix 6. HDAC7 detection by Western blotting 
Appendix 6. HDAC7 detection by Western blotting in H460 cells. 
NIH3T3 cell line was used as a positive control. 
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